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Abstract 
 
This thesis describes the synthesis of several naphthoquinone- and carbazole-1,4-quinone-
derived conjugates of a mycothiol-like scaffold designed to act as redox cycling subversive 
substrates of the enzyme, Mtr, or potentially inhibit other mycothiol-dependent or 
biosynthetic enzymes, in order to develop novel antitubercular lead compounds.  The 
expression and purification of Mtr, as well as the attempts made towards the cloning and 
expression of active Mycobacterial glyoxalase I, in order to generate enzymes on which to 
assay the synthesised molecules, are also described. 
 
Linking of the quinone functionalities to the mycothiol-like scaffold, phenyl-1-thio-D-
glucosamine, was envisaged to facilitate delivery of this class of redox active molecules to 
the active-site of the mycothiol enzymes.  Successful completion of the synthesis of 
naphthoquinone conjugates of this scaffold was not achieved due to a persistent side 
reaction that took place during an N-tert-butoxycarbonyl deprotection step.  However, this 
unexpected result led to the discovery of a new synthetic route to benzo[g]indoles and 
benzo[h]quinolines.  This route differs from traditional quinoline and indole syntheses in that 
the aromatic C-N bond is generated by a condensation reaction between a quinone carbonyl 
and an aliphatic amine, rather than via the traditional condensation of an aromatic amine 
with a distal carbonyl group. 
 
Successful synthesis of the carbazole-1,4-quinone conjugates of phenyl-1-thio-D-
glucosamine was achieved, affording three derivatives, 3.35, 3.36 and 3.37, which were 
tested for activity against M. tuberculosis strain H37Rv.  Assays were carried out in vitro to 
determine minimum inhibitory concentration (MIC) using the microplate alamar blue assay 
(MABA), and all three conjugates were found to be inactive, with MIC values >128 µm.  The 
addition of the linker and phenyl-1-thio-D-glucosamine unit to the carbazole quinone 
therefore significantly reduces the anti-TB activity of the parent carbazole quinone, a result 
which is consistent with the earlier findings of Knölker et al. that further substitution of the 
carbazole-quinone nucleus tends to dampen the anti-TB activity.  Attempts have been 
initiated to have the conjugates tested for activity against Mtr, MshB and related mycothiol-
processing enzymes, with results not available to date.  
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Chapter 1 
Introduction 
 
This project forms part of a wider body of research currently being undertaken in our 
research group with the goal of identifying potential novel antitubercular chemotherapeutic 
compounds that target the mycothiol biosynthetic pathway and related enzymes. 
 
1.1. Tuberculosis 
 
Tuberculosis (TB) is an infectious pulmonary disease caused by the bacterium, 
Mycobacterium tuberculosis (Mtb).  Approximately one-third of the world’s population is 
currently infected with the TB bacillus, of which five to ten percent (of non-HIV infected 
peoplei) develop active tuberculosis and become infectious.1  Transmission of the disease 
takes place when infected individuals propel droplets containing the bacterium into the air by 
coughing, talking, sneezing or spitting, and these are subsequently inhaled, causing 
infection.  Infection does not necessarily lead to disease, and in healthy individuals, the 
bacilli can lie dormant in the macrophages of the lungs for many years without generating 
any symptoms.  However, once a person’s immune system becomes suppressed, the latent 
bacilli become active and the symptoms of the disease develop.  These symptoms include 
chest pain, breathing difficulty, fatigue, fever, weight loss (giving rise to the historical 
colloquial term for the disease, consumption) and in advanced cases, haemoptysis 
(coughing up of blood or blood stained sputum).  
 
Mycobacterium tuberculosis is an aerobic, non-motile, bacillus with a slow replication rate, 
(generation time of 17-18 h).2  Although a member of the Gram-positive bacteria (due to it 
lacking an outer cell membrane), Mtb is poorly coloured by Gram stain due to its lipid-rich 
cell wall.  However, it can be visualised under microscope by the Ziehl-Neelsen stain, which 
stains the organism bright red and is a commonly used technique for the identification of 
tuberculosis infection in sputum samples.3  
 
                                               
i People co-infected with HIV and TB have a considerably higher probability of developing active 
tuberculosis. 
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1.1.1 Pathogenesis and Macrophage Interaction 
 
TB infection occurs when aerosol droplets containing Mtb are inhaled, allowing the bacteria 
to reach the pulmonary alveoli, where they enter the endosomes of alveolar macrophages.4,5  
Here they replicate and generate what is termed the Ghon focus, the primary site of infection 
in the lungs consisting of a small area of granulomatous inflammation.  From here the 
bacteria can spread to the lymph nodes by dendritic cell transport, and can further spread 
via the bloodstream to other areas of the body where secondary lesions may occur.6  The 
formation of a granuloma by macrophages, T cells, B cells and fibroblasts aids in the 
containment of the infection.  Bacteria within the granuloma can become dormant, giving rise 
to a latent infection with asymptomatic results.  The latent bacteria are generally not 
completely eliminated from the host and can lie dormant for many years until the immune 
system is compromised.  Once this occurs, the latent bacteria become virulent and develop 
into active tuberculosis.  This ability to withstand the host’s immune response, and to remain 
uncompromised within a granuloma consisting of macrophages and lymphocytes is a 
remarkable adaptation that has allowed Mtb to persist as a human parasite for centuries.  
The means by which Mtb is able to evade the immune response is by inhibition of 
phagolysosome biogenesis.7 This results in immature phagolysosomes lacking the means to 
kill the Mtb bacilli, and permitting their persistence. 
 
1.1.2 Global Incidence of TB 
 
Tuberculosis is a world-wide problem, with most of the disease burden falling on developing 
countries where immunisation schemes and appropriate health care facilities are poorly 
supported. The World Health Organisation (WHO) has been monitoring the epidemiology of 
TB globally, and since 1997 has published sixteen global reports on tuberculosis, providing 
comprehensive information on the progress of the disease as well as measures that have 
been taken at a global, regional and country level to stop TB, using data provided by 198 
countries accounting for 99 % of the world’s TB cases. 
 
The region with the highest total number of new TB cases is South East Asia, which 
accounted for 40 % of global incidence in 2010.  The region with the highest rate of new 
cases of TB (per 100,000 population) in 2010 was Africa, with a rate of 276 – considerably 
greater than the second highest incidence region of SE Asia (rate of 193).  The values for 
the incidence (the number of new cases arising during a defined period), prevalence (the 
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number of cases - new and previously occurring - that exists at a given point in time) and 
mortality for each WHO region are given below in Table 1. 
 
Table 1. Estimates of the burden of the disease caused by TB, per WHO region 
 YEAR POPULATION MORTALITY 
(EXCLUDING HIV) 
PREVALENCE 
(INCLUDING HIV) 
INCIDENCE 
(INCLUDING HIV) 
Global 2010 6.87 billion 1.1 million 12 million 8.8 million 
Africa  837 million 250,000 2.8 million 2.3 million 
Americas  933 million 20,000 330,000 270,000 
E. Mediterranean  597 million 95,000 1 million 650,000 
Europe  896 million 61,000 650,000 420,000 
SE Asia  1.808 billion 500,000 5 million 3.5 million 
W. Pacific  1.798 billion 130,000 2.5 million 1.7 million 
[Data taken from WHO Global Tuberculosis Report 2011]8 
 
Globally it was estimated that there were 1.45 million deaths from TB in 2010 (including HIV-
associated), with the greatest number of these deaths occurring in Africa.  In all six WHO 
regions, the estimated per capita incident rate was stable or decreased between 2006 and 
2010, suggesting that the programs that have been instigated around the world are 
beginning to have an effect on the spread of TB.  However, despite this global decrease in 
incident rate, high population growth in Africa meant that this region had an increase in the 
absolute number of TB cases between 2006 and 2010, the only region globally that this was 
so.8  These results and figures indicate that TB is still a global problem, particularly in Africa, 
and that urgent attention and advanced treatment strategies are required to successfully 
combat the disease. 
 
1.1.3 Incidence of TB in South Africa 
 
South Africa has one of the highest rates of incidence of TB in the world, with a rate of 981 
new cases per 100,000 population in 2010.  This gave a total of 490,000 new cases of TB in 
2010, with a WHO estimate of prevalence at 400,000, suggesting a considerable number of 
these new cases were either cured or died during the year (Table 2).  60% of TB patients 
that were tested were HIV-positive, although the HIV status of only 54% of patients was 
known, suggesting the co-infection rate could be even higher. 
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Table 2. Estimates of the mortality, prevalence and incidence of TB in South Africa compared to 
global and African figures for 2010 
 YEAR POPULATION MORTALITY 
(EXCLUDING HIV) 
PREVALENCE 
(INCLUDING HIV) 
INCIDENCE 
(INCLUDING HIV) 
Global 2010 6.87 billion 1.1 million 12 million 8.8 million 
Africa 2010 837 million 250,000 2.8 million 2.3 million 
South Africa 2010 50 million 25,000 400,000 490,000 
[Data taken from WHO Global Tuberculosis Report 2011]8 
 
1.1.4 HIV and Tuberculosis  
 
The Human Immune deficiency Virus (HIV) weakens the immune system and thereby greatly 
increases the chances that people suffering from the Auto Immune Deficiency Syndrome 
(AIDS) will develop active tuberculosis when also infected with the TB bacillus.  From the 
1980’s till about 2004, the number of TB cases and TB mortality increased greatly as a result 
of the HIV epidemic, particularly in Southern and Eastern Africa.8  Globally, 13% of TB cases 
occur among people with HIV.  In the Africa region, which accounts for 82% of new HIV-
positive TB cases globally, approximately 900,000 (39%) of the 2.3 million people who 
developed TB in 2010 were HIV-positive.  As mentioned above, this value is considerably 
higher (>60%) in South Africa.  There were approximately 350,000 deaths worldwide from 
TB among HIV-positive people in 2010. 
 
1.1.5 Current TB Drugs and Their Biological Targets 
 
The current first line TB drugs in clinical use are isoniazid, rifampicin, ethambutol and 
pyrazinamide (Figure 1). 
N
H
H
N
HO
HO
ethambutol
N
O
H
N
NH2
isoniazid
N
N
O NH2
pyrazinamide
OH
OH
OH
O
O
O
O
O
HO
OH
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O
N
N
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rifampicin  
Figure 1. Chemical structures of first line TB drugs 
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The biological targets of the first-line drugs are varied.  Isoniazid is a prodrug that is 
activated by the catalase peroxidase enzyme, KatG, and then reacts non-enzymatically with 
nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate 
(NADP) to generate several isonicotinoyl adducts, one of which – the 4-S isomer of 
isoniazid-NAD – targets the enoyl-acyl carrier protein reductase, known as InhA,9,10 thus 
inhibiting the biosynthesis of mycolic acid, an essential component of the mycobacterial cell 
wall.   
 
Rifampicin is a semi-synthetic compound isolated from the bacterium, Amycolatopsis 
rifamycinica, and derives its activity by inhibiting bacterial RNA polymerase.  This blocks 
transcription to RNA which in turn inhibits the formation of polypeptides and proteins.11 
 
Ethambutol acts by obstructing the formation of the mycobacterial cell wall.  A critical 
component of the cell wall is a macromolecular complex between arabinogalactan, mycolic 
acid and peptidoglycan.12  Ethambutol disrupts arabinogalactan biosynthesis by inhibiting 
several arabinosyl transferases which reduce the formation of this complex and resulting in 
increased cell wall permeability.13,14  This allows other co-administered TB drugs (such as 
rifampicin) to enter the bacterial cell more readily and exert their mode of activity.15   
 
Pyrazinamide is included in first line drug regimens since it has been shown to reduce the 
duration of treatment from 9 months to 6 months.16  It is a prodrug that is converted to its 
active form, pyrazinoic acid, by nicotinamidase/pyrazinamidase (PZase).17  Its mode of 
action is somewhat disputed and has been proposed to proceed by inhibition of the fatty acid 
biosynthetic enzyme, fatty acid synthase (FAS) I,18 by depleting cellular ATP reserves,19 and 
by binding to the ribosomal protein S1 (RpsA) thus inhibiting trans-translation (this process is 
essential for liberating scarce ribosomes in non-replicating organisms, and its inhibition could 
explain the ability of pyrazinamide to eradicate dormant mycobacteria).20 
 
The second-line TB drugs consist of those classes of compounds that are either less active 
than the first-line drugs (e.g. p-aminosalicylic acid), have toxic side-effects (e.g. cycloserine) 
or are not widely available (e.g. fluoroquinolones).  These include the aminoglycosides (e.g. 
kanamycin), polypeptides (e.g. capreomycin), thioamides (e.g. ethionamide) and 
fluoroquinolones (e.g. ciprofloxacin, moxifloxacin) (Figure 2). 
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Figure 2. Chemical structures of second-line TB drugs 
 
The mode of action of p-aminosalicylic acid has not been confirmed but it has been 
postulated to interfere with the salicylate-dependent biosynthesis of the iron-chelating 
mycobactins involved in iron assimilation.21  Cycloserine is a structural analogue of D-
alanine, and a competitive inhibitor of D-alanine racemase and D-alanyl-D-alanine 
synthetase.  It has been implicated in disruption of the cell wall biosynthesis by targeting the 
mycolylarabinogalactan-peptidoglycan complex.22  The aminoglycosides inhibit protein 
synthesis through irreversible binding to the ribosomal subunit, whereas the polypeptides 
appear to inhibit translocation of peptidyl transfer RNA thus preventing the initiation of 
protein synthesis.23,24  The thioamide class of antitubercular agents, which includes 
ethionamide, appear to inhibit mycolic acid biosynthesis, although the exact mechanism of 
action has not been elucidated.  Like isoniazid, ethionamide is a prodrug requiring activation, 
but by the monooxygenase, EthA, followed by formation of an adduct with NAD that 
subsequently inhibits the enoyl-ACP reductase, InhA.25,26,27 Fluoroquinolones are the primary 
choice of drug for treatment of patients with multidrug-resistant (MDR-TB) and extensively 
drug resistant tuberculosis (XDR-TB) and produce the highest level of success in clinical 
outcomes of any other class of drugs.28,29 The bactericidal effects of the fluoroquinolones are 
based upon their interaction with Type II topoisomerase (DNA gyrase), a tetrameric enzyme 
that catalyses the supercoiling of DNA.30,31  Inhibition of its activity prevents supercoiling and 
subsequent processes that rely on DNA topology such as replication and transcription.21  
 
The current short course treatment is six months long and consists of isoniazid, rifampicin, 
pyrazinamide and ethambutol for two months, followed by four months of isoniazid and 
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rifampicin alone.  The rationale for using a multiple drug regimen is based on a statistical 
argument: in order to reduce the probability of spontaneous mutations leading to drug 
resistance, combinations of drugs are taken concurrently.  This strategy also reduces the 
possibility of selecting a drug to which the infection strain may already have resistance.  With 
the exception of XDR-TB, it is unlikely that resistance to all four front-line drugs will be 
present in the particular strain, and therefore the likelihood of successful treatment is 
enhanced.  
 
1.1.6 Drug Resistant Tuberculosis 
 
Since the development of the first TB drugs 50 years ago, resistant strains of the bacterium 
have started to develop, and in fact have been reported in every country surveyed by the 
WHO.  Lack of patient compliance with the long duration of drug regimen is the greatest 
cause of resistance development.  Some strains have developed resistance to more than 
one of the major TB drugs, resulting in MDR-TB and XDR-TB forms of the disease.  MDR-
TB is defined as resistance to at least isoniazid and rifampicin, the two most effective anti-TB 
drugs currently commercially available.  XDR-TB is defined as resistance to at least isoniazid 
and rifampicin from among the first line anti-TB drugs, as well as resistance to any member 
of the fluoroquinolone family and to at least one of three injectable second-line anti-TB drugs 
(capreomycin, kanamycin and amikacin).32 
 
Treatment of drug-resistant TB is generally possible, but requires extensive periods of 
chemotherapy (up to two years) with second-line TB drugs, which are more costly than first-
line drugs and have more side effects.  Although more difficult to treat and with higher rates 
of mortality, XDR-TB has been reported to be treatable, with a study in Russia reporting that 
48 % of patients with XRD-TB successfully completed treatment.33  However, a study from 
Tugela Ferry, South Africa, reported 52 of 53 patients with XDR-TB died, with a median 
survival of 16 days from the time of diagnosis.  Most patients were co-infected with HIV.34 
 
Drug-resistant TB is a concerning problem that threatens to develop into an epidemic 
because of the limited available treatment possibilities and could reverse the gains made 
since 2006 against the disease.  It is therefore of great importance that new tools are 
developed for prevention, treatment and diagnostics.  In particular, novel chemotherapeutic 
agents are required that are capable of treating drug-resistant infections. These drugs would 
have to act on alternate biological targets within the organism circumventing current 
resistance pathways that the bacterium has developed.  One biological pathway not 
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currently covered by existing TB medicines is the mycothiol biosynthetic pathway and its 
associated enzymes, and it is these enzymes that form the focus of this project. 
 
1.2. Mycothiol  
 
Low molecular weight thiols play a key role in protecting cells from reactive oxygen and 
nitrogen species, and maintaining a reducing environment necessary for regular metabolic 
processes to take place.  In eukaryotes and gram-negative bacteria, the dominant thiol 
performing this role is the tripeptide, glutathione (GSH)(Figure 3).35  Mycobacteria, in 
common with other Actinobacteria, lack glutathione and instead produce the 
pseudodisaccharide, mycothiol (MSH)(Figure 3), which performs an analogous detoxification 
and redox stabilising function.36  The discovery of MSH was first reported in 1994, 
independently by Spies and Steenkamp,37 and by Sakuda and co-workers.38   
 
 
Figure 3. Chemical s ructures of glutathione and mycothiol 
 
The structure consists of an N-acetylated cysteine coupled to D-glucosamine which is α(1-
1)-linked to myo-inositol.  Although initially unconfirmed, the absolute stereochemistry of 
MSH was finally resolved by total chemical synthesis of the bimane derivative, MSmB, which 
was shown to have the same optical rotation, circular dichroism and mycothiol-S-conjugate 
amidase (Mca) substrate properties as MSmB obtained from cell extracts.39,40 
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1.2.1 Overview of Mycothiol biosynthesis 
 
The mycothiol biosynthetic pathway begins with L-myo-inositol-1-phosphate (L-myo-Ins-1-P), 
which is obtained from glucose-6-phosphate by the action of inositol-1-phosphate synthase.  
Conversion of L-myo-Ins-1-P to mycothiol proceeds via five enzymatic stages, as outlined in 
Scheme 1. 
 
 
Scheme 1. Mycothiol biosynthetic pathway 
 
The first step involves the formation of a glycosidic linkage between uridine diphospho 2-
acetamido-2-deoxy-glucose (UDP-GlcNAc) and L-myo-Ins-1-P, catalysed by the 
glycosyltransferase, MshA.41  The phosphate on the GlcNAc-Ins-3-P is then removed by an 
unspecified phosphatase, designated MshA2, followed by deacetylation of the N-acetyl of 
GlcNAc-Ins by the zinc-dependent deacetylase, MshB.42  The cysteine side-chain is 
subsequently attached by the ATP-dependent cysteine ligase, MshC.43  Finally, acetylation 
of the cysteinyl amine by the acetyl-CoA-dependent acetyltransferase, MshD, completes the 
biosynthesis of MSH.44   
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The biosynthetic enzymes involved in this process, as well as a few selected mycothiol-
dependent proteins are described in greater detail below. 
 
1.2.2 Mycothiol Glycosyltransferase, MshA, and Phosphatase, MshA2 
 
Commencement of the MSH biosynthesis by glycosylation of the L-myo-Ins-1-P with UDP-
GlcNAc is proposed to proceed as illustrated in Scheme 2.   
 
Scheme 2. Proposed catalytic mechanism for MshA-mediated formation of GlcNAc-Ins-P45 
 
The exact substrates and biochemistry of MshA were only elucidated several years after the 
identification of its role in MSH biosynthesis.46 This was done by proving that M. smegmatis 
extracts synthesised GlcNAc-Ins-P from the racemic 1-D,L-Ins-1-P and UDP-GlcNAc, but not 
from myo-inositol nor 1-D-Ins-1-P and UDP-GlcNAc.  This demonstrated that the substrate 
for MshA was 1-L-Ins-1-P.  Protein crystal structure analysis revealed that active-site binding 
of UDP-GlcNAc, which generates the binding site for 1-L-Ins-1-P,45 involves a considerable 
conformational change.  The inositol phosphate was shown to be stabilised by electrostatic 
interactions and multiple hydrogen bonds to amino acid residues within the binding site, 
which could explain why myo-inositol lacking the phosphate group could not serve as a 
source of inositol for the enzyme reaction.47  The first step of the proposed mechanism is 
elimination of the UDP by delocalisation of the glucosamine ring oxygen lone pair to 
generate an oxocarbenium ion, followed by glycosylation with the inositol-1-P in a semi-
concerted process that involves deprotonation of the acceptor hydroxyl by the eliminated 
UDP phosphate group.  The inositol-1-P is presumably held in the correct orientation by the 
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afore-mentioned electrostatic and H-bond interactions of the phosphate (and inositol 
hydroxyl groups) with residues in the active site, thus directing the α-glycosylation. 
 
Dephosphorylation of GlcNAc-Ins-P to generate the substrate for MshB is carried out by the 
as yet unidentified phosphatase, MshA2.  Screening of M. smegmatis MSH-deficient mutant 
libraries with mutant phosphatases proved fruitless.  It is therefore possible that more than 
one mycobacterial phosphatase with MshA2 activity exists.  Even alkaline phosphatase has 
been shown to be capable of dephosphorylating GlcNAc-Ins-P.45,47 Consequently, MshA2 
may not be a viable target for tuberculosis drug development, and it continues to remain 
uncharacterised.  
 
The requirement of MshA for the production of mycothiol was established in Streptomyces 
coelicolor, a member of the actinobacteria that also produces mycothiol.48  The study was 
able to identify the homologues of mshA, mshB, mshC and mshD in the Streptomyces 
genome, and they were shown to serve the same role as their corresponding genes in the 
mycobacteria.  The production of mycothiol was halted when the mshA gene was disrupted 
by PCR mutagenesis, and then fully restored when the mutant was complemented with the 
mshA gene.  This finding established that MshA is necessary for the production of mycothiol 
within this organism.  Extension of this finding to include the mycobacteria was done by 
Fahey and co-workers,49 who demonstrated the requirement of MshA for the production of 
MSH in M. smegmatis.  A subsequent study confirmed the requirement of the mshA gene for 
the growth of M. tuberculosis Erdman.50  These results indicate that MshA is a viable drug 
target. 
 
1.2.3 Mycothiol Deacetylase, MshB 
 
MshB, the deacetylase responsible for converting GlcNAc-Ins to the free amine, GlcN-Ins, is 
a zinc metalloprotein and a homologue of mycothiol S-conjugate amidase, Mca, since both 
enzymes cleave the glucosamine amide bond (see below for a more detailed description of 
Mca).51  The proposed catalytic mechanism based on the crystal structure is illustrated 
below in Scheme 3.   
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Scheme 3. Catalytic mechanism for deacetylation of GlcNAc-Ins by MshB52 
 
The reaction is initiated by deprotonation of a molecule of water, by the conserved Asp15 
residue.  Coordination of the amide carbonyl to the zinc atom results in enhanced 
electrophilicity at the carbonyl carbon, which is attacked by the generated hydroxide.  The 
resulting negative charge on the amide oxygen is stabilised by coordination to the phenolic 
proton of Tyr142.  This function was initially thought to performed by Asp146, but this has 
recently been shown to be too far from the active site to perform such a role.52  Conversion 
of the tetrahedral intermediate to the reaction products proceeds by protonation of the 
departing free amine by His144. 
 
A study of the substrate specificity of MshB led to several interesting findings (Figure 4).  
The des-myo-inositol substrate had a 70-fold decrease in activity over the natural substrate, 
clearly illustrating the importance of that subunit.  Mycothiol was shown to be a very poor 
substrate with a relative activity of just 0.3.  This is an interesting result, which indicates a 
highly necessary adaptation that precludes MshB from undoing the work of the subsequent 
mycothiol biosynthetic enzymes.  As mentioned above, there is some overlap of activity with 
Mca, and some of the MSR-type substrates of Mca were shown to be reasonable substrates 
for MshB as well, albeit with lower rates of cleavage than the natural substrate.  Surprisingly, 
the monobimane derivative, CySmB-GlcN-Ins was 60 times more reactive with MshB than 
Mca, and was almost 5 times more reactive with MshB than the substrate, GlcNAc-Ins.  This 
is presumably due to favourable interactions of the bimane or the cationic amine with 
residues near to the active site. 
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Figure 4. Activities (nmol/min/mg) of M. tuberculosis MshB and Mca (where available) with various 
substrates at 0.1 mM53 
 
The overlap in amidase activity between MshB and Mca has been proposed to explain the 
redundancy of MshB as a crucial enzyme in the production of MSH.  Disruption of mshB in 
M. smegmatis caused the levels of MSH production to fall to 5-10% of that of the parent 
strain, but not to completely cease, suggesting that another enzyme is capable of carrying 
out the GlcNAcIns deacetylation.  Epichromosomal expression of Mca in the mshB mutants 
did not restore MSH levels to those of the parent strain, suggesting that perhaps Mca was 
not the complementary deacetylase responsible for the background production of MSH.54  
However, a recent comprehensive study performed by Jacobs and co-workers55 on the 
independent deletion mutants for all four genes involved in MSH biosynthesis in M. 
smegmatis, demonstrated that mshA and mshC single deletion mutants produced no MSH, 
the mshB deletion mutant generated decreased levels of MSH, and the double mshB- and 
mca-mutant completely ceased production of MSH.  This study also demonstrated that MSH 
production was essential for isoniazid (INH) and ethionamide (ETH) susceptibility in M. 
smegmatis, with MSH-deficient mutants being resistant to both INH and ETH, whereas the 
low levels of MSH produced by the mshB mutant were sufficient to convey sensitivity to INH 
but not to ETH.  This appears to implicate MSH in the activation of these two prodrugs. 
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1.2.4 Mycothiol Cysteine Ligase, MshC 
 
The fourth step in the biosynthesis of MSH involves coupling of L-cysteine to the amine 
group of GlcN-Ins, carried out by the mycothiol cysteine ligase, MshC.  The enzyme activity 
was first discovered by Steenkamp and co-workers41 from crude M. smegmatis cell extracts.  
Purified enzyme was then obtained by Fahey and co-workers56 after purification of ligase 
activity from M. smegmatis cell extracts, followed by N-terminal sequencing, and cloning and 
expression of the identified gene.  MshC is a homologue of cysteine tRNA synthetase due to 
its mode of activating cysteine by forming a cysteine-AMP intermediate, which is 
subsequently attacked by the GlcN-Ins amine resulting in the formation of the amide product 
(Scheme 4).56  
 
Scheme 4. Mechanism of mycothiol cysteine ligase 
 
As such, MshC has been shown to be inhibited by the cysteine adenylate analogue, 5’-O-[N-
(L-cysteinyl) sulfamoyl]adenosine (Figure 5), which is a known cysteine and proline tRNA 
synthetase inhibitor, having an ATP competitive inhibition constant of 304±40 nM against 
His-tagged M. smegmatis MshC.57  The crystal structure of M. smegmatis MshC was 
elucidated by Blanchard and co-workers in 2008.58 
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Figure 5. Chemical structure of cysteine adenylate and its sulfamoyl derivative, a nanomolar inhibitor 
of tRNA synthetases  
 
The importance of MshC for the growth of Mtb was demonstrated by the combined findings 
of two studies.  Firstly, a study by Av-Gay and co-workers59 confirmed the importance of 
MshC for the growth of mycobacteria.  M. smegmatis MSH-deficient mutants were 
developed by both chemical and transposon mutagenesis, and consequently lacked MshC 
activity.  They were found to be more sensitive to alkylating agents, oxidative stress and had 
a 3- to 16-fold enhanced sensitivity to a range of antibiotics including penicillin G, 
erythromycin, vancomycin and azithromycin over the wild-type strain.  This demonstrated the 
importance of MSH for the protection of M. smegmatis against such stresses.  Supporting 
the later findings of Jacobs and co-workers,55 these mutant strains demonstrated a 16- to 
125-fold enhanced resistance to isoniazid, further confirming the involvement of MSH in the 
activation of the isoniazid prodrug.  Secondly, a study by Fahey and co-workers discovered 
that after targeted disruption of the native mshC gene in M. tuberculosis Erdman, no viable 
clones possessing MSH were found.60  This was found to be reversible, and when the mshC 
gene was inserted into the chromosome, normal levels of MSH were produced and the 
clones survived.  These studies suggest that MshC, and mycothiol, are essential for 
mycobacterial survival and pose a viable drug target for future drug development. 
 
1.2.5 Mycothiol Synthase, MshD 
 
Mycothiol synthase, also referred to as mycothiol acetyltransferase or MshD, is the fifth and 
final enzyme involved in the biosynthesis of MSH, and catalyses acetylation of the amino 
group of Cys-GlcN-Ins with acetyl-CoA.47 The presence of MshD activity was first 
demonstrated in M. smegmatis,41 and the purified Mtb enzyme was later cloned in 
Escherichia coli (E. coli). 61  A study of the M. smegmatis transposon mutagenesis mutant, 
mshD::Tn5, lacking the mshD gene, showed that it produced only 1% of the normal amount 
of MSH and accumulated high levels of Cys-GlcN-Ins.  This demonstrated the importance of 
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the enzyme in the biosynthesis of MSH.  Another study on mshD::Tn5 showed that in the 
absence of MSH, two novel thiols were formed, N-formyl-Cys-GlcN-Is and N-Succinyl-Cys-
GlcN-Ins, that acted as surrogates for MSH and enabled the mutant to resist oxidative 
challenge by peroxides.62  However, under a simulated macrophage environment, N-formyl-
Cys-GlcN-Ins was found to be incapable of supporting normal cell growth of an mshD-
deficient mutant of M. tuberculosis.63  These findings seem to suggest that MshD is a 
potential target for drug development, and since the crystal structure is known, structure-
based design of small molecule inhibitors should be possible.64 A catalytic mechanism, 
based upon the crystal structure of the mixed disulfide of Cys-GlcN-Ins and CoA and on the 
pH dependence of enzyme activity was proposed, and is illustrated below in Scheme 5.  
Glu234 is proposed to act as a general base that initiates a proton transfer from the substrate 
via an interstitial water molecule, which promotes nucleophilic attack of the acetate thioester 
by the substrate amine.  Electrophilicity of the acetate carbonyl carbon is enhanced by 
coordination to the amine of Leu238.  Finally, a proton transfer from Tyr294 releases CoA in 
the thiol form (CoASH) and produces MSH.47 
 
COO
E234
H2O H2N-Cys-GlcN-Ins
S
O
CoA
HO
Y294
COOH
E234 H2O HN-Cys-GlcN-Ins
H
S CoA
OY294
NHL238 O
 
 
Scheme 5. MshD active-site mechanism of acetyl transfer from acetyl-CoA to Cys-GlcN-Ins47 
 
1.2.6 Mycothiol S-Conjugate Amidase, Mca  
 
When MSH reacts with an intracellular toxin, it forms a mycothiol S-conjugate, which is 
subsequently cleaved by the enzyme, mycothiol S-conjugate amidase, or Mca, at the 
glucosamine amide bond to cysteine (details of process summarised in Figure 6 below).  
Upon cleavage, a mercapturic acid conjugate (AcCySR) of the form, Cys-toxin, is formed 
and subsequently excreted from the cell.  The liberated GlcN-Ins is recycled back into the 
mycothiol biosynthetic pathway as a substrate for MshC.  Mca was first isolated from M. 
smegmatis and analysis of its N-terminal sequence was used to identify the orthologous 
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gene in M. tuberculosis, which was subsequently cloned and expressed and found to be a 
zinc-dependent protein.65   
 
Substrate specificity of Mca is reserved for the MSH functionality of substrate conjugates, 
and those lacking the N-acetyl or inositol groups have a 900-fold reduction in activity.  
Replacement of the N-acetyl with an N-formyl results in a 20-fold drop in activity.  A wide 
range of substituents on the sulfur are tolerated, as would be expected from the range of 
xenobiotic particles likely to be intercepted by MSH.  Aryl CH2 groups attached to the sulfur 
are the most reactive, whilst MSH itself is poorly active and has been shown to inhibit Mca at 
intracellular millimolar concentration levels.66 
mBBr
mBBr
MSH MSmB
Mca
GlcN-Ins    +   AcCySmB
AcCySmB
mercapturic acid
ATP, Cys
AMP, PPi
Cys-GlcN-Ins
MshC
AcCoA
CoA
MshD
extracellular
intracellular
 
Figure 6. Mycothiol-dependent detoxification pathway of MCA with a simulated toxin, 
monobromobimane (mBBr).   The thiol-reactive reagent mBBr reacts with MSH to form MSmB, which 
is cleaved by Mca to generate GlcN-Ins and the mercapturic acid, AcCySmB, which is subsequently 
excreted.  The generated GlcN-Ins is recycled back into the MSH biosynthetic cycle as a substrate for 
MshC.47 
 
Mca has potential as a drug target due to its unique role in the MSH detoxification pathway.  
A mutant of M. smegmatis lacking the mca gene was reported by Av-Gay and co-workers67 
to lack amidase activity and to accumulate MSH conjugates of mBBr inside the cell, in 
contrast to the wild-type strain that rapidly cleaved off and excreted the bimane mercapturic 
acid.  The mutant was also shown to have enhanced sensitivity to alkylating agents and 
several antibiotics.35  In a separate study, Bewley and co-workers68 screened 1500 natural 
product extracts and identified several inhibitors of Mca as lead compounds.  Two 
bromotyrosine-derived compounds were shown to be competitive inhibitors of Mca, and after 
a library of related bromotyrosine derivatives were prepared and screened, one lead 
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compound, EXEG1706, was shown to display low inhibitory values against a number of 
bacterial organisms, including M. smegmatis and M. bovis BCG.69,70  This demonstrated the 
broad spectrum of activity of this class of compounds and a lack of specificity for Mca, which 
is not necessarily a negative attribute for such inhibitors since in order to inhibit MSH-related 
amidase activity, inhibition of both Mca and MshB is required.   
 
OH2N
Br
Br
N
O
HN
N
H
NH2
NH
OH
OH3N
Br
Br
N
O
HN
N
H
NH2
NH2
OH
CF3COO
CF3COO
EXEG1706
H
 
Figure 7. Chemical structures of hydroxamate inhibitors of Mca. H, a bromotyrosine alkyloid from the 
marine sponge Oceanapia sp., and a related synthetic analogue, EXEG1706. 
 
 
1.2.7 Mycothiol Disulfide Reductase, Mtr 
 
During the natural process of redox buffering, MSH is oxidised to its symmetrical disulfide 
MSSM.  Regeneration of the active thiol monomer from MSSM is carried out by the 
flavoprotein, mycothiol disulfide reductase or Mtr (also called mycothione reductase).  Mtr 
maintains a high thiol:disulfide ratio by the reduction of MSSM using  NADPH as a co-factor.  
This process occurs in a similar manner to that of the glutathione- (GR) and trypanothione-
reductase (TryR) pathways found in eukaryotes and Gram negative bacteria, and 
trypanosomes, respectively.40  Mtr appears to have a considerable degree of specificity 
towards disulfide substrates, although it is able to tolerate substitutions at some sites better 
than others (Table 3).  Due to the scarcity of the natural substrate, Mtr was first 
characterised using the truncated substrate des-myo-inositol mycothiol disulfide, which first 
demonstrated the non-essentiality of the inositol substituent.71,72  It was also found that the 
inositol could be replaced by a methyl or benzyl without considerable loss of activity.73  Since 
the synthesis of the GlcN-Ins with the Ins in the correct stereochemical orientation is non-
trivial, this provides a synthetically accessible route for the preparation of potential Mtr 
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inhibitors.  Substitutions at the cysteinyl amine, including removal of the acetate or its 
replacement by a formyl or succinyl residue, however, were found to result in considerable 
loss of activity.62  NADPH and NADH are both tolerated as co-factors, although NADH has a 
20-fold lower activity than NADPH.   
  
Table 3. Relative activities of various disulfides with Mtr, using NADPH as a co-factor, MSSM rate 
normalized to 100 (adapted from Newton et al)47 
 
Thiol source of disulfide     Relative rate 
AcCys-COOH.............................................................................. <10-3 
AcCys-COOCH3 ......................................................................... <10-3 
AcCys-GlcN (DI-MSH)................................................................ 6,a 25b 
AcCys-GlcN-1-O-CH3................................................................. 15b 
AcCys-GlcN-1-O-CH2Ph............................................................. 68b 
AcCys-GlcN-Ins (MSH)............................................................... 100 
HCO-Cys-GlcN-Ins...................................................................... 13c 
Cys-GlcN-Ins............................................................................... ≤4c 
HOOCCH2CH2CO-Cys-GlcN-Ins............................................... 0.8c 
a From reference 72 
b From reference 73 
c From reference 62 
 
Kinetic studies on M. tuberculosis Mtr have provided a detailed mechanism for the reduction 
of MSSM, which has been proposed to proceed by an analogous route to GR and TryR.  
The mechanism is described below in Scheme 6.  Binding of NADPH to the oxidised enzyme 
is fast and is followed by transfer of a hydride to the flavin adenine dinucleotide (FAD) and 
reduction of the active-site disulfide.  The thiolate anions are stabilised by the FAD and 
His444, respectively.  NADP is then lost and binding of MSSM leads to cleavage of the 
substrate disulfide with liberation of one equivalent of MSH and the formation of a mixed 
disulfide between the active-site Cys39 thiolate and the substrate.  This is then reduced to 
liberate a second equivalent of MSH and regenerate the active-site disulfide. 
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Scheme 6.  Mechanism of Mtr40 
 
It is currently uncertain whether Mtr is essential for the growth of mycobacteria.  A Himar-1 
transposon mutagenesis screen indicated that Mtr is essential to the survival of the Mtb 
H37Rv strain.74  However, it has also been reported that an Mtb transposon mutant in mtr 
was viable, suggesting it is non-essential.75 Full phenotypic characterisation of an 
actinomycete mtr mutant, which would be able to give a clearer picture, has not yet been 
reported.35  Further investigation by Hayward and co-workers76 reported that application of 
antisense M. tuberculosis mtr oligonucleotides produced a 66% drop in the growth index 
after 7 days’ incubation, relative to the control culture.   
 
Transcriptional analysis of the related organism, M. bovis BCG, revealed that mtr is actively 
transcribed during growth, but that mtr mRNA is absent in the stationary phase, suggesting 
its necessity for maintaining the redox balance is limited to the growth phase,76 although Av-
Gay and co-workers35,77 have also reported that MSH levels remain high during the 
stationary phase, suggesting disulfide reductase activity. It is possible that there is a 
homologous thiol reductase within Mtb capable of performing a substitutionary role for Mtr in 
a similar manner to that of thioredoxin reductase which is capable of reducing glutathione 
disulfide.78,79 
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Since the discovery of Mtr over a decade ago,71,72 neither the crystal structure nor Mtr-
specific inhibitors have been reported, and these represent important areas for future study. 
Several quinones have been shown to function as “subversive substrates” of Mtr, through 
promotion of redox cycling and the subsequent generation of superoxide, and are toxic to 
mycobacteria.  Similar subversive substrates have been shown to act against the analogous 
GR and TryR targets.80,81 Mtr itself recognises a range of quinone and naphthoquinone 
derivatives as subversive substrates and therefore this pathway provides a potential strategy 
for the development of antitubercular chemotherapeutic agents.72  
 
1.2.8 Glyoxalase 
 
The ubiquitously present glyoxalase (Glx) system is responsible for the detoxification of 
methylglyoxal (MG), an unavoidable side product of glycolysis.82,83  MG is formed during 
glycolysis when the deprotonation of dihydroxyacetone phosphate (DHAP) by triose 
phosphate isomerase (TIM) results in phosphate elimination rather than protonation and 
equilibration to the aldehyde (Scheme 7).84  While protonation takes place considerably 
more frequently than phosphate elimination, a high cellular concentration of TIM can result in 
the accumulation of large quantities of MG.  Due to the reactive nature of MG and its ability 
to form adducts with proteins and nucleic acids, inhibit protein biosynthesis and generate 
advanced glycation endproducts,85,86 the Glx system is crucial to maintaining the integrity of 
the cell. 
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Scheme 7. The triose phosphate isomerase (TIM) pathway leading to the formation of methylglyoxal 
(MG) (with elimination of inorganic phosphate, Pi) and D-glyceraldehyde-3-phosphate (DGAP) from 
dihydroxyacetone phosphate (DHAP)84 
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In organisms that produce glutathione, GlxI is a metal-dependant isomerase that converts 
the methylglyoxal thiohemiacetal of glutathione to S-D-lactoylglutathione via an enediolate 
intermediate.  GlxII completes the cycle by the hydrolysis of S-D-lactoylglutathione to 
regenerate GSH and form D-lactate (Scheme 8). 83,87  GSH may be substituted with alternate 
low molecular weight thiols in different organisms, such as trypanothione in the 
trypanosomatidae, or mycothiol in the actinomycetes.  In such cases, the essential function 
of the Glx system remains the same, with the thiol forming a thiohemiacetal with MG, and 
ultimately being regenerated by GlxII.   
 
H
CH3
O
O
Methylglyoxal (MG)
+ CH3
O
GS
H
HO
Thiohemiacetal
GlxI
OH
CH3
GS
O
GS
OH
O
CH3
GS
O
CH3
HO H
S-D-lactoyl
glutathione
O
CH3
O
HO H
GlxII
H2O
+   GSH
Enediolate intermediate
HOOC
N
H
O
HS
H
N
O
COOH
NH2
Glutathione
 
Scheme 8. Glutathione-dependent detoxification of MG by the two enzyme glyoxalase (Glx) system, 
composed of GlxI and GlxII 
 
The Glx enzyme system has been identified in a wide range of organisms including 
humans,88 yeast,89,90 plants,91 insects,83 protozoa (including trypanosomatids)92,93, and over 
forty bacterial species83,94 (including E. coli).95,96  The presence of a glyoxalase pathway in 
such a diverse range of organisms supports the possibility of its presence in the 
mycobacteria.  The discovery of such a pathway and the enzymes involved would 
provide a novel target for the development of anti-mycobacterial agents due to its 
essential role in the removal of cytotoxic MG.   
 
The glyoxalase enzyme system of Trypanosoma and Leishmania parasitic protozoa is 
distinct from glutathione-dependent homologues in their dependence on the dithiol, 
trypanothione (Figure 8), for detoxifying MG.97,98,99 A second difference between the two 
enzyme systems is the metal cofactor, with the Trypanosome GlxI having a nickel centre and 
the eukaryote GlxI having a zinc centre. These differences indicate a considerable variation 
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between the active sites of the Trypanosomatid enzyme and that of the mammalian 
counterpart, which suggests that the Glx system of the protozoan parasite is a potential 
chemotherapeutic target.93   
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H
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H
HOOC
O
NH2
NH2
S
S HN
O
 
Figure 8.  Chemical structure of trypanothione 
 
Similarly, an as yet undescribed mycothiol-dependent glyoxalase system may exist within 
the mycobacteria, and could provide a viable target for chemotherapy with the basis for drug 
selectivity based on the large structural difference that exists between MSH and GSH and 
the likely divergent substrate specificity that would exist between the two Glx systems.  The 
search for such a mycobacterial GlxI is described further in Chapter 5. 
 
1.3 Aims and Objectives 
 
The aims of this project were to synthesise several naphthoquinone- and carbazole-1,4-
quinone-derived conjugates of a mycothiol-like scaffold that would act as redox cycling 
subversive substrates of the enzyme, Mtr, or potentially inhibit other mycothiol-dependent or 
biosynthetic enzymes, in order to develop novel antitubercular lead compounds.  The 
synthesis of these compounds is described in Chapter 2 (naphthoquinone derivatives) and 
Chapter 3 (carbazole-1,4-quinone derivatives).  The cloning, expression and purification of 
Mtr, in order to generate purified enzyme on which to evaluate the activity of the conjugates, 
is described in Chapter 4.  A further investigation towards the cloning, expression, and 
purification of a mycobacterial GlxI was also undertaken, and is described in Chapter 5. 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 1. Introduction 
24 
 
                                               
References 
 
1. World Health Organisation Factsheet No. 104, November 2010, 
http://www.who.int/mediacentre/factsheets/fs104/en/index.html 
2. L.G. Wayne, Infect. Immun., 1977, 17, 528-530 
3. B.M. Madison, Biotech. Histochem., 2001, 76, 119-125 
4. E.N.G. Houben, L. Nguyen and J. Pieters, Curr. Opin. Microbiol., 2006, 9, 76–85 
5. S.H. Kaufmann and A.J. McMichael, Nat. Med., 2005, 11, S33–S44 
6. J.-L. Herrmann and P.-H. Lagrange, Pathol. Biol., 2005, 53, 35–40 
7. (a) I. Vergne, J. Chua, H.-H. Lee, M. Lucas, J. Belisle and V. Deretic, PNAS, 2005, 102, 
4033-4038; (b) V. Deretic, S. Singh, S. Master, J. Harris, E. Roberts, G. Kyei, A. Davis, S. de 
Haro, J. Naylor, H.-H. Lee, I. Vergne, Cell Microbiol., 2006, 8, 719-727 
8. Global Tuberculosis Report 2011, World Health Organisation, 
http://www.who.int/tb/publications/global_report/en/index.html 
9. D.A. Rozwarski, G.A. Grant, D.H. Barton, W.R. Jacobs, Jr. and J.C. Sacchettini, Science, 
1998, 279, 98–102 
10. F. Wang, P. Jain, G. Gulten, Z. Liu, Y. Feng, K. Ganesula, A.S. Motiwala, T.R. Ioerger, D. 
Alland, C. Vilchèze, W.R. Jacobs Jr. and J.C. Sacchettini, Antimicrob. Agents Chemother., 
2010, 54, 3776-3782 
11. E.A. Campbell, N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb and S.A. Darst, 
Cell, 2001,104, 901–912 
12. P.J. Brennan and H. Nikaido, Annu. Rev. Biochem., 1995, 64, 29-63  
13. K. Takayama and J.O. Kilburn, Antimicrob. Agents Chemother., 1989, 33, 1493-1499 
14. K. Mikusova, R.A. Slayd n, G.S. Besra and P.J. Brennan, Antimicrob. Agents Chemother. 
1995, 39, 2484-2489 
15. A.E. Belanger, G.S. Besra, M.E. Ford, K. Mikusova, J.T. Belisle, P.J. Brennan and J.M. 
Inamine, PNAS, 1996, 93, 11919-11924 
16. Hong Kong Chest Service/British Medical Research Council, Lancet, 1981, 317, 171-174 
17. Y. Zhang and D. Mitchison, Int. J. Tuberc. Lung Dis., 2003, 7, 6-21 
18. (a) O. Zimhony, J.S. Cox, J.T. Welch, C. Vilchèze and W.R. Jacobs, Jr, Nature Medicine, 
2000, 6, 1043-1047; (b) O. Zimhony, C. Vilchèze, M. Arai, J.T. Welch and W.R. Jacobs, Jr., 
Antimicrob. Agents Chemother., 2007, 51, 752–754 
19. P. Lu, A.C. Haagsma, H. Pham, J.J. Maaskant, S. Mol, H. Lill, D. Bald, Antimicrob. Agents 
Chemother., 2011, 55, 5354-5357 
20. W. Shi, X. Zhang, X. Jiang, H. Yuan, J.S. Lee, C.E. Barry 3rd, H. Wang, W. Zhang, Y. Zhang, 
Science, 2011, 333, 1630-1632 
21. I. Chopra and P. Brennan, Tubercle Lung Dis., 1998, 78, 89-98 
22. F.C. Neuhaus and J.L. Lynch, Biochemistry, 1964, 3, 471-480 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 1. Introduction 
25 
 
                                                                                                                                                  
23. H.L. David, A. Laszlo and N. Rastogi, Acta Leprol., 1989, 7, 189-194 
24. J.A. Caminero, G. Sotgiu, A. Zumla and G.B. Migliori, Lancet Infect. Dis., 2010, 10, 621-629 
25. A. Banerjee, E. Dubnau, A. Quemard, V. Balasubramanian, K.S. Um, T. Wilson, D. Collins, G. 
de Lisle and W.R. Jacobs, Jr., Science, 1994, 263, 227-230 
26. P.E.A. Da Silva and J.C. Palomino, J. Antimicrob. Chemother., 2011, 66, 1417-1430 
27. F. Wang, R. Langley, G. Gulten, L.G. Dover, G.S. Besra, W.R. Jacobs, Jr. and J.C. 
Sacchettini, J. Exp. Med., 2007, 204, 73-78 
28. J.A. Caminero, Int. J. Tuberc. Lung Dis., 2006, 10, 829–837 
29. E.D. Chan, V. Laurel, M.J. Strand, J.F. Chan, M.-L.N. Huynh, M. Goble and 
 M.D. Iseman, Am. J. Respir. Crit. Care Med., 2004, 169, 1103-1109 
30. A.S. Ginsburg, J.H. Grosset, W.R. Bishai, Lancet Infect. Dis., 2003, 3, 432-442 
31. K. Drlica, Curr. Opin. Microbiol., 1999, 2, 504-508 
32. World Health Organisation (2006). Press release, 
http://www.who.int/mediacentre/news/notes/2006/np29/en/index.html 
33. (a) H. Cox and C. McDermid, Lancet, 2008, 372, 1363-1365; (b) S. Keshavjee, I.Y. 
Gelmanova, P.E. Farmer, S.P. Mishustin, A.K. Strelis, Y.G. Andreev, A.D. Pasechnikov, S. 
Atwood, J.S. Mukherjee, M.L. Rich, J.L. Furin, E.A. Nardell, J.Y. Kim and S.S. Shin, Lancet, 
2008, 372, 1403-1409 
34. N.R. Gandhi, A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews 
and G. Friedland, Lancet, 2006, 368, 1575–1580 
35. M. Rawat and Y. Av-Gay, FEMS Microbiol. Rev., 2007, 31, 278-292 
36. G.L. Newton, K. Arnold, M.S. Price, C. Sherrill, S.B. delCardayré, Y. Aharonowitz, G. Cohen, 
 J. Davies, R.C. Fahey and C. Davis, J. Bacteriol., 1996, 178, 1990-1995 
37. H.S.C. Spies and D.J. Steenkamp, Eur. J. Biochem., 1994, 224, 203-213 
38. S. Sakuda, Z.-Y. Zhou, Y. Yamada, Biosci. Biotech. Biochem., 1994, 58, 1347-1348 
39. G.M. Nicholas, P. Kováč and C.A. Bewley, J. Am. Chem. Soc., 2002, 124, 3492-3493 
40. V.K. Jothivasan and C.J. Hamilton, Nat. Prod. Rep., 2008, 25, 1091-1117 
41. C. Bornemann, M.A. Jardine, H.S.C. Spies and D.J. Steenkamp, Biochem.J., 1997, 325, 623-
 629 
42. G.L. Newton, Y. Av-Gay and R.C. Fahey, J. Bacteriol., 2000, 182, 6958-6963 
43. D. Sareen, M. Steffek, G.L. Newton and R.C. Fahey, Biochemistry, 2002, 41, 6885-6890 
44. T. Koledin, G.L. Newton and R.C. Fahey, Arch. Microbiol., 2002, 178, 331-337 
45. M.W. Vetting, P.A. Frantom and J.S. Blanchard, J. Biol. Chem., 2008, 283, 15834-15844 
46. G.L. Newton, P. Ta, K.P. Bzymek and R.C. Fahey, J. Biol. Chem., 2006, 281, 33910-33920 
47. G.L. Newton, N. Buchmeier and R.C. Fahey, Microbiol. Mol. Biol. Rev., 2008, 72, 471-494  
48. J.H. Park, C.J. Cha and J.H. Roe, J. Microbiol., 2006, 44, 121-125 
49. G.L. Newton, T. Koledin, B. Gorovitz, M. Rawat, R.C. Fahey and Y. Av-Gay, J. Bacteriol., 
 2003,185, 3476-3479 
50. N. Buchmeier and R.C. Fahey, FEMS Microbiol. Lett., 2006, 264, 74-79 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 1. Introduction 
26 
 
                                                                                                                                                  
51. J.T. Maynes, C. Garen, M.M. Cherney, G.L. Newton, D. Arad, Y. Av-Gay, R.C. Fahey and 
 M.N. James, J. Biol. Chem., 2003, 278, 47166-47170 
52. X. Huang and M. Hernick, J. Biol. Chem., 2012, DOI: 10.1074/jbc.M111.320184 
53. G.L. Newton, M. Ko, P. Ta, Y. Av-Gay and R.C. Fahey, Protein Expres. Purif., 2006, 47, 542–
 550 
54. M. Rawat, S. Kovacevic, H. Billman-Jacobe and Y. Av-Gay, Microbiology, 2003, 149, 1341-
 1349 
55. X. Xu, C. Vilchèze, Y. Av-Gay, A. Gómez-Velasco and W.R. Jacobs, Jr, Antimicrob. Agents 
 Chemother., 2011, 55, 3133-3139 
56. D. Sareen, M. Steffek, G. L. Newton and R. C. Fahey, Biochemistry, 2002, 41, 6885–6890 
57. F. Fan, A. Luxenburger, G.F. Painter and J.S. Blanchard, Biochemistry, 2007, 46, 11421-
 11429 
58. L.W. Tremblay, F. Fan, M.W. Vetting and J.S. Blanchard, Biochemistry, 2008, 47, 13326-
 13335 
59. M. Rawat, G.L. Newton, M. Ko, G.J. Martinez, R.C. Fahey, Y. Av-Gay, Antimicrob. Agents 
 Chemother., 2002, 46, 3348-3355 
60. D. Sareen, G.L. Newton, R.C. Fahey and N.A. Buchmeier, J. Bacteriol., 2003, 185, 6736-
 6740 
61. T. Koledin, G.L. Newton and R.C. Fahey, Arch. Microbiol., 2002, 178, 331-337 
62. G.L. Newton, P. Ta and R.C. Fahey, J. Bacteriol., 2005, 187, 7309-7316 
63. N.A. Buchmeier, G.L. Newton and R.C. Fahey, J. Bacteriol., 2006, 188, 6245-6252 
64. M.W. Vetting, S.L. Roderick, M. Yu and J.S. Blanchard, Protein Sci., 2003, 12, 1954-1959 
65. G.L. Newton, Y. Av-Gay and R.C. Fahey, Biochemistry, 2000, 39, 10739-10746 
66. M. Steffek, G.L. Newton, Y. Av-Gay and R.C. Fahey, Biochemistry, 2003, 42, 12067-12076 
67. M. Rawat, M. Uppal, G. Newton, M. Steffek, R.C. Fahey and Y. Av-Gay, J. Bacteriol., 2004, 
 186, 6050-6058 
68. G.M. Nicholas, L.L. Eckman, G.L. Newton, R.C. Fahey, S. Ray and C.A. Bewley, Bioorg. 
 Med. Chem., 2003, 11, 601-608 
69. G.M. Nicholas, G.L. Newton, R.C. Fahey and C.A. Bewley, Org. Lett., 2001, 3, 1543-1545 
70. N. Pick, M. Rawat, D. Arad, J. Lan, A.S. Kende and Y. Av-Gay, J. Med. Microbiol., 2006, 55, 
 407-415 
71. M.P. Patel and J.S. Blanchard, J. Am. Chem. Soc., 1998, 120, 11538-11539 
72. M. P. Patel and J. S. Blanchard, Biochemistry, 1999, 38, 11827-11833 
73. M.J.G. Stewart, V.K. Jothivasan, A.S. Rowan, J. Wagg and C.J. Hamilton, Org. Biomol. 
 Chem., 2008, 6, 385-390 
74. C. Sassetti, D. Boyd, E. Rubin, Mol. Microbiol., 2003, 48, 77-84 
75. R.A. McAdam, S. Quan, D.A. Smith, S. Bardarov, J.C. Betts, F.C. Cook, E.U. Hooker, A.P. 
 Lewis, P. Woollard, M.J. Everett, P.T. Lukey, G.J. Bancroft, W.R. Jacobs Jr., K. Duncan, 
 Microbiology, 2002, 148, 2975-2986 
76. D. Hayward, I. Wiid and P.D. van Helden, IUBMB Life, 2004, 56, 131-138 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 1. Introduction 
27 
 
                                                                                                                                                  
77. M. Rawat, S. Kovacevic, H. Billman-Jacobe and Y. Av-Gay, Microbiology, 2003, 149, 1341-
 1349 
78. S.M. Kanzok, A. Fechner, H. Bauer, J.K. Ulschmid, H.M. Muller, J. Botella-Munoz, S. 
 Schneuwly, R. Schirmer and K. Becker, Science, 2001, 291, 643-646 
79. G. Salinas, M.E. Selkirk, C. Chalar, R.M. Maizels and C. Fernandez, Trends Parasitol., 2004, 
 20, 340-346 
80. C. Biot, H. Bauer, R.H. Schirmer and E. Davioud-Charvet, J. Med. Chem., 2004, 47, 5972-
 5983 
81. L. Salmon-Chemin, E. Buisine, V. Yardley, S. Kohler, M.A. Debreu, V. Landry, C. 
 Sergheraert, S.L. Croft, R.L. Krauth-Siegel and E. Davioud-Charvet, J. Med. Chem., 2001, 44, 
 548-565. 
82. I.A. Rose and J.S. Nowick, J. Am. Chem. Soc., 2002, 124, 13047-13052 
83. P.J. Thornalley, Biochem. Soc. Trans., 2003, 31, 1343-1348 
84. J.P. Richard, Biochem. Soc. Trans., 1993, 21, 549-553 
85. S.R. Thorpe and J.W. Baynes, Drug. Aging, 1996, 9, 69–77 
86. M. Krautwald and G. Münch, Exp. Gerontol., 2010, 45, 744-751 
87. I.R. Booth, G.P. Ferguson, S. Miller, C. Li, B. Gunasekera, S. Kinghorn, Biochem. Soc. 
 Trans., 2003, 31, 1406-1408 
88. a) A.D. Cameron, M. Ridderstrom, B. Olin, B. Mannervick, Structure, 1999, 7, 1067-1078; b) 
 A.D. Cameron, B. Olin, M. Ridderstrom, B. Mannervik, T.A. Jones, EMBO J., 1997, 16, 3386-
 3395; c) A.D. Cameron, M. Ridderstrom, B. Olin, M.J. Kavarana, D.J. Creighton, B. 
 Mannervik, Biochemistry, 1999, 38, 13480-13490 
89. Y. Inoue and A. Kimura, J. Biol. Chem., 1996, 271, 25958-25965 
90. Y. Inoue, K. Maeta, W. Nomura, Semin. Cell Dev. Biol., 2011, 22, 278-284 
91. V.S. Veena Reddy and S.K. Sopory, Plant J., 1999, 17, 385-395 
92. R. Iozef, S. Rahlfs, T. Chang, H. Schirmer and K.Becker, FEBS Lett., 2003, 554, 284-288 
93. S.C. Chauhan, P.K. Padmanabhan, R. Madhubala, Curr Drug Targets, 2008, 9, 957-65 
94. S.L. Clugston, E. Daub and J.F Honek, J. Mol. Evol., 1998, 47, 230-234 
95. M.M. He, S.L. Clugston, J.F. Honek, B.W. Matthews, Biochemistry, 2000, 39, 8719-8727 
96. C.E. Hand, Investigations into Intracellular Thiols of Biological Importance, PhD Thesis, 2007, 
 University of Waterloo, Ontario, Canada 
97. N. Greig, S. Wyllie, T.J. Vickers, A.H. Fairlamb, Biochem. J., 2006, 400, 217-223 
98. T.J.Vickers, N. Greig, A.H. Fairlamb, Proc. Natl. Acad. Sci. USA, 2004, 101, 13186-13191 
99. R.K. Padmanabhan, A. Mukherjee, R. Madhubala, Biochem. J., 2006, 393, 227-234 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
28 
Chapter 2 
Naphthoquinone-Derived Target 
Molecules 
 
2.1 Quinones in Drug Discovery 
 
The quinone scaffold is a common component of many natural products and has been 
shown to display a range of activities including anticancer, antibacterial, antimalarial, 
antifungal and antimycobacterial.1,2,3  The biological activity is derived from the quinone’s 
ability to accept one or two electrons and generate a radical anion or dianion.  Additional 
cytotoxic effects include alkylation of thiols, amines and DNA residues, and oxidation of 
essential protein thiols by activated oxygen species.  The capacity for accepting or donating 
single electrons is influenced by the substituents on the quinone, which modulate the redox 
properties that cause oxidative stress.4  The flavin cofactors in flavoenzymes, such as the 
disulfide reductases, can exist as stable semiquinone radicals. This allows flavoenzymes to 
catalyze the one electron reduction of quinone electron acceptors, such as the 
naphthoquinones, to semiquinones, which in turn can mediate the reduction of molecular 
oxygen to superoxide anion radicals with associated regeneration of the quinone.1,2  This 
redox cycling, with attendant superoxide generation, leads to high levels of hydrogen 
peroxide and cell damage.   
 
Many naphthoquinone drugs, including menadione, plumbagin and lapachol (Figure 1), 
display activity against the trypanosomes responsible for several human parasitic diseases, 
including African sleeping sickness (Trypanosoma brucei rhodesiense and Trypanosoma 
brucei gambiense), Chagas’ disease (Trypanosoma cruzi) and Kala-azar (Leishmania 
donovani).5,6,7  These parasitic protozoa are particularly sensitive to oxidative stress and 
utilize the unique antioxidant, trypanothione, T(SH)2 to maintain redox equilibrium.8  T(SH)2 is 
maintained in its reduced form by the flavoenzyme, trypanothione reductase (TryR), which is 
one of the enzymes targeted by naphthoquinones.  Selectivity of these naphthoquinones for 
TryR over human glutathione reductase (hGR) is reportedly based on charge differences at 
the catalytic sites of the two enzymes.9  Thus the active site of GR has positively charged 
residues that are complimentary to the carboxyl groups of the glycine residues  present in 
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glutathione and these glycines are in amide linkage to spermidine in trypanothione. 1,4-
Naphthoquinones,10,11,12 including menadione and plumbagin,13 have been shown to act as 
subversive substrates of Trypanosoma cruzi TryR by inhibiting the physiological reduction of 
T(S)2 and generating superoxide, following the single-electron reduction of the quinone by 
the flavoprotein, as described above.  Conversely, against GR, 1,4-naphthoquinones largely 
display weak, reversible inhibition.14,15 
O
O
O
OOH
O
O
Menadione Plumbagin Lapachol
OH
 
Figure 1.  Chemical structures of the 1,4-naphthoquinones, menadione, plumbagin and lapachol 
 
By analogy, it should be likely that this class of compounds also displays such subversive 
substrate activity against Mtr, which performs an analogous role to that of GR and TryR.  
Sufficient structural differences between the natural substrates should impart a considerable 
degree of selectivity to such inhibitors, if synthesised in such a way as to incorporate a 
fragment of the substrate through which the selectivity could be derived.   
 
Several 1,4-naphthoquinones were evaluated for their subversive substrate activity against 
Mtr, which was measured as maximum turnover rate (kcat) over the substrate binding 
efficiency (Km).  This value (kcat/Km) was used to compare subversive substrate activity with 
whole cell antitubercular activity, and the results are summarised in Table 1.16 
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Table 1.  Subversive substrate activity (kcat/Km) of naphthoquinones with Mtr compared with whole cell 
antitubercular activity, MIC (µM)17 
 
 
O
OOH
Juglone  
O
OOH
Cl
 
O
OOH
Methyljuglone  
Km (µM) 320 36 250 
kcat/Km (M-1.s-1) 3400 16000 9300 
MIC (µM) 6 22 3 
 
 
O
OOH
O
OOH
Diospyrin  
O
OOH
O
O
OH
Neodiospyrin  
Km (µM) 33 63 
kcat/Km (M-1.s-1) 3600 4900 
MIC (µM) 21 27 
 
 
Although several of these compounds displayed anti-tubercular activity in whole-cell assays, 
and several of them showed good subversive substrate activity, there was no direct 
relationship between the two properties, suggesting that the biological activity was derived 
from interaction with alternate or multiple redox-active proteins and enzymes.  This study 
supported earlier findings that 1,4-naphthoquinones display biological activity against M. 
tuberculosis.3  Despite the lack of selectivity for Mtr, it is conceivable that by attaching a 
mycothiol scaffold to the structure, the naphthoquinone might display enhanced activity 
against Mtr, or against one of the mycothiol biosynthetic enzymes.  This strategy has already 
been explored and reported by Gammon and co-workers,18 who attached a 1,4-
naphthoquinone to a phenylthioglucosamine scaffold to generate a class of inhibitors that 
displayed strong activity against the mycothiol enzymes, MshB and Mca (Figure 2).   
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O
HO
HO
SNH
OH
O
O
O
HO
n
n = 1-4
 
Figure 2. Naphthoquinone-glucosamine conjugates with inhibitory activity against MshB and Mca 
 
Following on from this, similar inhibitors with select structural differences were proposed as 
target molecules for this project, and their design and synthesis is described below. 
 
2.2 Target Molecule Design 
 
The general structure of the naphthoquinone-derived target molecules for this project is 
illustrated below in Figure 3.  This includes a naphthoquinone coupled to a mycothiol-like 
scaffold (glucosamine with N-acetyl cysteine side chain), and a myo-inositol surrogate at the 
anomeric position of the sugar, which could be either a phenylthio or glyceryl unit. Previously 
published findings from our research group have demonstrated the inhibitory activity of 
similar naphthoquinone derivatives, where X=SPh and the NHAc is absent on the linker, 
against the mycothiol enzymes MshB and Mca.18  In this study, the utility of this class of 
inhibitors has been extended to include the enzyme Mtr. 
 
O
HO
HO
NH
OH
XO
OH
O
O
NHAc
n
Mycothiol-like scaffold, n = 1, 2
X = Thiophenol or glycerol
Naphthoquinone radical acceptor/cycler
O
HO
HO
NH
OH
O
HS NHAc
O
HO
OHOH
OH
OH
Mycothiol
 
Figure 3. Chemical structure of MSH and target inhibitors 
 
The structure of the target molecule with n = 1 is similar to MSH, except for the glycosyl 
substituent and the replacement of the sulfhydryl group with a naphthoquinone.  The 
positioning of the electrophilic quinone C=C at the point where the disulfide bond of 
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mycothiol disulfide (MSSM) would be, invites the possibility of alkylation of the Mtr active-site 
thiolate, Cys39-S-.  This thiolate has the native function of liberating free MSH from MSSM by 
nucleophilic attack at one of the sulfurs of the disulfide bond.19,20  There is potential, 
therefore, for this compound to irreversibly inhibit Mtr, in addition to the possibility of acting 
as a subversive substrate.  The naphthoquinone used was 5-hydroxy-2-methyl-1,4-
naphthoquinone, also known as plumbagin (due to its isolation from the plant genus 
Plumbago).  Although several different naphthoquinones with different substitution patterns 
exist, this particular derivative was selected since (i) it is commercially available, (ii) it has a 
methyl at the 2-position thereby controlling substitution of the quinone exclusively at the 3-
position, and (iii) derivatives of this type were shown to display the highest activity as 
subversive substrates against the related enzymes, trypanothione reductase and lipoamide 
dehydrogenase.2  
 
The substrate specificity of Mtr with respect to the N-acyl substituent on the natural 
substrate, MSSM, has been demonstrated by comparative assays of the symmetrical 
disulfides of the N-formyl (fCys-GlcN-Ins), N-succinyl (succ-Cys-GlcN-Ins) and des-acetyl 
(Cys-GlcN-Ins) derivatives of MSSM (Figure 4).21   
 
O
HO
HO
NH
OH
O
HS NH
O
HO
OHOH
OH
OH
R O  
Figure 4. Chemical structure of mycothiol and its acyl derivatives 
 
These results indicated that the relative rates of reaction, relative to MSSM (100 %), were 13 
%, 0.8 % and ≤ 4 %, respectively, for fCys-GlcN-Ins, succ-Cys-GlcN-Ins and Cys-GlcN-Ins.  
This illustrates that an acetate on the cysteinyl amine contributes significantly to binding in 
the active site of Mtr.  Consequently, the design of the target molecules has taken this factor 
into account, and includes an NHAc group in appropriate configuration on the linker between 
the naphthoquinone and glucosamine, derived from aspartic (n = 1, Figure 3) and glutamic 
(n = 2, Figure 3) acids respectively, in order to maximise active-site binding.   
 
The incorporation of the myo-inositol substituent on mycothiol is a laborious, multi-step 
process that requires several selective protecting group manipulations to arrive at the 
product with the correct stereochemistry,22 which is clearly an undesirable factor when trying 
R = CH3 MSH 
R = H fCys-GlcN-Ins 
R = -OOCCH2CH2 Succ-Cys-GlcN-Ins 
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to develop a new drug.  A range of analogues with alternative aglycones has been 
synthesised as substrate analogues of various mycothiol enzymes in order to simplify the 
synthetic route.  These alternative anomeric substituents have included quinic acid,23 
methoxy and benzyloxy groups,24 cyclohexylthiol,25 cyclohexylsulfone,26 and thiophenol,18 
the latter being one of the target aglycones in this project.  Most of these substitutions 
resulted in a significant reduction in active-site binding/activity relative to the natural 
substrate, suggesting that the myo-inositol fragment is a crucial component of substrate 
recognition for the mycothiol biosynthetic enzymes.  It also appears that the correct 1-D-
myo-inositol stereoisomer is required, since the 1-L-myo-inositol isomer was shown to 
display no deacetylase activity as a substrate for MshB.27   
 
Notwithstanding the foregoing evidence for the requirement of the myo-inositol component in 
alternative substrates and/or inhibitors, the practical need for a simplified derivative led to 
consideration of two alternatives.  Firstly, phenylthio-glycosides were considered, due to the 
literature reports of moderate activity of these analogues, and secondly, (2S)-glyceryl 
glycosides, which could be considered to be truncated inositol fragments, with the correct 
stereochemistry in the vicinity of the glycosidic linkage, and with freely rotating hydroxyl 
groups that would be available to participate in active-site hydrogen-bonding, should this be 
a factor, thus maintaining a similar binding affinity to that of the natural substrate (Scheme 
1). 
O
HO
HO
ONH
OH
HO OH
OH
OH
OH
O
NH SH
O
O
HO
HO
ONH
OH
OH
OH
O
HO
HO
ONH
OH
O
O
O
AcO
AcO
HO
N3
OAc
O
O
LG
+
R
R
S
mycothiol  
Scheme 1.  Retrosynthetic analysis of the general structure of a mycothiol derivative with a 
glycerol aglycone.  The theoretical disconnection positions on the 1-D-myo-inositol substituent 
of mycothiol is indicated, illustrating the rationale behind the selection of the (S)-enantiomer of 
isopropylidene glycerol as glycosyl acceptor.  The acetylated 2-azidoglucose with a leaving 
group (LG) at the anomeric position is given as the donor.   
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2.3 Retrosynthetic analysis of Target Molecules 
 
A retrosynthetic analysis of the naphthoquinone-derived target molecules is given below in 
Scheme 2.  The final structure I was envisaged to have been formed from intermediate II, 
after removal of the acetate protecting groups and conversion of the Boc-protecting group to 
the desired acetate.  The requirement of the Boc protecting group was firstly due to a lack of 
commercial availability of the N-acetate, and secondly due to its resistance to cleavage 
under the basic conditions that were used for debenzylation in the second step of the 
synthesis.  Performing a disconnection of II at the C-N bond affords the two amide coupling 
partners, III and IV.  Intermediate III can be obtained from the azido sugar, V, by 
hydrogenation.  This intermediate represents the glycosylated product where X = thiophenol 
or glycerol, both of which are proposed to be prepared from starting material, tetra-O-acetyl 
2-azidoglucose VI.  Disconnection of peptide coupling partner IV at the quinone junction, 
with an oxidative decarboxylation in mind, gives the plumbagin starting material VII and 
selectively-protected aspartic and glutamic amino acids VIII.   
 
O
HO
HO
NH
OH
XO
OH
O
O
NHAc
n
Deprotection,
protecting group 
modification
O
AcO
AcO
NH
OAc
XO
OH
O
O
NHBoc
n
C-N
Amide
O
AcO
AcO
NH2
OAc
X
OOH O
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Scheme 2. Retrosynthetic analysis of the naphthoquinone-derived target molecules 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 2: Naphthoquinone-Derived Target Molecules 
 35 
2.4 Results 
2.4.1 Synthesis of the Glucosamine-Derived Thioglycoside 
 
The synthesis of thioglycoside 2.5, having a selectively unprotected 2-amino group, is 
outlined in Scheme 3 and Scheme 4 below. This compound is a key intermediate in the 
synthesis of a number of target molecules in this project, and its preparation requires the 
amine to be protected or masked as in a non-participating form to facilitate selective 
synthesis of an α–thioglycoside.  The classic 2-azido-glucose approach was thus chosen, 
and the introduction of the azide at C-2 achieved by diazotransfer to glucosamine using triflic 
azide 2.2.  This reagent was prepared by reacting triflic anhydride 2.1 with sodium azide in 
an emulsion of H2O/toluene at 0 °C (Scheme 3), to provide a 1 M stock solution after work 
up.28  This reagent is shock-sensitive and had to be handled with care. 
 
CF3
S
O
S
F3C
O OO O
F3C
S
N3
O O(i)
2.1 2.2  
Scheme 3. (i) NaN3, H2O/toluene, 0 °C 
 
The triflic azide 2.2 was then reacted with glucosamine hydrochloride 2.3 in the presence of 
CuSO4 as catalyst to yield the unprotected 2-azidoglucose 2.4.  After prolonged drying under 
reduced pressure, this was acetylated with acetic anhydride in pyridine to produce 2.5 in 89 
% yield over two steps.    
 
O
AcO
AcO
N3
OAc
OAc
OHO
HO
N3
OH
OH
OHO
HO
NH3
OH
OH
Cl
(i) (ii)
(iii)
2.3
O
AcO
AcO
NH2
OAc
O
AcO
AcO
N3
OAc
(iv)(v)
S
2.4
2.6a
S
2.7
O
AcO
AcO
N3
OAc
2.6
S
2.5
 
Scheme 4. Synthesis of acetylated thioglycoside: (i) 2.2, NaHCO3, CuSO4.5H2O, H2O/MeOH/toluene, 
15 h, r.t.; (ii) Ac2O, pyridine, 0 °C – r.t., 18 h, 89 %; (iii) BF3.OEt2, dry CH2Cl2, PhSH, reflux, 80 %; (iv) 
recrystallisation from EtOH (80 %; α: 46 % isolated); (v) H2, Pd/C, Et2O, 24 h, 99 %. 
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Thioglycosylation of acetylated intermediate 2.5 was attempted in dry CH2Cl2 using BF3.Et2O 
as Lewis acid, according to a reported literature procedure.29  However, several attempts on 
a small-scale (60 - 84 mg) were unsuccessful in producing any detectable product, even 
after prolonged stirring at room temperature or refluxing for several days.  A trial reaction (51 
mg of 2.5) using SnCl4 as the Lewis acid was also attempted with no detectable product.  It 
was only when the reaction was scaled-up that the desired product was detected.  On a 
scale of 142 mg of 2.5 the thioglycoside product was produced as a mixture of α/β anomers 
in 48 % yield after refluxing for 14 h.  From these results, it appeared that the reaction was 
highly sensitive to moisture, and that on a small scale the proportion of residual water in the 
reaction mixture was sufficient to prevent the reaction from proceeding due to hydrolysis of 
the Lewis acid.  It should be noted that a reaction on a 60 mg scale required 92 l of 
BF3.OEt2 which could be easily consumed by a relatively small amount of water (~38 l).  
Following this finding, the reaction was scaled up to start with 10 g of 2.5, and after refluxing 
for 14 h, the starting material was completely consumed and the desired thioglycoside 
obtained as an α/β mixture in 80 % yield.  The α isomer crystallized selectively from EtOH in 
46 % yield. 
 
Reduction of the azide was achieved by mild hydrogenation over Pd/C.  Initially, the reaction 
was performed in ethanol, requiring a subsequent relatively long period of heating under 
vacuum on the rotary evaporator to remove solvent.  It appeared that these conditions 
promoted an undesired acetyl migration to the free NH2 group.  The solvent was then 
changed to Et2O, which resulted in a longer reaction time for complete reduction (24 h vs. 16 
h for ethanol), but a far simpler recovery of the product as the Et2O was removed relatively 
easily at room temperature on the rotary evaporator.  Initially the product was purified by 
column chromatography, but the problem of removing the solvent was once again 
encountered, and in subsequent attempts the amine product was used without purification in 
the next step.  The reduction proceeded cleanly in Et2O, with the only impurity being the NAc 
side product, which if handled carefully, could be reduced to a trace impurity.  Consequently 
the reaction yields increased to near quantitative after filtration through Celite and removal of 
solvent. 
  
The metal-catalysed diazo transfer reaction for the synthesis of azido sugars from amino 
sugars [step (i), Scheme 4] was first reported by Wong and co-workers,30 who later also 
proposed the likely mechanism.31  This is illustrated below in Scheme 5.  Amine 
complexation to the Cu(II) catalyst gives rise to intermediate 2.8.  Due to the electron-
withdrawing nature of the triflic group, the terminal nitrogen of the azide is electrophilic and 
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can be attacked by the glucosamine nitrogen under basic conditions to form the copper-
stabilised tetrazene 2.10 after deprotonation of intermediate 2.9.  The tetrazene can then 
undergo one of two pathways, indicated in blue and red, to either form the 2-azidoglucose 
product (red pathway) or regenerate the starting triflic azide (blue pathway), possibly via a 
reverse [3 + 2] dipolar cycloaddition.  Both pathways would lead to the formation of an imido 
complex, either 2.11 or 2.13, in equilibrium with one another, as supported by computational 
results by Brandt et al.32  From here, coordination of the glucosamine starting material to 
2.11 could eventually lead to the formation of 2.8 and thereby continue the catalytic cycle to 
the stabilised tetrazene 2.10 and subsequent 2-azidoglucose reaction product.  Alternatively, 
interaction of 2.13 with triflic azide could also give rise to the tetrazene intermediate. 
 
 
 
Scheme 5. Proposed mechanism of copper-catalysed diazotransfer reaction31 
 
2.4.2 Attempts Toward the Synthesis of a Glycerol Glycoside  
 
The synthesis of a glycerol glycoside required careful consideration of several variables 
associated with the glycosylation reaction.  Firstly, since an α-glycoside was required, the 
glycosyl donor had to have a non-participating group at C-2.  This was to be the site of 
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further derivatisation, and therefore an azide was selected for its non-participating character 
and also since it can be considered to be a masked amine.   
 
Secondly, the influence of the protecting groups on the success of the glycosylation could 
also be a factor, and this was investigated by performing the reaction with both acetate 
(potentially disarming) and benzyl (potentially arming) protecting groups.  There has been 
extensive literature published on this effect and it seemed prudent to evaluate it as a factor.33  
 
Thirdly, an appropriate glycosylation strategy had to be selected.  In general, the standard 
methods for 1,2-cis O-glycosylations include (i) the Schmidt trichloroacetimidate approach,34 
(ii) the use of a glycosyl halide donor,35,36 and (iii) the use of a thioglycoside donor,37,38 
although numerous other approaches do exist.39  Each of these three glycosylation 
strategies were investigated, with procedures selected from the literature that utilised 
substrates with the greatest structural similarity to the target reaction.  These are described 
in detail below.   
 
The first strategy employed a 2-azidoglucosyl trichloroacetimidate as donor, which was 
treated with an isopropylidene glyceryl acceptor using trimethylsilyl triflate (TMSOTf) or 
BF3.OEt2 as activator.  Precedent for this reaction was provided by the published synthesis 
of an isopropylidene glyceryl glucose derivative by Wu et al (Table 2).40 
 
Table 2. Glycosylation of (S)-isopropylidene glycerol with trichloroacetimidate donor40 
 
Entry 2.14 (equiv.) Solvent Time/h α:βa Yield/% 
1 1.2 CH2Cl2 0.5 5:1 94.0 
2 1.2 CH2Cl2:Et2O = 1:1 1.0 5:1 90.1 
3 1.2 CH2Cl2:Et2O = 1:5 6.0 8:1 80.2 
4 1.2 Et2O 6.0 Only αb 78.2 
a Determined from the 1H NMR spectrum 
b Trace β isomer, which could be isolated in later steps 
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The published reaction gave excellent yields in CH2Cl2, Et2O and mixtures of the two 
solvents, and increasing α-selectivity as the proportion of Et2O in the solvent mix increased.  
The conversion of an α-trichloroacetimidate donor to an α-enriched product suggests that 
the reaction proceeded via an oxocarbenium ion, and the selectivity results suggest that the 
oxocarbenium ion was stabilised by coordination of Et2O in a β-orientation, which then 
facilitated SN2 attack by the acceptor to generate an α-product. 
 
The reaction conditions utilised for this approach are summarised below in Scheme 6.  In the 
preparation of the glycosyl donor, the tetra-O-acetyl-2-azidoglucoside 2.5 was used as 
starting material.  Selective anomeric deprotection of 2.5 was successfully achieved using 
ethylene diamine and acetic acid: under these conditions the mono-protonated ethylene 
diamine was generated as the reactive species, which then selectively removed the 
anomeric acetate by transacetylation, forming alcohol 2.18 in quantitative yield.  The 
trichloroacetimidate was then generated by treatment of the anomeric alcohol with 
trichloroacetonitrile in the presence of K2CO3 in a respectable yield of 74 %.  A mixture of 
anomers was employed for the glycosylation since the literature suggested the reaction 
outcome was independent of the starting material stereochemistry (Table 2).  The reaction 
was first carried out utilising trimethylsilyl triflate (TMSOTf) as activator in anhydrous 
diethylether, in accordance with the most successful literature conditions, however, this 
failed to generate the desired glyceryl glycoside with no reaction product visible by thin layer 
chromatography (TLC).  BF3.OEt2 was then employed as an alternative activating agent, 
since it has been successfully used in our laboratory as an activator of glycosyl 
trichloroacetimidates.41  However, this approach also failed to generate the desired product, 
instead forming the anomeric alcohol starting material, 2.18.  An attempt was made, perhaps 
ambitiously, to convert the acetate protecting groups of the trichloroacetimidate to more 
activating benzyl groups, in a single step employing the conditions described by Misra and 
co-workers,42 although this resulted in decomposition of the substrate due to the harsh 
reaction conditions and the high reactivity of the imidate.  Time constraints precluded the 
possibility of preparing the benzylated trichloroacetimidate and it could therefore not be 
evaluated as a glycosyl donor, although it might have displayed superior reactivity to the 
acetylated analogue by way of the inductive effect of the benzyl groups. 
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Scheme 6. Attempted synthesis of glycerol glycoside. (i) Ethylene diamine, AcOH, 18 h, r.t., quantitative; (ii) 
trichloroacetonitrile, K2CO3, dry CH2Cl2, r.t., 2 h, 74 %; (iii) BnBr, TBAI, NaOH, THF, r.t., 1h; (iv) 2.15, TMSOTf, 
dry Et2O, r.t., 1 h 15 min; (v) 2.15, BF3.OEt2, dry CH2Cl2, 0 °C, 3 h;   
 
The second procedure that was explored utilised a glycosyl fluoride as donor, with BF3.OEt2 
as activator. The literature precedent for this approach was provided by the reported 
glycosylation of a myo-inositol derivative in high yield and α-selectivity using an acetylated 
glucosyl fluoride acceptor in previously published work by our group (see Scheme 7).43  After 
a reaction time of 2 h, the glycosylated product was obtained in 73 % yield, predominantly as 
the α anomer (α:β >99:1).  Interestingly, isomerisation of the double bond on the substituent 
at the 2-position of the sugar took place during the glycosylation.  Structurally, the fluorinated 
donor in this published reaction bears a close resemblance to the fluorinated donor that was 
used in the glycerol glycosylation reaction, with the only difference being the identity of the 
non-participating group at the 2-position (prenyl vs. azide).  There is, however, a great 
difference structurally between the benzylated myo-inositol in the reported reaction and the 
isopropylidene glycerol acceptor of the proposed glycosylation reaction. 
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Scheme 7. Reported glycosylation of an inositol derivative utilising a glucosyl fluoride as donor and 
BF3.OEt2 as activator. (i) Hydrazine acetate (2 eq), DMF, 60 °C, 30 min, 98 %; (ii) DAST (3 eq), THF, 
r.t., 30 min, 90 % (α:β=2:1); (iii) 2.24 (1.4 eq), 2.25 (1.0 eq), BF3.Et2O (5 eq), anhydrous CH2Cl2, 4 Å 
ms, r.t., 2 h, 73% (α:β >99:1).43 
 
Precedent for the use of a 2-azidoglucosyl fluoride as donor in a glycosylation reaction with a 
myo-inositol derivative as acceptor is given by the reported reaction of Cottaz et al (Scheme 
8).36  Here they employed a benzyl-protected 2-azidoglucosyl fluoride donor and 
zirconocene dichloride, tetramethyl urea and silver perchlorate activating agents to 
selectively effect α-glycosylation of a selectively-protected myo-inositol acceptor.  They 
report a 34 % yield for the reaction after removal of a para-methoxybenzyl (PMB) protecting 
group and subsequent chromatography. 
 
O
BnO
BnO
FN3
OBn
HO
PMBO
OBnBnO
OBn
OBn
O
BnO
BnO
N3
OBn
HO
OBnBnO
OBn
OBnO
+
(i) - (ii)
2.27 2.28 2.29  
Scheme 8. Reported glycosylation of a myo-inositol derivative utilising a 2-azidoglucosyl fluoride as 
donor. (i) Donor (1.4 eq), acceptor (1.0 eq), zirconocene dichloride (5.5 eq), AgClO4 (1.1 eq), 1,1,3,3-
tetramethylurea (1.2 eq), Et2O, r.t., overnight; (ii) CAN (2.1 eq), CH3CN-H2O, 0 °C, 1 h, 34 % over two 
steps35  
 
The combination of these two results seemed to suggest that the acetylated 2-azidoglucosyl 
fluoride donor would be a suitable candidate for the glycosylation of the “truncated inositol” 
2.15, since acetylation did not lower the yield of glycosylation relative to benzylation.  The 
choice of BF3.OEt2 was also demonstrated to be a suitable one, since the glycosylation step 
in which it was used gave a high yield with high selectivity.  The details of the synthetic 
procedure carried out are given below in Scheme 9.  Intermediate 2.18 was prepared from 
the acetylated 2-azidoglucose 2.5 as described above.   
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Scheme 9.  Attempted synthesis of glyerol glycoside. (i) Ethylene diamine, AcOH, 18 h, r.t., quantitative; (ii) 
DAST, dry THF, 0 °C – r.t., 45 min, 85 %; (iii) 2.15, BF3.OEt2, dry CH2Cl2 or dry THF or dry Et2O, MS (4 Å), r.t. – 
50 °C, 24 h. 
 
Fluorination at the anomeric position was then carried out using diethylaminosulfur trifluoride 
(DAST) in anhydrous THF resulting in formation of the glycosyl fluoride 2.30 within 45 min in 
85 % yield.  A mixture of anomers (α:β = 1:2.2 by 1H NMR) was obtained, in accordance with 
literature results,44 although it was surprising that in the equilibrium mixture the anomeric 
enrichment was in favour of the β-anomer since the anomeric effect would predict that the α-
anomer would predominate.  It was also interesting to note that this constituted a reversal of 
α/β enrichment of the starting material (α:β = 1.6:1), supporting the view that fluorination 
occurs via an SN2-type mechanism (Scheme 10).45   
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F
2.18 2.30  
Scheme 10. Mechanism of fluorination by DAST 
 
The mixture of fluoride anomers was, however, not a concern since the mechanism of 
fluoride substitution has been reported to follow an SN2-type pathway, rather than generating 
an oxocarbenium intermediate, and preferentially forms via the β-anomer, resulting in an 
enriched α-glycosyl product.  This is due to the lower activation energy of the β-fluoro 
anomer as a result of the kinetic anomeric effect and the α-anomer has a lower reactivity 
due to ground-state stabilisation by an endo anomeric effect.45  In fact, selective α-
glycosylation (α:β > 99:1) has been reported from an anomeric mixture (α:β = 2:1),43 which 
seems to suggest that either there is anomerisation during the glycosylation reaction, with an 
α-glycosyl product favoured, or that once the β-fluoride anomer has been substituted by the 
acceptor, the liberated fluoride then substitutes an α-fluoride, forming a reactive β-anomer 
which is then substituted by the acceptor in a cyclic process until the starting material is 
consumed (Scheme 11). 
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Scheme 11. Possible mechanism of glycosylation of glycosyl fluorides leading to α-anomeric 
enrichment 
 
Several different reaction conditions were investigated in the attempts to effect glycosylation, 
with each proving to be unsuccessful.  Initially the reaction was carried out in dry THF at r.t. 
under argon with furnace-dried, powdered, 4 Å molecular sieves and BF3.OEt2 as activator.  
The reason for the choice of THF was based on the ability of ethers to coordinate to the 
oxocarbenium intermediate and block the β face, thereby promoting the formation of a 
predominantly α product, 46 as evinced in the reported trichloroacetimidate-diethyl ether 
approach – see Table 2.  After 2 h there was no product visible by TLC, and so additional 
BF3.OEt2 (4 eq) was added and the reaction left overnight, by which stage there was still no 
product.  The reaction was then repeated in dry THF, and after 2 h there was once again no 
product detectable by TLC.  The temperature was then raised, first to 40 °C for 2.5 h (still no 
product), and then to 50 °C overnight, after which there was still no product, and only 
polymerised THF – as determined by 1H NMR spectroscopy.  The solvent was then changed 
to dry CH2Cl2, and similar conditions employed.  After 5 h there was no discernable product 
formed, and the reaction was left overnight.  After 22 h the starting material was consumed 
and the product extracted, purified and characterised.  It was found to be the hydrolysis 
product 2.18, present as a mixture of anomers with α:β = 2:1 (by 1H NMR).  It was interesting 
to note the reversal of α/β enrichment from the starting material (α:β = 1:2.2).  The attempted 
glycosylation reaction was then repeated in dry Et2O under the same reaction conditions, 
and after 19 h partial conversion of the starting material to 2.18 had again occurred.   
 
The fact that the glycosyl fluoride gave rise to the hydrolysis product in two cases indicated 
that the donor was in fact activated by the BF3.OEt2, but that the glycerol was not sufficiently 
nucleophilic to effect the glycosylation, even after prolonged reaction times.  Traces of H2O 
that entered the reaction vessel after these extended periods resulted in the formation of the 
hydroxylated glycoside.  It is possible that the deactivating acetate protecting groups 
contributed negatively to the outcome of the reaction, although the success of the reported 
glycosylation with benzylated myo-inositol utilising an acetylated glycosyl fluoride would 
suggest that this is not a considerable dominating factor.  Future attempts towards a 
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successful reaction will have to be aimed at modifying the structure of the acceptor to 
enhance its reactivity. 
 
The third glycosylation strategy employed a phenylthio donor, activated by N-
iodosuccinamide (NIS).  Precedent for this approach was provided by the publication of a 
synthetic route to substituted glyceryl-type glycosides utilising a phenylthio-2-azidoglucoside 
donor (Scheme 12).47  This reported reaction selectively generated the desired α-glucoside 
in 66 % yield (over two steps) after 2 h reaction time.  Here there were some notable 
differences between the reactants reported and those to be used in the glycerol 
glycosylation.  Firstly, the protecting groups at the 3- and 4-positions of the sugar were para-
methoxybenzyl groups, which are highly activating/arming due to their electron-donating 
inductive effect, and the substituent at the 6-position was an azide, whereas the donor used 
for the glycerol glycosylation study incorporated three O-acetates or three O-benzyl groups 
at the 3-, 4- and 6-positions.  The glycerol-type acceptor also differed in that it had a tert-
butyldimethylsilyl (TBS)-protected alcohol at the 2-position and an azide at the 3-position of 
the propyl chain – differences that are likely to make the reactivity of the free hydroxyl group 
differ from that in isopropylidene glycerol. 
 
O
PMBO
PMBO
N3
N3
SPh
HO N3
OTBS
O
PMBO
PMBO
N3
N3
O N3
OH
(i)
(ii)
2.31
2.32
2.33  
Scheme 12. Reported glycosylation using phenylthioglycoside donor, activated by NIS. (i) 2.31 (1.0 
eq), 2.32 (1.5 eq), NIS (2. 0 eq), MS (4 Å), Et2O/CH2Cl2 (4:1, 0.03M), 2 h, -30 – 0 °C; (ii) silyl-ether 
(1.0 eq), TBAF (1.2 eq), THF (0.1M), 1 h, 0 – 23 °C, 66% over two steps.47 
 
The glycosylation reaction utilising the thiophenol donor was expected to proceed with high 
reactivity, since the related published procedure had been performed at -30 °C and was 
complete after 2 h.47  Unfortunately, this reactivity did not materialise.  Both the acetylated 
and benzylated phenylthio-2-azidoglucosides (2.6 and 2.34) were treated in turn with N-
iodosuccinimide (NIS) and isopropylidene glycerol in anhydrous CH2Cl2 and anhydrous 
CH2Cl2:Et2O (1:4), respectively, and in neither case was the isopropylidene glycerol able to 
displace the thiophenol substituent, despite relatively high temperatures (r.t.) and extended 
reaction times (~20 h) (Scheme 13).   
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O
AcO
AcO
N3
OAc
OAc
2.5
O
RO
RO
N3
OR
SPh
(i)
(ii) 2.6:   R = Ac
2.34: R = Bn
(iii)
X
O
AcO
AcO
N3
OAc
O
2.21
O
O
 
Scheme 13. Attempted synthesis of glycerol glycoside.  (i) BF3.OEt2, dry CH2Cl2, PhSH, reflux, 80 %; 
(ii) conversion of the Ac protecting groups to Bn: 1. NaOMe (cat.), MeOH, 16 h, 0 °C – r.t., 96 %; 2. TBAI, NaOH, 
BnBr, THF, r.t., 2.5 h, 79 %; (iii) 2.6 or 2.34, 2.15, NIS, dry CH2Cl2, -40 °C – r.t. – reflux overnight. 
 
In both cases the starting materials remained unchanged, suggesting ineffective activation of 
the phenylthio group.  As was seen with the glycosyl fluoride glycosylations, it appears that 
the isopropylidene glycerol alcohol is insufficiently nucleophilic to displace the thiophenol. 
 
2.4.3 Oxidative Decarboxylation to Generate the Tethered Naphthoquinone 
 
There are several examples in the literature of radical conjugate additions to quinones.  
These have been shown to be promoted by organotellurium compounds and by carbon-
centred radicals generated by metal ions such as Mn(III) and Ce(IV).48,49 One of the most 
common procedures utilizes the Barton decarboxylation,50 which involves a thiohydroxamic 
ester (Barton ester) as intermediate (Scheme 14).  Homolytic cleavage of the nitrogen-
oxygen bond in the N-hydroxypyridyl compound, initiated by light or heat, leads to a 2-
pyridylthiyl radical and an alkyl radical (R.) after decarboxylation of the acyloxy radical 
intermediate.51  Double alkylation of the quinone proceeds by trapping of the alkyl and 2-
pyridylthiyl radicals, and after rearomatisation affords the alkylated thiylated quinone.52  A 
drawback of this reaction is the difficulty in desulfurisation of the product after alkylation, in 
the case of naphthoquinones.53 
 
R OH
O
N
HO
S
N
O
S
R
O h
R  +
N S
(i) O O
- CO2
O
O
R
pyS
(ii)
2.39
2.40
2.41
2.42
2.43
2.44
 
Scheme 14. Barton-type radical decarboxylation and addition to benzoquinone. (i) SOCl2 or (COCl)2 
or DCC 
 
It therefore seemed advantageous to employ the procedure reported by Salmon-Chemin et 
al2 using Ag(NO3) as catalyst and ammonium persulfate (APS) as radical initiator to achieve 
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naphthoquinone alkylation by radical decarboxylation.  This approach was employed for the 
synthesis of similar substituted naphthoquinones in earlier work published by our group.18  
The ease of handling and direct access to the desired product in a single step were 
sufficiently advantageous for the low reported yields to be overlooked, although optimisation 
of the reaction was investigated in this project.54 This strategy was first reported by Anderson 
and Kochi in 1970,55 and involved generating a carbon-centred radical by reacting a 
carboxylic acid in a mixture of CH3CN/H2O.  A related procedure is the Minisci reaction, 
which involves radical-based C-C bond formation between an alkyl radical, obtained by 
oxidative decarboxylation in the presence of Ag(I) and APS, and an electron-deficient 
heteroaromatic compound.56 
 
The first step in the synthesis involved coupling of the selectively-protected amino acids, 
aspartic acid and glutamic acid, to the naphthoquinone, plumbagin, in a logical extension of 
the earlier work (Scheme 15).18  The reaction was highly temperamental and generally low 
yielding, with yields ranging from 18 – 36 % and 24 – 51 % for the aspartic and glutamic 
alkylations, respectively.  Despite these low yields, the ability to recover unreacted 
plumbagin starting material and recycle it in subsequent reactions diminished the cost 
associated with loss of expensive reagents, and could be said to give the reaction a higher 
yield based on recovered starting material.   
HO
O
O
NHBOCO
OH
O
O
+
O
O
HN
OH
O
O
O
O
2.46: n = 1: BOC-Asp-OBn
2.47: n = 2: BOC-Glu-OBn
2.48 n = 1: 36 % 
2.49 n = 2: 51 %n
n
(i)
2.45
 
Scheme 15. Synthesis of the naphthoquinone-amino acid conjugate: (i) (NH4)2S2O8, AgNO3, 30 % 
(aq) MeCN, 60 °C, 6 h. 
 
Several attempts were made to optimise the reaction, including modifying the rate of addition 
of APS to the reaction mixture (as well as the amount added), increasing the amount of 
amino acid added, degassing the solvent to remove oxygen (which may have been 
poisoning the radical intermediates), and changing the order in which the reagents were 
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added.  These modifications had no positive improvement on the yield or selectivity, with the 
exception of degassing, which appeared to give a slight improvement in yield.  It was not 
possible to lower the temperature of the reaction, as this resulted in precipitation of the 
reactants. While elevating the temperature resulted in increased proportions of side 
products.  Possible enhancements to the reaction by changing the catalyst were not 
investigated, partly since it was reported that the addition of Cu(II) acetate to the reaction 
mixture resulted in a decrease in radical decarboxylation and an increase in reaction time 
(from 1 h to 20 h),55 and partly in maintaining reaction conditions close to the most 
successful reported procedures.  Many of these findings are supported by the results of 
Desolin and co-workers54 who performed an extensive study of the parameters required to 
optimise the yield of radical addition to naphthoquinones using this procedure.  
 
The reaction mechanism is outlined in Scheme 16.  The first step involves thermal homolytic 
cleavage of the persulfate bond to generate two sulfate radicals which oxidise the Ag(I) 
catalyst to Ag(II).  The Ag(II) then coordinates to the carboxylate of the acid and oxidises it to 
COO. and is itself reduced back to Ag(I).  Decarboxylation then occurs to form the alkyl 
radical, which alkylates the plumbagin at the unsubstituted carbon of the quinone.  The 
resultant intermediate, undergoes keto-enol tautomerism to regenerate the aromaticity of the 
naphthalene ring.  Oxidation to the naphthoquinone product is finally achieved by a second 
equivalent of sulfate radical.  
 
O
OOH
OBn
O
NHBOC
O
OOH
OBn
O
NHBOC
H
O
OHOH
OBn
O
NHBOC
[O]
SO4.
O
OOH
OBn
O
NHBOC
OBn
O
NHBOC
O
O
-CO2
OBn
O
NHBOC
O
HO
Ag(II)
+ Ag(I) + H+
O S
O
O
O O S
O
O
O
O S O
O
OO
S
O
OO +  Ag(II)
Ag(I)

+
2.47 2.50 2.51
2.522.532.49  
 
Scheme 16.  Mechanism of radical addition to plumbagin55 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 2: Naphthoquinone-Derived Target Molecules 
 48 
2.4.4 Amide Coupling 
 
Following the success of the oxidative alkylation step the next step involved saponification to 
deprotect the carboxylic acid in preparation for amide coupling to the phenylthio-2-
aminoglucoside 2.7 (Scheme 17).  Debenzylation was achieved by treatment with LiOH in 
aqueous THF in excellent yields of 89 % and 91 % for aspartic and glutamic derivatives, 
respectively.   
 
 
Scheme 17.  Debenzylation and amide coupling. (i) LiOH, aqueous THF, r.t., 4 h; (ii) EDC.HCl, HOBt, 
DIEA, dry THF, r.t., 42 h; (iii) EEDQ, dry THF, 40 °C, 15 h; (iv) EEDQ, dry THF, r.t., 39 h. 
 
The amide coupling between 2.7 and the plumbagin-coupled amino acid 2.54 was then 
investigated.  It was initially attempted using the standard peptide coupling reagents 
EDC.HCl and HOBt in anhydrous THF, giving coupled product 2.56 in a yield of 33 % after 
stirring at r.t. under argon for 42 h (Scheme 17).  In an attempt to increase the yield, an 
alternative coupling agent, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) was 
then used, and this reagent gave more satisfying results with yields of 69 % and 85 % 
obtained for 2.56 and 2.57 respectively, when the reaction was performed at r.t..  The yield 
for the aspartate derivative 2.56 increased from 69 % to 98 % when the temperature was 
raised to 40 °C and the equivalents of amine were increased from 1.2 to 2.1 (in order to 
account for the transacetylation side reaction that takes place in solution at this 
temperature). 
 
The use of EDC is preferred over other diimide reagents (such as 1,3-
dicyclohexylcarbodiimide) since the urea side product is easily removed during aqueous 
work up by protonation of the nitrogen in the side chain.  The use of EEDQ as a coupling 
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agent also circumvents this problem since the reaction generates only quinoline, ethanol and 
CO2 as by-products, which are removed with relative ease.  The mechanism for EEDQ-
mediated coupling is illustrated in Scheme 18. 
 
N OEt
OEtO
N
OEtO
RCOOH
RCOO- N
OEtO
O O
R
NO O
R
OEt
O
+R'-NH2
R NHR'
O
+ CO2
+ EtOH
2.59 2.60 2.61
2.62 2.632.64  
Scheme 18. Reaction mechanism of EEDQ-mediated amide coupling57 
 
Protonation of the ethyloxy substituent at the 2-position of the dihydroquinoline facilitates its 
elimination by delocalisation of the lone-pair on the nitrogen at the 1-position.  The driving 
force for this elimination is conjugation of the quinoline.  There is a subsequent equilibrium 
set up between the conjugated quinoline with a positively-charged nitrogen, and the addition 
product of the carboxylate to the 2-position to alleviate the cationic quinoline.  Eventually 
there is an intramolecular rearrangement that results in the formation of the active mixed 
anhydride and conjugated quinoline.  The amine then attacks the anhydride at the ester 
carbonyl, rather than the carbonate (since it is the more electrophilic centre and is also 
entropically-favoured due to the release of CO2 and EtOH), to give the amide product.  
 
2.4.5 Attempted Removal of the tert-Butyloxycarbonyl Protecting Group 
and Serendipitous Discovery of Novel Route to Benzo[g]indoles and 
Benzo[h]quinolines  
 
Having now prepared the hybrid sugar-naphthoquinone structures via the amino acid tether, 
the conversion of N-Boc to N-acetate was necessary in order to mimic the cysteine side 
chain of mycothiol.  In the case of the aspartic acid derivative, the Boc deprotection was 
attempted using the standard conditions of trifluoroacetic acid and anisole in CH2Cl2 at 0 °C, 
with warming to room temperature, with the intention to immediately acetylate the product 
using acetic anhydride in pyridine.  However, initial attempts to deprotect the aspartic 
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derivative resulted in decomposition of the starting material without conversion to an obvious 
product.  Reaction times of 3.5 h, 6 h, 32 h and 5 days were recorded for reactions 
containing 0.07, 0.23, 0.03, 0.03 % TFA, respectively, in all cases resulting in decomposition 
of the starting material.  Eventually, however, it was discovered that staining the TLC with 
ferric chloride revealed a different product to the starting material that was otherwise not 
visible by staining with acidic anisaldehyde or acidic ceric ammonium sulfate (CAS) 
solutions, and allowed the reaction to be monitored and stopped before decomposition set 
in.  The starting material and product had very similar Rf values.  The anisaldehyde and CAS 
stained both spots black, whereas ferric chloride stained the starting material black and the 
reaction product dark brown.  There was also a difference observed when directly applying a 
sample from the reaction mixture to the TLC plate, and carrying out a mini work-up to 
neutralise the acid, and then spotting a sample from the reaction on TLC.  In the former 
case, the product (Rf 0.41, EtOAc:hexane, 2:3) moved faster than the starting material (Rf 
0.38, EtOAc:hexane, 2:3), whereas in the latter case, the product (Rf 0.36, EtOAc:hexane, 
2:3) was fractionally slower than the starting material.  The reaction mixture was purified and 
the product isolated and characterised.  The 1H NMR spectrum indicated that the tert-butyl 
group had been successfully removed.  The phenolic proton was evident from a singlet at 
11.8 ppm, the aromatic region contained the correct number of signals, and signals for the 
acetylated glucosamine were also accounted for.  The signals for the free amine were 
initially not obvious, but a D2O wash revealed an exchangeable proton signal within the 
multiplet at 7.55 ppm (Figure 5) that showed a coupling to the H9 proton in the COSY 
spectrum.  Another exchangeable proton was indicated by the signal at 6.85 ppm which 
showed a correlation to the signal for H2 in the COSY spectrum.  The interesting feature of 
the NH signal at 7.55 ppm was that it integrated for one hydrogen and not two, suggesting 
that the amine was alkylated or acylated.  Evidence for the true nature of this attachment 
was provided by the 13C spectrum.  In addition to the expected naphthoquinone, 
carbohydrate and acetate signals, there were two quartets at 157.5 (q, 1C, J = 37.9 Hz, C12) 
and 115.5 (q, 1C, J = 287.7 Hz, C13) ppm.  These signals are indicative of the presence of 
the trifluoroacetyl group, since the three fluorine atoms couple to the methyl carbon and to 
the carbonyl carbon, giving large geminal and smaller vicinal coupling constants.  This result 
suggested that after deprotection of the Boc carbamate, the liberated amine was acylated by 
TFA, or by trifluoroacetic anhydride present as an impurity in the reagent bottle. 
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Figure 5.  
1H NMR spectrum indicating the aromatic region before (A) and after (B) D2O wash.  The 
reduction in the integration of the multiplet at 7.55 ppm by one hydrogen is noted. 
 
Consequently, this unexpected reaction is revised as in Scheme 19 below.  Although there 
was some degradation during the reaction, a considerable yield of 70 % was obtained.   
 
(i)
2.65
O
AcO
AcO
SNH
OAc
O
NH
OH
O
O
O
O
O
AcO
AcO
SNH
OAc
O
NH
OH
O
O
O
F3C
2.56  
Scheme 19. Removal of Boc protecting group from aspartic derivative and subsequent acetylation by 
TFA: (i) TFA, anisole, CH2Cl2, r.t., 4 h, 70 %. 
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Despite this unexpected result, it seemed prudent to complete the synthesis by deprotecting 
the sugar to obtain the TFA derivative of the target molecule.  Due to the similar atomic size 
of fluorine (van der Waals radius = 1.35 Å)58 to hydrogen (van der Waals radius = 1.20 
Å)58,59, the trifluoromethyl group is similar in size to the methyl group of a conventional 
acetate (van der Waals volume of CF3 = 39.8 Å3; van der Waals volume of CH3 = 21.6 Å3),58 
and does not therefore significantly alter the topology of the molecule.  In fact, fluorine is a 
known bioisostere of hydrogen and there have been numerous examples in medicinal 
chemistry where a hydrogen atom has been substituted by a fluorine to enhance the 
biological or physicochemical properties of a molecule without significantly altering its 
chemical structure.60,61  Some of these effects include fluorine/hydrogen substitution to 
enhance membrane permeability,62 reduce lipophilicity,63 modulate metabolism,64 modulate 
basicity of adjacent amide groups,65 and influence conformation via intramolecular 
electrostatic interactions with dipolar bonds.66  
 
The deprotection of the glucosamine acetates was carried out utilising the standard Zemplén 
conditions of catalytic sodium methoxide (20 mol %) in methanol (Scheme 20).  After 2 h of 
reaction time, there were two products evident from TLC, which remained after a further 6.5 
h of reaction.  After 8.5 h, despite the reaction not proceeding to completion, TLC indicated 
that decomposition was under way, and the reaction was therefore stopped and worked up.  
Purification was attempted by automated flash chromatography, but the products appeared 
to decompose during the chromatography while a considerable portion of material remained 
strongly adhered to the silica.  This was eluted after the addition of 1 % AcOH to the mobile 
phase.  Unfortunately, a considerable amount of material was lost during the purification and 
two products were obtained in small quantities (3 mg and 7 mg, respectively).  Neither of the 
two products showed characteristics of the desired product in their 1H or 13C NMR spectra.  
The less polar product was submitted for an overnight quantitative 13C experiment in the 
hope of identifying the characteristic quartets for the trifluoromethyl acetate group.  However, 
these signals were missing, suggesting that the deacetylation had cleaved the 
trifluoroacetate.  The more polar product decomposed in solution and was not identifiable by 
1H NMR spectroscopy.  This lack of stability in solution precluded the possibility of testing its 
activity in the enzyme assays, and it was therefore not pursued further.       
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(i)
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X
2.65  
Scheme 20.  Attempted Zemplén deacetylation to form the trifluoro bioisostere of the final target 
aspartic molecule. (i) NaOMe (20 mol %), MeOH/CH2Cl2, r.t., 8.5 h. 
 
Attention then turned to the deprotection of the glutamic acid derivative 2.57, which 
appeared to proceed with greater success than the aspartic derivative. Treatment of 2.57 
with TFA in CH2Cl2 resulted in the formation of a product that was at first difficult to 
characterise, but migrated as a single spot on TLC [Rf (EtOAc:hexane, 6:4) product 0.37; 
starting material 0.61].  The 1H NMR spectrum indicated that the Boc group had been 
successfully removed, as seen by the disappearance of the tert-butyl signal at 1.44 ppm.  
The signals for the glucosamine ring as well as the phenylthio substituent were present, as 
were the expected naphthoquinone proton signals (two doublets of doublets and a triplet); 
however, the expected methylene signals for the alkyl linker were missing and there was an 
unexpected aromatic A-B system present as indicated by the signal at ~8.2 ppm, indicating 
the presence of a cis double bond (two doublets, J = 8.6 Hz).  Other noted differences from 
the starting material were a downfield shift of the phenolic OH singlet (from 12.02 to 13.75 
ppm) and a shuffling around of the naphthoquinone signals in the aromatic region.  The 13C 
spectrum indicated the disappearance of the quinone carbonyl signals at 189.9 and 184.1 
ppm, with the most downfield carbonyl signal appearing at 172.6 ppm (corresponding to an 
ester C=O).  This suggested that a reduction of the quinone ring had taken place.   
 
Combining this evidence, it appeared that the glutamic side chain had undergone a 
condensation-elimination sequence, resulting in the formation of a cis double bond in a fused 
aromatic system, and consequently the loss of the quinone carbonyl signals in the 13C 
spectrum.  Such a condensation/cyclisation would be expected to have an influence on the 
chemical shifts of all the 1H signals on the naphthoquinone ring, including the methyl and 
hydroxyl substituents.  A benzo[h]quinoline structure 2.67 was thus proposed for the reaction 
product (Scheme 21).  
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2.67
2.57   
Scheme 21. Removal of the Boc protecting group and resulting cyclised product: (i) TFA, CH2Cl2, r.t., 
2.5 h, 85 %. 
 
Expansions of the 1H NMR spectrum are given below in Figure 6 and Figure 7, and provide 
the graphical representation of the above-mentioned results. The A-B system at 8.2 ppm 
(subsequently assigned as H3’ and H4’) can be clearly seen in Figure 6.  The other aromatic 
signals include a multiplet at 7.58 ppm, assigned as the ortho H’s on the thiophenyl ring and 
the amide H7 (confirmed by a coupling in the COSY spectrum to C2), two doublets of 
doublets at 7.50 and 7.18 ppm (assigned as H7’ and H9’), a triplet at 7.46 ppm (assigned as 
H8’) and a multiplet at 7.28 ppm (assigned as the meta and para H’s on the thiophenyl ring).  
These benzoquinoline signals appear at similar chemical shifts to those of the corresponding 
H’s on the naphthoquinone ring (see Figure 5 for comparison). 
 
 
Figure 6. 1H NMR spectrum of aromatic region of the cyclised glutamic product indicating the A-B 
system at 8.2 ppm 
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The disappearance of the signals corresponding to the tert-butyl (1.44 ppm) and methylene 
groups (2.65, 1.95 and 1.75 ppm) of the side chain can be seen in the 1H NMR spectra of 
starting material (A) and product (B) in Figure 7 below.  The change in chemical shift of the 
quinone methyl (H10’) from 2.09 ppm in A to 2.53 ppm in B (H11’) is also confirmed.  
 
 
 
Figure 7. 1H NMR spectra of the aliphatic regions of the Boc-protected (A) and Boc deprotected (B) 
glutamic conjugates.  The disappearance of the tert-butyl signal at 1.44 ppm and the methylene 
signals at 2.65, 1.95 and 1.75 ppm is demonstrated. 
 
An attempt was made to deacetylate the glucosamine ring in order to obtain the 
benzo[h]quinoline conjugate of thiophenyl glucosamine.  However, deprotection under 
standard Zemplén conditions resulted in a product with very poor solubility.  In fact, as the 
deacetylation reaction progressed, the product precipitated out of solution and could not be 
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dissolved again in any solvent except DMSO.  The precipitate was washed with EtOAc and 
MeOH in order to remove any remaining starting material, and submitted for 1H NMR 
analysis in deuterated DMSO, but this gave a spectrum that could not be unambiguously 
assigned.  This suggested that the precipitate consisted of a range of partially deprotected 
acetates, and with such poor solubility, was unlikely to be a suitable candidate for biological 
evaluation.  However, the novelty of the reaction prompted further investigations, both into its 
applicability to other substrates, and into the structure of the final product. 
 
In order to further investigate the cyclisation reaction, samples of 2.48 and 2.49 were 
subjected to treatment with TFA, followed by acetylation, to explore the generality of this 
methodology for the preparation of fused heterocycles.   
 
In the case of the aspartic acid derivative, it was hoped that it could be established whether 
appropriate conditions would result in deprotection without trifluoroacetylation, and that 
either the desired N-acetylation could be achieved, or alternatively cyclization to substituted 
benzoindoles. 
 
When 2.48 was treated with TFA in CH2Cl2 a compound with an almost identical Rf on TLC 
was formed, and was only identified as a new product after the staining reagent was 
changed from anisaldehyde (or CAS) to ferric chloride (in the same way that the aspartic 
derivative coupled to the glucosamine was identified).  Once again, the anisaldehyde and 
CAS stained both spots black, whereas ferric chloride stained the starting material black and 
the product dark brown.  
 
After work up and purification, the product was subjected to acetylation (acetic anhydride in 
pyridine), and isolation and characterisation of this product revealed that the tert-butyl group 
of the Boc was missing, suggesting that deprotection had been successful.  However, the 
NH signal integrated for just 1 hydrogen in the 1H NMR spectrum, suggesting that N-
acetylation had taken place.  In addition, the phenolic OH signal was missing, suggesting 
initially that it too had been acetylated.  However, there were only two methyl singlets in the 
1H spectrum, at 2.39 and 2.15 ppm respectively, and since one of these methyl signals 
corresponded to the methyl substituent at C3 of the naphthoquinone, the other had to 
correspond to either the phenolic or amine acetate, but could not be both.  The presence of 
the two quinone carbonyl signals in the 13C spectrum suggested that imine condensation had 
not taken place, precluding that as a possibility for the lower than expected amine proton 
integration.  Once again the 13C spectrum was carefully examined and provided the clue to 
the structure of the product.  There were two quartets present, one at 157.1 ppm (J = 38.0 
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Hz) and one at 115.6 ppm (J = 287.6 Hz), each integrating for 1 carbon (in the spectrum of a 
quantitative 13C experiment).  This indicated that the amine had been acetylated by the TFA 
to produce a trifluoromethyl amide 2.68 (Scheme 22).    
 
2.68
O
O
NHBoc
O
OBn
OH
O
O
HN
O
OBn
O
CF3
O
(i)-(ii)
O2.48  
Scheme 22. Synthesis of trifluoromethyl amide under Boc deprotection conditions. (i) TFA, anisole, 
CH2Cl2, 3.5 h, 0 °C – r.t.; (ii) Ac2O, pyridine, 17 h, r.t. 
 
Confirmation that the amine, and not the phenolic OH, had been acetylated by the TFA was 
provided by an HMBC 2D spectrum (Figure 8).  This spectrum clearly shows a 2J through-
bond coupling between the C5 carbonyl carbon and the H4 proton on the nitrogen, as well as 
a 3J through-bond coupling between the C5 and the H2 proton.  These couplings would not 
be present if the TFA was on the phenolic OH and the amine was acetylated by a non-
fluorinated acetate.   
 
Figure 8. Expansion of the HMBC spectrum of the TFA-acetylated Plum-Asp-OBzl indicating a 2J and 
3
J through-bond coupling between the TFA carbonyl carbon and the NH and CH protons, respectively. 
 
The second product (Rf 0.12, EtOAc:hexane, 1:4) that formed during the reaction of 2.48 
with TFA appeared at a considerably lower Rf on the TLC than the starting material (Rf 0.52, 
                                H4                                                                   H2 
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EtOAc:hexane, 1:4), and was highly fluorescent under UV.  Unfortunately, this product 
degraded with time in solution, making full characterisation difficult.  After chromatography, a 
relatively pure fraction (by TLC) was collected and subjected to NMR spectroscopic analysis, 
and an assignable 1H spectrum obtained (Figure 9).  The 1H NMR experiment was run in 
CD3OD, which resulted in none of the exchangeable proton signals being visible (due to H-D 
exchange with the NMR solvent).  However, this solvent was preferred over CDCl3 since it 
allowed the singlet at 7.27 ppm, which was assigned as H3 on the proposed newly-formed 
indole ring (Figure 9), to be clearly seen without interference from a CHCl3 signal at 7.25 
ppm.  The rest of the 1H spectrum supported the hypothesis that an imine 
condensation/cyclisation to the benzo[g]indole, in a similar mechanism to the 
benzo[h]quinoline described earlier, had taken place.  The molecule appeared to be achiral, 
as evidenced by the appearance of the signal for the benzylic methylene group appearing as 
a singlet at 5.4 ppm, and the signals corresponding to the aspartic alkyl chain were also 
absent, suggesting a similar reduction/aromatisation had taken place. 
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Figure 9.  Expansion of the 1H NMR aromatic region of the cyclised benzo[g]indole product.  The 
NMR experiment was run in CD3OD to allow identification of the newly-formed indole by the presence 
of a singlet at 7.27 ppm. 
 
The poor quality of the 13C spectrum (due to compound degradation) precluded a complete 
assignment, despite the likely product structure given in Figure 10.    
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HNOH
OH
O
O
2.69  
Figure 10.  Chemical structure of the benzo[g]indole product formed by TFA-mediated cyclisation. 
 
In an attempt to gain further evidence for this structure, a fraction of this semi-purified 
product (18 mg) was then subjected to acetylation in acetic anhydride and pyridine.  A more 
stable product was indeed isolated, and full characterisation of the doubly acetylated 
benzo[g]indole product was possible.  The 1H NMR spectrum confirmed the structure of the 
product as a di-acetyl benzo[g]indole (Figure 11), and this was supported by the presence of 
an exchangeable NH signal at 10 ppm and three methyl signals at 2.5 ppm. 
 
Figure 11.  1H NMR spectrum and chemical structure of acetylated benzo[g]indole 
 
The expansion of the aromatic region (Figure 12) shows that, in keeping with the proposed 
structure, there are nine aromatic protons.  Due to considerable overlap, unambiguous 
assignment of all the signals was difficult, although a general assignment was possible. 
Using the expansion of the aromatic region of the HSQC it was possible to identify the 
signals corresponding to protons H6, H7 and H8, as well as the aromatic benzyl protons 
(ArBn), which appear in close proximity to one another in the 13C spectrum.  The signal at 
108.6 ppm in the 13C and 7.40 ppm in the 1H, is the H3 singlet, which appears at a 
considerably different chemical shift to the other signals, and gives a small, well resolved 
signal in the HSQC. 
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Figure 12. Expansion of the aromatic region of the HSCQ spectrum of the benzo[g]indole identifying 
the likely position of the characteristic aromatic singlet at H3 
 
The proposed reaction mechanism giving rise to the product is given below in Scheme 23.  
The Boc deprotection proceeds in the standard manner, with protonation of the carbamate 
carbonyl leading to loss of the tertiary butyl cation (which is mopped up by the anisole 
additive).  Decarboxylation leads to the free amine with a loss of CO2.  Under the acidic 
conditions, the quinone carbonyl is protonated, thereby promoting condensation with the free 
amine, and after loss of H2O the imine is formed.  Reduction of the quinone followed by a 
proton transfer gives rise to the dihydroxylated benzo[g]indole, which is acetylated in the 
following reaction by acetic anhydride in pyridine.  
                                                H3 
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Scheme 23.  Proposed mechanism for the formation of the benzo[g]indole under acid-catalysed 
conditions.  The role of anisole in mopping up the liberated tert-butyl cation is given. 
 
Having demonstrated the intramolecular condensation-aromatization sequence for the 
aspartic acid derivative, the glutamic derivative 2.49 was subjected to the same Boc 
deprotection conditions of trifluoroacetic acid and anisole in CH2Cl2 at 0 °C, with warming to 
room temperature, followed by acetylation with acetic anhydride in pyridine.  Treatment with 
TFA in CH2Cl2 resulted in the formation of a product migrating as a single new spot on TLC, 
and after complete consumption of starting material, the reaction was worked up.  The crude 
product was then subjected to acetylation before being purified and analysed.  The reaction 
proceeded in a good yield of 85 % over the two steps.  Characterisation of the product 
demonstrated that cyclisation had successfully taken place and the benzo[h]quinoline had 
formed. 
 
The 1H NMR spectrum (Figure 13) indicated once again that alkyl chain signals were 
missing and that there was a new cis double bond system as indicated by coupled doublets 
at 8.51 and 8.36 ppm (J = 8.54 Hz).  Other notable differences from the starting material 
were a downfield shift of the phenolic OH singlet (from 12.08 to 14.70 ppm) and a shuffling 
around of the naphthoquinone signals in the aromatic region.  Acetylation appeared to have 
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taken place at one of the phenolic hydroxyls, since there were two methyl signals at 2.50 
and 2.52 ppm (once again indicating a downfield shift of the naphthoquinone methyl signal 
from 2.06 ppm).  Apart from the change to the benzylic CH2 signals, the aromatic benzyl 
signals remained largely unchanged. 
 
 
 
Figure 13. 1H NMR spectrum of the glutamic product of the Boc deprotection and acetylation reaction 
 
Combining the above NMR spectroscopic evidence, a product structure 2.77 was proposed, 
shown in Figure 14 below.   
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O
NOH
O
O
O
2.77  
Figure 14.  Chemical structure of novel benzo[h]quinoline synthesised by reaction of 2.49 with TFA, 
then Ac2O/pyridine.  Acetylation is proposed to have occurred at the 6-position. 
 
Unambiguous assignment of the spectra proved difficult, however, since the position of the 
single acetate could not be confirmed.  It was likely to have occurred at the 6-position since 
the phenolic signal in the 1H spectrum (14.70 ppm) is closer in position to the phenolic signal 
(12.08 ppm) of the starting material than that of the 6-position (6.13 ppm) of the cyclised 
glucosamine-coupled product 2.67 described above.  Consequently, crystals of the product 
were grown and the structure analysed by single crystal X-ray diffraction.  This provided 
unambiguous proof of the tricyclic benzo[h]quinoline structure as illustrated in Figure 15 
below.   
 
 
Figure 15. Chemical structure of synthesised benzo[h]quinoline derived from crystal structure 
determination 
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The data collection and refinement parameters are given in Table 3 below.67 
 
Table 3. Data collection and refinement parameters for 2.77 
Crystal system Monoclinic 
Space group C2/c 
Unit cell constants  
a (Å) 31.457(3) 
b (Å) 7.8845(7) 
c (Å) 20.492(2) 
β (°) 129.843 (1) 
Volume (Å3) 3902.4(6) 
Z 8 
Densitycalc (g.cm-3) 1.366 
F (000) 1680 
Temperature of data collection (K) 173(2) 
Crystal size (mm) 0.13 x 0.09 x 0.07 
Range scanned θ (°) 1.69 – 30.56 
Index ranges h: -44, 44; k: -11, 11; l -29, 25 
Total no. of reflections collected 20089 
No. of independent reflections 5968 
No. of reflections with I > 2σ(l) 4053 
No. of parameters 277 
S 1.022 
R1 [I > 2σ(l)] 0.0463 
wR2 0.1310 
Max. and Av. Shift/Error 0.00, 0.00 
Min. and Max. Resd. Dens. [e/Å3] -0.207, 0.376 
 
 
Fusion of the benzene ring with the quinoline was confirmed to have taken place at the 
eighth side of the quinoline ring, and is hence designated “h”.  The crystal structure indicates 
that acetylation took place at the phenolic OH generated by the reduction of the quinone (6-
position, C3 in crystal structure diagram), and not at the phenolic OH present of the starting 
material (10-position).  Presumably this is due to its enhanced nucleophilicity as a result of 
electronic induction by the nitrogen para to the OH.  The alkyl side chain was found to be 
subjected to elimination, with the drive to aromaticity promoting that reaction.  The stable, 
sterically-favoured 6-membered ring that forms as a result of the imine condensation drives 
the reaction to take place initially, with aromatisation following that initial step.   
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A proposed mechanism for the formation of 2.77 is presented in Scheme 24 below.  The 
initial mechanism follows the standard Boc deprotection pathway, but once the amine is 
liberated it condenses with the nearest carbonyl group under the acidic conditions, liberating 
water and resulting in cyclisation to the 3,4-dihydrobenzo[h]quinoline.  The drive to 
aromaticity promotes elimination of hydrogen resulting in the fully aromatic 
benzo[h]quinoline.  Acetylation of the newly-formed hydroxyl takes place in the second 
reaction to form the final acetylated compound. 
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2.802.812.822.83
2.84  
Scheme 24. Mechanism of TFA-mediated cyclisation to benzo[h]quinoline 
 
A study of the literature provided a possible reason for this unexpected TFA acetylation of 
the aspartic acid-derived intermediates.  Prior to using the TFA, it was purified by distillation 
over P2O5.  However, a paper published by Tojo et al68 reported that the symmetric 
anhydride of TFA can be prepared by stirring TFA over P2O5 in a dehydration reaction.  The 
preparation they report contained a mixture of the acid and anhydride, which would account 
for the one-pot removal of the Boc and acetylation of the liberated amine by TFA anhydride.  
Subsequent attempts to remove the Boc protecting group of the aspartic derivative with 
fresh, untreated TFA resulted in exclusive cyclisation to the benzoindole.  It is interesting to 
note that deprotection of the glutamic derivative with the mixture of TFA and TFA anhydride 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 2: Naphthoquinone-Derived Target Molecules 
 67 
did not yield any detectable N-acyl product.  It would appear that the cyclisation to the 
benzoquinoline is a faster reaction than the cyclisation to the benzoindole, presumably due 
to the high stability of the aromatic tricyclic ring system.  Obviously this full aromaticity is not 
possible with the benzoindole due to the presence of the NH in the ring, and this allows a 
fraction of the free amine to be trapped by the TFA anhydride. 
 
2.4.6 Attempts Towards the Preparation of an N-Acetylated Amino Acid  
 
Following the failure to convert the N-Boc to the N-acetate group as described above, 
several attempts were made to install the acetate on the amine of the amino acid starting 
material prior to oxidative coupling with the naphthoquinone in order to circumvent the 
reductive cyclisation reaction (Scheme 25).   
 
O
O
HN
HO
O
Boc
O
O
HN
HO
O
O
(i), (ii)
2.852.46
X
 
Scheme 25. Proposed synthesis of the N-acetylated amino acid. (i) TFA, anisole, CH2Cl2, 0 °C – r.t., 
4 h; (ii) Ac2O, pyridine, r.t., overnight. 
 
This proved to be problematic for several reasons.  Firstly, it was difficult to visualise the 
amino acid on the TLC plate.  Despite the presence of a benzyl ester, the UV visibility was 
poor, and several staining agents, including anisaldehyde, ceric ammonium sulfate, ferric 
chloride, vanillin and iodine were unable to stain the substrate.  Ninhydrin provided a 
moderately suitable staining agent, but the product migrated as very broad, diffuse spots 
making it difficult to accurately monitor the progression of the reaction.  None-the-less, in the 
first attempt the Boc removal step was carried out under similar conditions to those 
described above.  The Boc-protected amino acid was stirred in 20 % TFA in CH2Cl2 for 4 h 
before the solvent was removed and the residue dissolved in Ac2O and pyridine and stirred 
overnight.  After removal of the solvent under reduced pressure attempts were made to 
purify the residue by chromatography.  However, there were no pure fractions isolated that 
could be identified as a possible product.  It appeared that at some stage in the process 
considerable degradation took place, precluding this route as a potential pathway to the 
target molecule. 
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As an alternative, the possibility of acetylating the Boc-protected amine was explored, with a 
view to selectively removing the Boc group from the N-acetyl-N-Boc derivative.  This 
proposed synthetic route is outlined below in Scheme 26. 
 
2.86
(i) or (ii)
O
O
HN
Boc
O
O
OH
O
O
N
O
O
O
OBoc
O
O
HN
O
O
O
O
(ii)
O
O
HN
Boc
O
O
O
O
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X
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2.48 2.87
2.88
 
Scheme 26. Proposed synthetic route to prepare the acetylated Boc-protected amine. (i) Ac2O, 
pyridine, r.t., 2 - 4 days; (ii) AcCl, dry CH2Cl2, Et3N, 0 °C – r.t., 27 h; (iii) TFA, anisole, CH2Cl2, 0 °C – 
r.t., 4 h. 
 
In the first attempt of this sequence, acetic anhydride in pyridine was employed, and after 4 
days in the presence of these reagents at r.t. under argon, considerable degradation of the 
starting material was visible by TLC, and no major product was isolable. 
 
In the second attempt, the N-Boc substrate was treated with acetyl chloride and 
triethylamine in anhydrous methylene chloride under argon, and a single product was 
obtained and identified as the O-acetate 2.86.  Despite a reaction time of 27 h, double 
acetylation did not take place.   
 
2.5 Discussion and Conclusion 
 
The inability to generate the final conjugate of naphthoquinone derivative and 2-amino-1-
thioglucoside or related glycerol glycoside unfortunately precludes verification of the 
proposed target molecules as potential subversive substrates/inhibitors.  The failure to 
prepare the glycerol glycoside and the problems associated with the NHAc substituent on 
the linker were the two most significant challenges in this study.  The failure to achieve a 
successful glycosylation, despite numerous careful attempts and a variety of strategies, 
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appears to be due to a combination of poor reactivity of the glycerol-derived acceptor, and 
possible “disarming” of the glycosyl donor by the protecting groups.  Future attempts of this 
reaction might be successful if a more reactive donor was used bearing a closer 
resemblance to the benzylated trichloroacetimidate donor that was successfully employed by 
Wu et al.40  The acetate protecting groups on the protected glucoside used in this project 
would have deactivated the anomeric position and increased the energy requirement for 
glycosylation.  The failure of glycosylation with the glycosyl fluoride and phenylthioglycoside 
donors is difficult to rationalise based on the structures of the reactants, since high-yielding 
glycosides have been achieved with analogous compounds.  Problems such as these are 
not unprecedented in carbohydrate chemistry, and may simply point to a limited 
understanding of subtle steric, conformational and stereoelectronic factors which combine to 
affect reactivity. 
 
However, this study has been successful in other respects.  Firstly, conditions have been 
established for reproducible application of the oxidative decarboxylation route to 2-alkyl-1,4-
naphthoquinones, including the preparation of a potentially useful series of naphthoquinonyl 
amino acids.  Several factors influencing the outcome of this reaction, in particular, the 
reactivity of the alkyl radical, are described in further detail in Chapter 3. Secondly, the 
serendipitous discovery of the new route to benzo[g]indoles and benzo[h]quinolines has 
suggested a novel approach to these important classes of biologically-active 
heterocycles,69,70,71,72,73 and illustrated the differences in reactivity of analogues with differing 
length of the side chain.  This methodology differs from the classical Friedländer synthesis of 
quinolines,74,75,76 which uses 2-aminobenzaldehydes and ketones in a condensation reaction 
to construct the N-heterocycle, or the related Niementowski approach,77,78 or Camps 
cyclisation.78,79  These methods all employ an aniline-type amine, with the N-C bond 
established in the starting material.  The Fischer indole synthesis80 similarly generates the 
cyclisation from an aryl hydrazine, with the N-C aryl bond extant in the starting material.  Our 
approach is different in that the imine condensation generates the N-C aryl bond from the 
tethered amine.  Other reported syntheses of benzoquinolines and benzoindoles include 
electroreductive coupling of phthalimides followed by rearrangement of the resulting silyl 
ketene acetals,81 N-heterocyclisation of naphthylamines with diols catalysed by an iridium 
chloride/BINAP system,82 and irradiation of aryl-substituted 3-amino-2-alkene imines to 
effect cyclisation to benzoquinolines.83  Soleiman et al84 used a 1,4-naphthoquinone and 
glycine to generate a benzo[f]indole, which they erroneously describe as a benzo[g]indole.  
However, this approach produced the 5-membered N-heterocycle on the quinone C=C, 
rather than through an imine condensation, which conserved the quinone structure and 
resulted in a considerably different substitution pattern to that observed with our approach. 
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Treatment of the glutamic derivatives (2.49 and 2.57) with the mixture of TFA and TFAA 
gave the cyclised product exclusively, with no detectable N-acylated product, whereas 
treatment of the aspartic derivatives (2.48 and 2.56) with this mixture resulted in the 
formation of both the linear N-acylated product and the cyclised benzo[g]indole product.  
This difference in reactivity can be rationalised by the enhanced stability of the fully 
conjugated benzo[h]quinoline ring system relative to the less conjugated benzo[g]indole.  It 
appears that in the formation of the benzo[h]quinoline the rate of cyclisation is greater than 
the rate of acylation of the liberated amine with TFAA, whereas in the formation of the 
benzo[g]indole the rate of cyclization is considerably slower.  
 
It is clear therefore that a revised strategy will be necessary in order to obtain the desired 
conjugates with an N-acetyl group in the linker. An obvious variation to consider in future 
work is to avoid using the acid-labile N-boc protecting group in the starting amino acid so as 
to avoid the acidic deprotection step which leads to the inadvertent cyclisation. While there 
are no doubt other viable ways of preparing the desired naphthoquinone derivatives, it might 
also be worth considering a quite different class of redox cycling subversive substrates, 
where the quinone unit is replaced by a ferrocenyl unit.  Ferrocene derivatives have been 
reported to be effective redox cyclers and could in principle operate in a similar manner to 
that of the quinone redox cyclers.85,86,87,88  A general approach to these such as that 
proposed in Scheme 27 below from commercially-available amino acid derivatives 2.90 (n = 
1, 2) and ferrocene could give access to subversive substrates with the desired NHAc 
substituent appropriately positioned n the linker between redox-active ferrocene and the 
MSH-like scaffold. 
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Scheme 27. Proposed synthetic scheme of ferrocene conjugate of phenylthioglucosamine with linker 
containing the desired NHAc substituent.  Synthetic steps include alkylation of the ferrocene by amino 
acid derivatives 2.90, followed by saponification and amide coupling to the phenylthioglucosamine, 
and then Boc removal, amine acetylation and acetate deprotection. 
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Chapter 3 
Carbazole-1,4-Quinone-derived 
Target Molecules 
 
3.1 Introduction 
 
Carbazole alkaloids have been isolated from a wide range of biological sources, including 
higher plants, microbes, marine cyanophyta as well as bovine urine and human pathogenic 
yeast.  The most abundant source of carbazoles is the Rutaceae family of plants from which 
carbazoles have been isolated from the genera Murraya, Glycosmis, Clausena and 
Micromelum.1  These alkaloids have been reported to display a range of biological activities, 
including anti-inflammatory, antioxidant, mosquitocidal, antimicrobial,2,3 anticancer,4 and 
antimalarial,5 among others.6  Within the context of tuberculosis drug research, the carbazole 
alkaloid clausine K (or clauszoline J) (Figure 1), which has been isolated from various 
sources,7,8,9 was shown to display weak antituberculosis activity (MIC of 100 µg.ml-1 against 
the H37Ra strain),10,11 and micromeline (Figure 1), isolated from the bark of Micromelum 
hirsutum, was also found to have anti-TB activity (MIC of 31.5 µg.ml-1 against M. 
tuberculosis H37Rv).12 
N
H
COOH
OMeMeO
N
H
CHOHO
3.1 clausine K (or clauszoline J) 3.2 micromeline  
Figure 1. Chemical structures of the carbazole alkaloids, clausine K (or clauszoline J) and 
micromeline 
 
Based on these preliminary results, Knölker and co-workers13 screened a series of carbazole 
alkaloids for their in vitro anti-TB activity and established several trends in the substitution 
patterns that affected the observed activities.  It appeared that activity was highly sensitive to 
subtle changes in substitution about the tricyclic ring system.  Using the general carbazole 
numbering scheme illustrated in Figure 2, substituents at the nitrogen atom were found not 
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to contribute to antitubercular activity, although the presence of a nitrogen-containing 
substituent at either the 3- or 7-position resulted in a substantial increase in activity.  3,6-
Dibromo, 2-hydroxy, 2-hydroxy-3-methyl and 1-methoxy substitutions gave little or no 
activity, and neither did the 2,7- or 3,6-dioxygenated derivatives.  
 
N
H
1
2
456
7
8 9
3
 
Figure 2. General chemical structure of carbazoles 
 
An example of the subtlety in substitution differences having a marked bearing on activity 
was seen with the furo[3,2-a]carbazole alkaloid furoclausine A (3.3) which was found to 
show anti-TB activity, whereas its corresponding methyl ether (3.4) was inactive (Figure 3). 
N
H
CHO
ORO
3.3 R = H
3.4 R = Me  
Figure 3. Carbazole alkaloids with slight structural differences but considerable differences in MIC 
(3.3: 55 µM; 3.4: >128 µM) 
 
The greatest activity was observed with the 3,4-dioxygenated carbazole derivatives 3.5 - 3.7, 
indicated below in Figure 4.  
N
H C7H15
Me
OMeMeO
N
H
Me
OMeMeO
N
H
Me
OMeAcO
OAc
O
Br
OAc
3.5 3.6 3.7
MIC = 11 M MIC = 8 M MIC = 55 M
 
Figure 4. Chemical structures of 3,4-dioxygenated carbazole derivatives with good antitubercular 
activity 
 
The study was then extended to include the carbazole quinones and quinols.  Precedent for 
quinone analogues displaying anti-tuberculosis activity was given by the investigation of 
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Tran et al14 that identified low to moderate activity in a number of quinone derivatives.  The 
carbazole-1,4-quinol alkaloids evaluated were found to be inactive against TB, and although 
carbazole-1,4-quinone 3.8 was inactive as well, carbazole-1,4-quinone 3.9 displayed one of 
the lowest MIC values of the study (9 µM; 2.2 µg.ml-1).  It was noted that this derivative was 
a 3,4-dioxygenated carbazole, which this investigation seemed to suggest was a 
requirement for anti-TB activity. 
N
H
R
3.8 R = C7H15
3.9 R = OMe
O
O
Me
 
Figure 5. Chemical structures of carbazole quinones.  Derivative 3.9 demonstrated the highest anti-
TB activity of all the carbazoles evaluated in the study with an MIC of 9 µM.  Derivative 3.8 displayed 
poor activity with an MIC of 117 µM. 
 
In a continuation of the findings of Knölker and co-workers,13 several carbazole-1,4-quinones 
with structural similarity to 3.9 were coupled to a mycothiol-type phenylthio glucosamine 
scaffold in order to evaluate such conjugates as potential antitubercular compounds.  The 
biological target of 3.9 has not yet been determined, and since the quinone functionality 
overlaps with that of the 1,4-naphthoquinone conjugates that were developed in our group 
and shown to have inhibitory activity against the mycothiol enzymes, MshB and Mca,15 it 
seemed plausible that similar conjugates with carbazole-1,4-quinones might display 
comparable activities against these or other mycothiol enzymes.  Consequently, a range of 
substituted carbazoles were considered for coupling to a phenylthio glucosamine unit. 
 
3.2 Target Molecule Design 
 
It was envisaged that the carbazole-1,4-quinone would be alkylated or acylated with a 
carbon chain of variable length, terminating in a carboxylic acid to allow for formation of an 
amide linkage to the glucosamine unit.  Potential linker sites on the carbazole quinone 
structure were proposed and evaluated.  These proposals were largely directed by the 
Knölker strategy for assembly of carbazole quinones and included attaching the linker at 
either the carbazole nitrogen, or the 2- or 3-position of the quinone.  The nitrogen site was 
selected for attachment, despite the possibility that it may reduce the activity of the 
derivative, as suggested by the Knölker study,13 since it provided a relatively facile point of 
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attachment synthetically, and also since substitution at that position would still afford a 3,4-
dioxygenated derivative, which was suggested would enhance anti-TB activity.  Substituting 
the 2- and 3-positions was not shown to negatively affect the activity, and in keeping with the 
findings by Knölker and co-workers, these derivatives were prepared such that the 3,4-
dioxygenated carbazole pharmacophore was retained. 
 
The retrosynthetic analysis for the proposed target molecules is outlined below in Scheme 1.  
The final carbazole-1,4-quinone conjugates of phenylthio glucosamine were envisaged to be 
prepared by amide coupling of the tethered carbazole with the glucosamine nitrogen, 
followed by deprotection of the acetate protecting groups.  The 3-substituted carbazole 
derivatives IV with the required terminal carboxylic acid functionality were proposed to be 
prepared from terminal diols III by oxidation following an addition-elimination-type 
substitution at the vinylogous ester 3-position by alkyl diols to generate III.   
 
The 2-substituted derivatives VI were proposed to originate from the nor-methyl carbazole 
quinone 3.10 under similar conditions to those used for the substituted naphthoquinone 
derivatives, namely, oxidative decarboxylation to generate the C-C bond.  Since the 
chemistry required to functionalise a quinone at such n unsubstituted position was known, it 
seemed a suitable approach to follow.  
 
Generation of N-alkylated carbazole quinones VIII could conceivably be prepared from 
starting material 3.11 by a Finkelstein-type alkylation of an alkyl halide.  Attachment at the 
nitrogen could also conceivably be achieved by N-acylation.  Intermediate X could be 
generated from starting material 3.11 by amide coupling with an alkyl acid chloride. 
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C-N 
Acylation
C-N 
Alkylation
2
3
N
H
O
O
O
R
3.10: R = H
3.11: R = Me
N
H
O
O
O
Me
OH
N
H
O
O
O
Me
OH
O
N
H
O
O
O
OH
O
n
N
H
O
O
O HN
O
O
HO
HO
OH
S
n
1) C-N amide
N
O
O
OH
OHO
O
n
O
HO
HO
NH
OH
S
N
O
O
HO
O
O
Me
n
1) C-N amide
2) deacetylation
N
O
O
OH
HO
O
n
O
HO
HO
NH
OH
S
N
O
O
HO
O
Me
n
O
HO
HO
OH
S
N
H
O
O
O
Me
HN
O
1) C-N amide
2) deacetylation
2) deacetylation
2) deacetylation
1) C-N amide
C-C oxidative 
decarboxylation
substitution
n
n
n
oxidation
III
IV
V
VI
VII
VIII
IX
X
XI  
Scheme 1. Retrosynthetic analysis of proposed carbazole-1,4-quinone phenylthio glycosyl conjugates 
 
Starting carbazoles 3.10 and 3.11 were prepared in the laboratory of Prof Knölker 
(Technische Universität Dresden, Germany) according to a published synthetic procedure,16 
and supplied for use in this project as part of a research collaboration. 
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3.3 Results 
3.3.1 Substitution at the 3-Position 
 
Generation of a 3-substituted carbazole quinone was attempted with dihydroxy alkanes (of 
differing chain lengths) and NaH as base.  Ethane-1,2-diol, propane-1,3-diol and pentane-
1,5-diol linkers were selected for this approach with differing outcomes.  In the first attempt, 
3.11 and NaH were dissolved in ethane-1,2-diol and heated at 50 °C overnight (Scheme 2).  
This afforded a single product in 74 % yield, identified by GC/MS as having the expected M+ 
= 271.1, and the reaction was found to be reproducible on a 100 mg scale under milder 
conditions (r.t. for 3 h15 min).   
 
N
H
O
O
O
OH
n
(i)
N
H
O
O
O
N
H
O
O
O
O
(ii)
N
H
O
O
O OH
(i)
X
3.13
3.14: n = 3
3.15: n = 5
3.11
3.12
3.11
 
Scheme 2. Synthesis of the 3-substituted carbazole quinone derivatives. (i) NaH, ethylene glycol, r.t, 
3 h, 69 %; (ii) NaH, alkyl diol, 50 °C, 18 – 42 h, 3.14: 65 %, 3.15: 74 %. 
 
However, the 1H NMR spectrum was not consistent with the expected 3-O-alkylated 
carbazole quinone.  The carbazole methyl group appeared as a doublet at 1.2 ppm, instead 
of the expected singlet at ~2.0 ppm, and there were signals corresponding to five aliphatic 
protons, instead of the expected two multiplets corresponding to the methylene signals of the 
alkyl chain.  The differentiation of the methylene signals indicated that they were in different 
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chiral environments.  The analysis of the analytical data led to the proposed structure 
indicated in Figure 6, incorporating an ethylene ketal at C-3’. 
 
 
Figure 6. 1H NMR spectrum (top) and expansion of the aliphatic region (bottom) indicating the 
splitting of the carbazole quinone methyl and differentiation of the methylene signals in the ethyl 
chain.  The signals at 1.95 and 2.70 ppm correspond to the acetone solvent and water signals, 
respectively. 
 
A plausible mechanism for the formation of 3.13 involves two sequential additions to the 
vinylogous ester (Scheme 3).  After deprotonation of the diol by NaH to form the alkoxide, 
the first addition-elimination step takes place at C-3’ with loss of MeO-.  The terminal 
alkoxide (generated by excess NaH) then adds at the same position to form the dioxolane 
enolate, which is quenched during aqueous workup. 
 
N
H
O
O
Me
O
O
9'
5'
6'
1'
2'
3'4'
7'
8'
4a'
8a' 9a'
4b'
10'
11'
12'
13'
H
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H
-H2
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3.13
 
Scheme 3. Mechanism of formation of the dioxolane product by treatment of the carbazole quinone 
with the dialkoxide of ethylene glycol. 
 
A possible strategy for obtaining controlled addition to the desired terminal alcohol product 
would be to use 1 eq of NaH and ethylene glycol. 
 
The propane diol and pentane diol derivatives were prepared in the same manner as the 
ethane diol (Scheme 2), but despite GC/MS evidence supporting their formation, 1H NMR 
spectroscopy indicated considerable contamination by the diol which was not readily 
removed by aqueous workup and chromatography.  These derivatives were not pursued 
further.  
 
3.3.2 Substitution at the 2-Position 
 
Since the carbazole quinone bears a resemblance to plumbagin, the possibility of attaching 
a tethered carboxylic acid at the quinone in an oxidative decarboxylation reaction similar to 
that achieved with the naphthoquinone was explored.  This approach was found to be 
successful, but low yielding.  For this reaction, the nor-2-methyl carbazole quinone derivative 
3.10 (Scheme 4) was used for the reaction with glutaric and adipic acid, respectively.  The 
same conditions were employed for the oxidative decarboxylation, namely, the use of 
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ammonium persulfate as oxidant and silver (I) nitrate as catalyst in a 60 % acetonitrile/water 
mix.  Due to the successive low pressure cycles used to degas the solvent, which resulted in 
evaporation of some CH3CN, a solvent mixture containing a slightly higher ratio of CH3CN to 
water was used to arrive at a mixture of approximately 60 %. 
 
N
H
O
O
O
N
H
O
O
O
OH
O
n
(i)
+ HO OH
OO
n
3.18: n = 1
3.19: n = 23.10
3.16: n = 1
3.17: n = 2  
Scheme 4.  Oxidative decarboxylation reaction to attach the tethered carboxylic acid at the 2-position 
of the carbazole quinone. (i) (NH4)2S2O8, AgNO3, 60 % (aq) CH3CN, 65 – 70 °C, 4 h, 3.18: 31 %, 3.19: 
38 %. 
 
The reaction resulted in a yield of 31 % for the glutaric and 38 % for the adipic derivatives, 
respectively, with unreacted starting material recycled for use in subsequent reactions.  This 
afforded a stable carboxyalkyl carbazole quinone in a single step, in a form allowing for 
direct amide-coupling to the glucosamine thioglycoside. 
  
3.3.3 Substitution at the Carbazole Nitrogen 
 
Attachment of a linker via the carbazole nitrogen was initially attempted by reacting the free 
carbazole quinone 3.11 with an acid chloride.  The glutaric and adipic acid-derived 
derivatives 3.22 and 3.23 (Scheme 5) were prepared from their respective acid chlorides in 
dry THF with Et3N, and obtained in 74 and 44 % yield, respectively.  The reactions were 
difficult to monitor due to the product and starting material having similar Rf values on TLC, 
and purification by chromatography appeared to result in some conversion of the product 
back to the starting carbazole-1,4-quinone 3.11.  
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3.22: n = 1: 74 %
3.23: n = 2: 44 %
3.11
3.11 3.25
3.24
3.20: n = 1
3.21: n = 2
 
Scheme 5.  Synthesis of the N-acyl substituted carbazole quinone. (i) Et3N, THF, r.t., 2-5 h; (ii) LiOH, 
THF:H2O (1:1), 47 h. 
 
The labile nature of this amide bond is due to the fact that the carbazole quinone amine can 
be considered to be part of a vinylogous amide that extends into the quinone (Figure 7).  
This results in low reactivity of the amine towards acylation, and also causes any 
subsequent acyl bond to be highly labile and easily cleaved during chromatography due to 
the electron-withdrawing character of the quinone on the amine.   
 
N
H
O
O
O
 
Figure 7.  Chemical structure of carbazole quinone with the vinylogous amide bond given in bold. 
 
This high lability was realised in the subsequent reaction where the methyl ester was treated 
with LiOH in order to effect saponification (Scheme 5).  The reaction was unsuccessful and 
resulted in conversion back to starting material 3.11, and in one case even resulted in 
demethylation of the 3-methoxy substituent (to form 3.25).  The difficulties in this approach 
prompted the use of a benzyl ester as protecting group, to allow for a milder, non-basic 
hydrogenolytic deprotection step.   
 
Monobenzylated glutaric acid 3.27 was thus prepared by reacting glutaric anhydride and 
benzyl alcohol in the presence of Et3N and DMAP in dry CH2Cl2 (Scheme 6).  The product 
was obtained in quantitative yield, and used in the subsequent step without further 
purification.  The benzylglutaric acid chloride 3.28 was prepared by treatment of a CH2Cl2 
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solution of the carboxylic acid with oxalyl chloride and a drop of DMF, and the acid chloride 
was then added by canula to a solution of the carbazole quinone in dry THF.  Once the 
product 3.29 was formed, attempted purification by flash chromatography once again 
resulted in reversion to the original carbazole quinone.  A small fraction of partially purified 
product was, however, subjected to hydrogenation using Pearlman’s catalyst (palladium 
hydroxide on carbon) to remove the benzyl protecting group, but once again, attempted 
purification resulted in formation of the carbazole quinone.  It was thus clear from these 
attempts that N-acyl derivatives, even if they could be formed, would be too labile for their 
intended further use, and an alkylation strategy was pursued instead.   
 
N
H
O
O
O
Cl OBn
OO
N
O
O
O
OBnO
O N
O
O
O
OHO
O
(iv)
HO OBn
OOO OO (i) (ii)
(iii)
(v) (v)
3.27 3.28
3.29 3.30
3.11
3.11
3.11
3.26
 
Scheme 6. Synthesis of the benzyl-protected glutaric acid tether, and unsuccessful debenzylation.  (i) 
Benzyl alcohol, Et3N, DMAP, dry CH2Cl2, 0 °C – r.t., 20 h, quant.; (ii) (COCl)2, dry CH2Cl2, DMF, 0 °C 
– r.t., 2 h; (iii) dry THF, Et3N, 0 °C – r.t.,1 h, <7 %; (iv) H2, Pd(OH)2/C, EtOAc, r.t.; (v) chromatography. 
 
Alkylation of the carbazole nitrogen with benzyl 6-bromohexanoate and NaI (under 
Finkelstein conditions) was achieved in the laboratory of Prof Knölker and supplied as the 
debenzylated carboxylic acid 3.33 (see Scheme 7) for coupling to the glucosamine 
thioglycoside. 
 
3.3.4 Amide Coupling and Acetate Deprotection 
 
Coupling of the tethered carbazole quinones to the glucosamine thioglycoside was achieved 
using EDC.HCl as coupling agent in dry THF containing 1-hydroxybenzotriazole (HOBt) and 
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diisopropylethylamine (DIEA).  The yields were quite varied, with the glutaric derivative 3.31i 
obtained in 72 %, the adipic derivative 3.32 in 14 %, and the N-hexanoic derivative 3.34 in 
68 % yield (Scheme 7).   
 
 
Scheme 7.  Coupling of the tethered carbazole quinones to the glucosamine thioglycoside. (i) 
EDC.HCl, HOBt, DIEA, dry THF, r.t., 3.31: 67 %, 3.32: 14 %, 3.34: 68 %. 
 
Following successful coupling of the carbazole-1,4-quinones to the glucosamine 
thioglycoside, final deprotection was accomplished using sodium methoxide in methanol 
(Scheme 8).  Due to poor solubility of the deprotected product and the partially deprotected 
intermediates, non-catalytic quantities of methoxide were required to effect complete 
deprotection, and various reaction conditions were explored.  The glutaric derivative was 
deprotected using 2.6 eq of methoxide, with the reaction complete after 45 min.  This 
quantity was initially reduced to 0.3 eq methoxide for the adipic derivative, however, 
conversion to the product was slow and after 24 h an additional 0.5 eq was added and the 
temperature increased to 50 °C (in order to improve solubility) and the reaction left to 
continue for a further 16 h before complete consumption of the starting material.  For the N-
hexylated product, 0.2 eq NaOMe was used and the reaction required 10 days to reach 
complete consumption of the starting material.  In all cases, the poor solubility of the 
deacetylated product was evident by the formation of a precipitate upon addition of the 
NaOMe.  Purification of the deprotected conjugates proved to be difficult and required 
                                               
i Prepared by Prof Knölker’s laboratory 
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combinations of polar solvents for the chromatography as well as recrystallization from 
methanol to eventually afford the purified products in moderate yields of 68 %, 37 % and 48 
% for the glutaric, adipic and N-hexylated derivatives, respectively. 
 
Scheme 8.  Deacetylation to form the final carbazole-glucosamine conjugates. (i) NaOMe, (0.8 - 2.6 
eq), MeOH, r.t. – 50 °C, 45 min – 36 h, n = 1: 68 %, n = 2: 37 %; (ii) NaOMe (0.2 eq), MeOH, r.t., 10 
d, 48 %.  
 
3.4 Discussion and Conclusion   
 
The two main challenges were encountered in substitutions of the 3-methoxy group on the 
carbazole ring using diols: preventing the addition of the second hydroxyl to form spiro 
dioxanes, and separation of unreacted diol from the product.  Potential solutions to the first 
challenge could be to use a mono-protected diol, with only one of the alcohol groups 
available for deprotonation and subsequent addition-elimination, as long as the protecting 
group was base-resistant, with examples being silyl, alkyl, alkoxymethyl and allyl ethers.  A 
potential solution to the separation problem would be to use fewer equivalents of diol and 
sodium hydride reagent (~1.5 eq).  It was in fact established that excess diol was not 
required for the reaction to proceed, and the use of an anhydrous solvent as substitute for 
the excess diol would be a better option.  Future attempts towards generating these types of 
3,4-dioxygenated derivatives would have to consider such modifications to the synthetic 
protocol to be successful. 
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The radical conjugate addition to the quinone to generate the C-C bond was found to be a 
low-yielding reaction, both with the carbazole-1,4-quinones and 1,4-naphthoquinones, 
although the reaction was reproducible, the unreacted starting material recoverable, and was 
able to generate the desired coupled product in a single step.  This is in keeping with 
literature findings on this type of reaction.15,17,18  The reason for the low yield has not yet 
been fully evaluated, although there are a number of likely reasons for this phenomenon.  
One possible reason could be that the quinone is poorly reactive.  Once the alkyl radical has 
been generated, it can react further via a number of competing reaction pathways (Scheme 
9).19  Ideally the radical would undergo selective conjugate addition to the quinone.  
However, the radical could also be oxidised by a second equivalent of Ag(II) to generate the 
corresponding carbocation, which could then undergo one of several reactions including 
elimination to the terminal olefin, protonation to the alkane, hydroxylation by water to form a 
primary alcohol, and esterification in the presence of the acid.  Evidence for these side 
reactions was reported by Anderson and Kochi.19 
OH
R
O
R
-CO2
R CH2
R CH3
R
OH
Ag(II) Ag(II)
R
O
R
O
R
R'
O
O
R''
R'
O
O
R'' R
 
Scheme 9.  Competing reaction of the alkyl radical generated by Ag(II)-mediated oxidative 
decarboxylation.  Oxidation by a second equivalent of Ag(II) generates the carbocation which can 
then undergo one of several reactions including elimination, protonation, hydroxylation or 
esterification.19  Successful alkylation of the quinone requires trapping of the radical by the quinone 
substrate in order to prevent oxidation to the carbocation. 
 
 
Since in our experience a large proportion of the unreacted quinone was recovered from the 
reaction, and since extended periods of stirring beyond the usual reaction time of 4 h did not 
result in a higher yield, it is likely that a considerable quantity of alkyl radical was inactivated 
by further oxidation by subsequent conversion to one of the products indicated in Scheme 9.  
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If the alkyl radicals were still present during the additional reaction time, they should have 
added to the quinone.  Consequently, in order to increase the yield of this reaction the 
reactivity of the quinone would have to be increased so that conjugate addition at this site is 
the energetically-favoured reaction pathway rather than oxidation of the alkyl radical to the 
carbocation.  This could be achieved by the addition of a catalyst or by a modification to the 
quinone structure to enhance its electrophilicity.  Attempts to slow the addition of APS to the 
reaction mixture did not result in a higher yield, suggesting that the additional oxidation was 
not preventable by slowing down the rate of formation of Ag(II), although perhaps a different 
strategy to achieve this may be possible.  
 
Employing a different synthetic route could potentially increase the yield of alkylated product, 
although achieving selective addition to the “soft” conjugate position on the quinone rather 
than 1,2-addition to the “hard” carbonyl carbon would be a considerable challenge to 
overcome.  Nucleophiles such as Grignard reagents, lithiated species and alkoxides would 
all tend to add predominantly to the carbonyl centre and generate an alcohol or hemiketal, 
as reported by Knölker and co-workers.16  However, the use of nitrogen or cuprate 
nucleophiles might be able to overcome this problem and facilitate addition of an appropriate 
linker to the 2-position of the quinone (Scheme 10).  The overall yield for such a strategy 
would have to be weighed against the low-yielding single step reaction of the oxidative 
decarboxylation reaction to evaluate whether such an alternative pathway would result in a 
product in superior overall yield. 
O
O
R'
R''
O
OH
R'
R''
O
O
R'
R''
RO/R
R/NHR
O
O
R'
R'' R/NHR
[O]
(i) MgXR or LiR or RO-
(ii) R2CuLi or 
     RNH2
 
Scheme 10. Addition of nucleophiles to a quinone - potential alternative pathways to substituting the 
quinone. (i) Addition of Grignard or lithiated species and alkoxides leads to 1,2-addition; (ii) addition of 
cuprates and nitrogen nucleophiles may generate the 2-substituted derivative, although this pathway 
also requires an additional oxidation step to regenerate the quinone.  
 
The failure of the N-acylation reactions is easy to rationalise based on the identification of 
the carbazole quinone nitrogen as part of a vinylogous amide.  The N-alkyl product was far 
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more stable than its N-acyl counterpart, since the C-N bond is less easily cleaved during 
chromatographic purification.  This position on the carbazole provides a facile site for the 
attachment of a linker to the phenylthioglycoside, and it would be interesting to investigate 
the impact that differing the chain length would have on subversive substrate/inhibitory 
activity. 
 
Further sites for the attachment of the linker could be the 6-position, based on the 
observation that carbazole derivative 3.6 had the lowest MIC of all the compounds evaluated 
in the Knölker study.  A synthetic target for ongoing studies might therefore have a structure 
such as 3.38 (Figure 8), with the glucosamine incorporated at the 6-position via an amide.   
 
Figure 8.  Chemical structures of the active carbazole 3.6 and a proposed derivative 3.38  
 
A considerable problem with the final compounds prepared in this study was the poor 
solubility properties they displayed, which presents significant challenges to their further 
development as lead compounds.  An attempt to address this by incorporating a glycerol unit 
at the anomeric position to replace the hydrophobic phenylthio group was described in 
Chapter 2, and incorporation of other polyhydroxylated inositol surrogates such as 
pentaerythritol20 or some other polyhydroxylated derivative might be advantageous.  It would 
indeed be interesting to evaluate the extent to which the inhibitory activity is related to the 
anomeric substituent, and whether the free glycose (OH at the anomeric position) has similar 
activity.  Furthermore, the contribution of the linker itself could be evaluated by considering 
alternatives such as a polyethylene glycol chain (see 3.40 in Figure 9) that would enhance 
hydrophilicity.  A further alternative would be to consider incorporating a protonatable 
nitrogen substituent on the carbazole, allowing for the preparation of a salt, and consequent 
enhancing of the aqueous solubility. It is interesting to note in this regard that enhanced anti-
TB activity was observed for the amino-carbazole 3.39 in the Knölker study.  
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N
NH2
MIC 55 M
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O
HO
HO
NH
OH
XO
N
H2N
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O OH
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HO COOH
OH
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quinic acid  
Figure 9. Chemical structures of the ant-TB compound 3.39 and a potential derivative 3.40 with 
modifications that may enhance the solubility of this conjugate.  These include incorporating a 
protonatable nitrogen at the 3-position of the carbazole, using a polyethylene glycol linker, and 
substituting the anomeric substituent with a hydroxylated alternative. 
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Chapter 4 
Cloning, Expression and Purification 
of Mycobacterium tuberculosis 
Mycothiol Disulphide Reductase 
 
4.1 Introduction 
 
Among the disulfide reductase class of flavoproteins are glutathione reductase (GR), 
trypanothione reductase (TryR), lipoamide dehydrogenase (LipDH), thioredoxin reductase 
(TrxR), and the mycobacterial mycothiol disulfide reductasei (Mtr).1,2,3  Mtr was first 
described by Patel and Blanchard in 1998,4 who subsequently cloned, expressed, purified 
and characterised the enzyme.1,5 Similar to its glutathione and trypanothione homologues, 
Mtr is a 100 kDa dimeric complex containing a single FAD cofactor per monomer adjacent to 
the redox-active disulfide.  During NAD(P)H-dependent reduction of the substrate, the 
active-site disulfide is reduced to the dithiol in a two-electron transfer process resulting in the 
formation of a dithiol-FAD charge-transfer complex.1  The mechanistic details of the reaction 
were described previously in Chapter 1. 
 
The potential for Mtr to act as a viable target for antitubercular chemotherapy is heightened 
by the finding that it displays no overlapping activity with the disulfides of GSH and 
coenzyme A (CoA) found in humans.1,4  This provides potential for the development of an 
inhibitor that is selective for the bacterial reductase over the human GR.  The enhanced 
sensitivity to oxidative stress that MSH-deficient mycobacteria display further supports the 
targeting of this enzyme system for potential antitubercular chemotherapy.6 
 
The biological importance of Mtr and its reported ability to react with naphthoquinones in a 
subversive substrate mechanism prompted the creation of this project in order to investigate 
the potential for naphthoquinone- and carbazole-derived conjugates of a MSH-like scaffold 
to display subversive substrate activity against Mtr.7  Consequently, the cloning, expression 
                                               
i Also referred to as mycothione reductase in earlier papers, based on the nomenclature of the related 
disulfide reductases of glutathione and trypanothione. 
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and purification of this disulfide reductase was carried out in order to generate purified 
enzyme for the study. 
 
4.2 Reagent Suppliers  
 
Kanamycin and Protease Inhibitor Cocktail set III were obtained from Calbiochem.  β-
NADPH, Tween® 80, acrylamide, HPLC grade acetonitrile (Chromasolv®) and TFA were 
obtained from Sigma-Aldrich.  N,N’-methylenebisacrylamide was purchased from Fluka.  
Ammonium persulfate, sodium dodecyl sulphate and TEMED were acquired from BDH.  
Middlebrook 7H9 Broth was exclusively obtained from Difco.  
 
4.3 Materials and Methods Utilised in the Isolation of Mycothiol From 
M. smegmatis 
 
Neither mycothiol (MSH), nor any of its later precursors, are commercially available (due 
largely to the low yield and high cost of their chemical synthesis8,9).  This lack of commercial 
availability poses a challenge to the study of enzymes that have MSH as a co-factor, since it 
is required for their assays.  The high reactivity of the sulphydryl group of MSH makes 
extraction from mycobacterial cells difficult, since it readily reacts with other thiols to form 
disulphides, with aldehydes and activated double bonds to form conjugates, and is 
irreversibly oxidised to sulphinic acid.10  Consequently, these side reactions need to be 
controlled in order to successfully extract MSH from cells in a reasonable yield.   
 
In order to obtain MSH for use in this study, extraction from cultured cells of M. smegmatis, 
using a modification to the procedure reported by Steenkamp and Vogt,10 was performed.  
This protocol minimises side reactions by rapidly derivatising MSH with the mixed disulphide, 
2-S-(2'-thiopyridyl)-6-hydroxynaphthyldisulphide, to form the heterodisulphide, MSSNaph 
(Scheme 1) upon cell lysis.  MSH reacts preferentially with the sulphydryl group of 2-thio-6-
hydroxynaphthalene rather than that of the 2-thiopyridine for two reasons.  Firstly, the 2-
thiopyridine has a lower energy of ionization than the 2-thio-6-hydroxynaphthalene, and 
secondly, the delocalization of charge from the thiolate anion into the pyridine ring renders 
the resultant pyridine-2-thione a more stable side product than the 2-thio-6-
hydroxynaphthalene which does not have this extra resonance ability.  The pH required for 
this reaction is intermediate between the pKa of the 2-thio-6-hydroxynaphthyl thiol and that 
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of the 2-thiopyridine, and under such conditions the reaction is strongly biphasic.  The 
reaction is outlined in Scheme 1 below. 
 
OH HO
S
S
N
S
HN
+
+
MSH
MSSNaph Pyridine-2-thione
2-S-(2'-pyridyl)-6-hydroxynaphthyldisulfide
O
HO
HO
ONH
OH
HO OH
OH
OHO
NHAcHS
OH
O
HO
HO
ONH
OH
HO OH
OH
OHO
NHAc
S
S
HO  
Scheme 1. Derivatisation of MSH with 2-S-(2'-thiopyridyl)-6-hydroxynaphthyldisulphide 
 
The isolation and purification of the mixed disulphide product, MSSNaph, is achieved by its 
adsorption onto reversed-phase materials.  After the removal of impurities, the MSH can be 
recovered by reduction of the disulphide with dithiothreitol (DTT) or 2-mercaptoethanol.   
 
4.3.1 Synthesis of 2-S-(2’-thiopyridyl)-6-hydroxynaphthyl-disulphide 
 
The procedure used for the synthesis of the heterodisulphide involved dissolving 6-
hydroxynaphyldisulphide (2.00 g, 5.71 mmol) in 1000 ml of a 1:1 (v/v) mixture of acetonitrile 
and water.  The disulphide was reduced by the addition of sodium borohydride (1.50 g, 
39.65 mmol) at room temperature, resulting in the appearance of a yellow colour in solution 
due to the formation of the thiolate anion.  Excess borohydride was destroyed by the addition 
of glacial acetic acid (~5 ml) and the pH of the resulting solution increased to 4.6 by the 
addition of dipotassium phosphate.  This pH was chosen to be considerably lower than the 
pKa of 6.4 of the 2-thio-6-hydroxynaphthalene in order to keep the thiol in its protonated form 
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and minimise oxidation back to the disulphide.10  The 2-thio-6-hydroxynaphthalene solution 
was then added drop-wise over 20 min to a stirred solution of 2,2’-dithiodipyridine 
(Aldrithiol®) (4.74 g, 21.52 mmol) in 500 ml 1:1 (v/v) acetonitrile/water.  The mixture was left 
stirring for a further 60 min after which 3 volumes of water (4.5 L) were added to reduce the 
acetonitrile concentration to ~12 %.  The solution was cooled to 4 C overnight and the 
resulting precipitate, consisting of primarily 6-hydroxy-2-naphthyl disulphide and 2-S-(2’-
thiopyridyl)-6-hydroxynaphthyl disulphide, was collected by centrifugation.  These 
components were separated on a Vydac TP1022 C18 reversed-phase preparative HPLC 
column (250 x 22 mm), using an isocratic mobile phase of 65 % acetonitrile and 35 % of 0.1 
% trifluoroacetic acid in water, at a flow rate of 10 ml/min, and monitored at 280 nm. 
A small aliquot of the mixture was analysed by HPLC on a Phenomenex phenyl hexyl C18 
HPLC analytical column (250 x 4.6 mm) using Method 1 (Table 1) as the mobile phase 
gradient programme, and the effluent monitored at 280 nm. 
 
Table 1. Method 1 gradient programme 
Time (min) 0 5 35 40 45 
% A 95 95 10 10 95 
% B 5 5 90 90 5 
5l injected, flow rate = 0.8 ml/min.  Solvents: A = 0.1 % TFA; B = 100 % CH3CN 
 
The 2-S-(2-thiopyridyl)-6-hydroxynaphthyl disulfide eluted at 31 min while the unreacted 6-
hydroxy-2-naphthyl disulfide eluted at 34 min, as shown by the elution profile in Figure 1.  
Impurities were negligible.  
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Time (min)
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Figure 1: Analytical HPLC elution profile of the heterodisulphide, 2-S-(2’-thiopyridyl)-6-
hydroxynaphthyl disulphide (31 min), and the starting material, 6-hydroxy-2-naphthyl disulphide (34 
min) 
 
Quantification of the desired 2-S-(2’-thiopyridyl)-6-hydroxynaphthyl disulphide was 
determined spectrophotometrically (Ocean Optics mini diode-array USB2000 spectrometer) 
at a wavelength of 298 nm using an extinction coefficient of 11,184 M-1.cm-1.  A 20 l aliquot 
of the heterodisulphide was mixed with 980 l of 25 mM potassium phosphate buffer (pH 8) 
in a 1 ml cuvette and the OD298 determined.  The eluted heterodisulphide solution was 
obtained at a concentration of 1.27 mM in 1.1 L (0.399 g, 1.397 mmol) with a yield of 24 %. 
 
4.3.2 Reaction between heterodisulphide and mycothiol-containing cell 
lysates 
 
A solution of 0.25 M perchloric acid containing 2 mM EDTA in water was prepared, and 
diluted in a 1:1 ratio with 40 % acetonitrile/water. This solution (500 ml) was added to 250 g 
of packed M. smegmatis cells (wet weight), and the mixture sonicated until a homogeneous 
mixture was obtained (~15 min).  This was then centrifuged at 10,000 x g for 15 min. The 
supernatant was decanted and its thiol concentration estimated by reaction with 4,4’-
dithiodipyridine (DTDP).  Reaction mixtures contained 24.25 µmoles of potassium phosphate 
buffer, pH 8, and 0.2 µmoles of DTDP in a volume of 980 l.  To this was added 20 l of the 
sample and its thiol concentration was determined by following the resultant absorbance 
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change at 325 nm (ΔЄ325 = 19.8 mM-1cm-1).  Total thiol content was estimated to be 849 
moles (in 510 ml). 
 
The pHs of both the cell lysate and heterodisulphide solutions were increased to 4.6 by the 
drop-wise addition of Et3N at room temperature, after which the cell lysate solution was 
added drop-wise to the heterodisulphide over a period of 30 min with stirring.  The reaction 
leading to the formation of 2-S-(mycothiolyl)-6-hydroxynaphthyldisulfide (MSSNaph) was 
monitored by HPLC analysis of aliquots of the reaction mixture (Figure 2). 
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Figure 2. Analytical HPLC elution profile of the cell lysate/heterodisulphide reaction mixture.  
Reaction progress was monitored after 30 min (A), 2 h (B), and 21 h (C).  The product, MSSNaph, 
eluted after 19 min. Method 1 was used for the analysis. 
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After 48 h there remained a significant excess of heterodisulphide over MSSNaph, and it 
was decided that more cell lysate should be added in order to increase the yield of 
MSSNaph.  Consequently, a further 115 g of M. smegmatis cells were lysed and prepared 
as described above, and added to the reaction mixture.  The thiol content of this second 
lysate mixture was estimated to be 412 moles (in 240 ml), based on reaction with DTDP.  
 
Upon consumption of all MSH in the cell lysate, the resultant MSSNaph solution was diluted 
with 2 volumes of distilled water (3.7 L) to reduce the acetonitrile concentration to ~10 %.  
This solution was then loaded onto a C18 silica gel column, and pure MSSNaph product was 
eluted in 30 % acetonitrile/water.  The acetonitrile was removed under reduced pressure, 
and dry MSSNaph obtained after lyophilisation in a final yield of 140 mg (0.212 mmoles; 17 
% of an initial total thiol content of 1.261 mmoles). 
 
2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide clearly has high specificity for MSH as there is 
but one prominent peak in the chromatogram corresponding to the MSSNaph conjugate (at 
19 min, see Figure 3), with minor uncharacterised side-products.  Even after an extended 
incubation time of 48 h, no other thiol present in the M. smegmatis cell extract formed a 
disulphide with the heterodisulphide reagent to a notable extent.  Other major characterised 
peaks in the HPLC trace included pyridine-2-thione (eluted at 5 min), 2-thiopyridyldisulfide 
(eluted at 27 min), excess 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide (eluted at 31 min) 
and 6-hydroxy-2-naphthyldisulfide (eluted at 34 min).  
 
 HPLC analytical profile of MSS-Naph
Time (min)
0 10 20 30 40 50
A2
80
 
Figure 3.  Analytical HPLC elution profile of purified MSSNaph. 
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The excellent chromatographic properties provided by the naphthalene chromophore, 
allowed for comparison of the relative quantities of naphthyl heterodisulphides, including 
MSSNaph, to be done by measuring the peak areas in the HPLC profiles.  
 
4.3.3 Conclusion 
 
It is indicated in the literature that an expected yield of MSH from M. smegmatis cells is 100 
mg from 250 g cells.10  In this isolation, 140 mg MSSNaph was obtained from 365 g cells, 
which could yield a maximum of 103 mg of MSH - approximately 70 % of the expected 
value.  This lower-than-expected result could be due to scale-up factors, which are often 
known to influence the yield of chemical reactions. While this value is lower than that 
reported by Steenkamp and Vogt,10 it is significantly greater than that achieved by chemical 
synthesis, and permits the acquisition of significant amounts of MSH needed for enzyme 
assays in a comparatively short period of time.   
 
4.4 Materials and Methods Used in the Cloning, Expression and 
Purification of Mtr  
4.4.1 Introduction 
 
The cloning, expression and purification of Mtr was carried out using a procedure that was 
based on the approach reported by Patel and Blanchard,11 involving transformation of M. 
smegmatis cells with a heat-shock inducible plasmid containing the Mtr gene.  Purification 
was envisaged to proceed by nickel immobilised metal affinity chromatography (IMAC) since 
the construct included a hexahistidyl tag (His6-tag) at the carboxyl terminus. 
 
4.4.2 Preparation of Middlebrook Medium  
 
Cultures of M. smegmatis cells that had been transformed with the construct containing the 
Mtr gene and heatshock inducible promotor region were grown in Bacto Middlebrook 7H9 
broth prepared as follows:  the powdered medium (18.8 g) was dissolved in H2O (3.6 L) and 
the mixture autoclaved at 121 °C and 15 psi for 20 min.  360 ml aliquots of this stock were 
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added to each of 10 x 1 L conical flasks.  To each of these 10 flasks was added 40 ml of 
ADS (Albumin, Dextrose, Sodium chloride) mix, which was prepared separately as follows: 
Bovine serum albumin (20 g), glucose (8 g), NaCl (3.4 g), glycerol (20 ml, to a final 
concentration of 0.5 %) and Tween 80 (2 ml, to a final concentration of 0.05 %) were 
dissolved in Millipore®-purified water (400 ml) and filter sterilized through Minisart® sterile 
cartridges.  Where bovine serum albumin was unavailable, casein digest (tryptone powder) 
was used as an amino acid source in its place.  Kanamycin (final concentration: 15 μg/ml) 
was added as antibiotic to each flask (concentration greater than that was found to be toxic 
to the M. smegmatis cells). 
 
4.4.3 Ni2+ Immobilised Metal Affinity Chromatography 
 
Iminodiacetic acid 6 % agarose resin was charged with 0.2 M NiSO4 solution, followed by 
washing and equilibration of the column with KH2PO4 (20 mM; pH 7.6) buffer, prior to being 
loaded with the clarified cell extract.  After sample loading, the column was washed in a 
step-wise gradient of NaCl (200 ml each of 50 mM, 100 mM, 200 mM), to remove cellular 
impurities bound by non-specific ionic attraction.  When the column eluent had an A280 < 
0.05, a low concentration of imidazole (100 ml, 10 mM, pH 7.6) in column buffer was added 
to elute any weakly bound impurities.  However, this had the surprising result of causing the 
bound (His)6-tagged enzyme to elute.  Due to the bound flavin, the enzyme fraction was 
bright yellow in colour, which allowed it to be monitored as it moved down the column.  The 
eluent was collected by automated fraction collector, and the active fractions identified by 
their yellow colour and by spectrophotometric enzyme assay. 
.   
4.4.4 2’,5’-Adenosine Diphosphate-Sepharose Affinity Chromatography 
 
The 2’,5’-ADP resin was suspended in binding buffer (20 mM KH2PO4, 50 mM NaCl, pH 7.6), 
poured into the column, and washed with additional buffer.  The enzyme sample was then 
added allowing for a fraction (8 %) of the protein to bind, although a considerable quantity 
(92 %) eluted without binding.  When this active, unretained fraction was reloaded onto the 
column, it again failed to bind, and eluted in the binding buffer.  The fraction that did bind 
was purified by washing with binding buffer, and then eluted in a step-wise gradient of NaCl 
(75 mM, 0.2 M, 1.0 M).   
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4.4.5 Anion Exchange Chromatography 
 
A Q-Sepharose High Performance (Q-HP) column (column volume of 30 ml) was used in 
conjunction with a Gilson 321 pump (at a flow rate of 2.5 ml/min), Waters 484 tunable 
absorbance detector (set at 280 nm) and a Gilson FC 204 fraction collector.  The data was 
transferred to a computer using a Gilson 506C system interface and was interpreted using 
Gilson Unipoint software, version 5.11.   
The Q-HP column was first reversed and washed with 2 column volumes (CV) 2 M NaCl, 
2 CV distilled water, 2 CV 1 M NaOH and again with 2 CV distilled water.  The column was 
then returned to the normal direction and equilibrated with 5 CV of 20 mM Tris-HCl, 300 mM 
NaCl, pH 7.6.  The pre-column sample was passed through a 0.45 μm filter and loaded onto 
the Q-HP column using a 50 ml GE healthcare superloop.  The sample was loaded onto the 
pre-equilibrated column, and cycled three times in order to increase enzyme interaction with 
the resin.  Thereafter, the column was washed with binding buffer (20 mM Tris-HCl, 300 mM 
NaCl, pH 7.6) and once the A280 < 0.05, a gradient elution was run (300 mM to 1 M NaCl) 
over 10 CV.    Fractions of 5 ml were collected in 60 tubes over 120 min.  Activity assays 
revealed active enzyme to be found in all collected fractions, with the greatest activity found 
in test tubes 6 – 24. 
 
4.4.6 Absorbance Spectrophotometry 
 
The eluents from the chromatographic columns used in the purification of Mtr were 
monitored at 280 nm in order to follow the progression of purification.  Impurities were 
assumed to have been eluted when the A280 < 0.05.   
 
4.4.7 SDS-Polyacrylamide Gel Electrophoresis 
 
4.4.7.1 Preparation of materials 
 
Resolving gel buffer: Prepared by dissolving Tris (18.18 g; 0.75 M) and SDS (0.4 g; 0.2 %) in 
200 ml distilled water and adjusting the pH to 8.8 with concentrated HCl. 
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Stacking gel buffer: Prepared by dissolving Tris (6.06 g; 0.25 M) and SDS (0.8g 0.4 %) in 
200 ml distilled water. The pH was adjusted to 6.8 with concentrated HCl. 
 
30 % Acrylamide-bis-acrylamide stock solution: Prepared by dissolving acrylamide (30.0 g) 
and bis-acrylamide (0.8 g) in 100ml distilled water. The solution was filtered and stored at 4 
°C in a foil-covered bottle.  
 
10 % Ammonium persulfate solution (APS): Prepared by dissolving APS (0.05 g) in 500 µl 
distilled water.  The solution was stored at -20 °C. 
 
N,N,N',N'-tetramethyl-1,2-diaminoethane(TEMED): The TEMED catalyst was used without 
dilution. 
 
Electrophoresis tank buffer: Prepared by dissolving Tris (3.03 g; 0.025 M), glycine (14.40 g; 
0.192 M) and SDS (1.00 g; 0.1 %) in distilled water (1.00 L).  This solution, at pH 8.3, was 
stored at 4 °C. 
 
Sample treatment buffer: Solution composed of stacking gel buffer (2.5 ml), 10 % (w/v) SDS 
solution (4 ml), glycerol (2 ml), 2-mercaptoethanol (1 ml), bromophenol blue, and 0.5 ml 
distilled water.  Stored at -20 °C. 
 
Coomassie blue staining solution: Coomassie Brilliant Blue (1.25 g) was dissolved in 227 ml 
methanol, 227 ml water and 46 ml glacial acetic acid, and the solution filtered.  
 
Destaining solution: The destaining solution was composed of ethanol, acetic acid and water 
in a ratio of 2:1:7. 
 
4.4.7.2 Preparation of the Gel 
 
SDS-polyacrylamide gel electrophoresis was performed on vertical slab gels.12  The 
resolving gel was prepared according to the recipe given in Table 2.  After combining the 
buffer, water, acrylamide solution and APS, the TEMED catalyst was added and the solution 
gently mixed, before being poured between the 2 glass plates in the gel assembly 
apparatus.  A 0.5 cm layer of water was carefully applied to the top of the gel solution to 
ensure a flat upper surface.  The gel was left to polymerise for approximately 45 min.  The 
stacking gel was prepared in the same way using the recipe given in Table 2, and was 
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added over the resolving gel.  A comb was added and the gel allowed to set over 1 h.  Once 
set, the comb was removed and the top tank assembled and filled with electrophoresis 
buffer. 
 
Table 2. SDS Polyacrylamide Gel Electrophoresis Composition 
Solutions Resolving gel Stacking gel 
 10 % electrophoresis gel  
Resolving buffer 20.00 ml - 
Stacking buffer - 6.00 ml 
Distilled Water 6.70 ml 4.20 ml 
30 % Acrylamide solution 10.25 ml 2.25 ml 
APS 15 mg 7.5 mg 
TEMED 15 µl 7.5 µl 
 
4.4.7.3 Sample preparation and loading  
 
Protein samples were mixed in a 1:1 ratio with sample treatment buffer (typically 100 µl + 
100 µl) and heated at 90 °C for 5 min, prior to loading.  The apparatus was connected and 
electrophoresis carried out at 30 mA.  An unstained protein molecular weight marker 
(Fermentas) was used to estimate protein size. 
 
4.4.7.4 Visualisation of Proteins Separated by SDS PAGE 
 
Gels were stained in the Coomassie blue staining solution and destained in the destaining 
solution, both processes carried out overnight with shaking to ensure uniform 
staining/destaining. 
 
4.4.8 Mtr Assay 
 
Mycothiol disulfide reductase (Mtr) activity was determined spectrophotometrically by 
monitoring the oxidation of NADPH at 340 nm (molar extinction coefficient, ε340 = 6220 M-
1cm-1) using an Ocean Optics spectrophotometer.  Since MSSNaph has been shown to be a 
suitable substrate for Mtr (unpublished results from our group), and since a method for its 
preparation from M. smegmatis extracts has also been developed in our group, it was used 
as a substitute for MSSM in the assay mixture.  The standard 1 ml assay mixture contained 
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0.110 mM NADPH, 0.034 mM MSSNaph and 2 µl of enzyme sample in 50 mM Tris-HCl 
buffer, pH 7.6, containing 2 mM EDTA.  These conditions were used to determine the 
specific activity of Mtr at each stage of purification. 
 
4.4.9 Biorad Protein Determination 
 
Standard protein samples of bovine serum albumin (BSA) were prepared containing 1.5, 3.0, 
5.0, 7.5 and 10 g/ml.  An 800 µl aliquot of each standard was pipetted into a 
microcentrifuge tube, in duplicate.  To each sample, 200 µl of the dye reagent concentrate 
was added and the tube vortexed.  Samples were incubated at room temperature for the 
duration of time it took to prepare all samples (5-10 min), and their absorbance at 595 nm 
recorded.  The cuvette was washed with methanol and rinsed with water after each 
determination.  A standard curve (Figure 4) was then plotted and used to determine the 
protein concentration of Mtr at each stage of purification.  Samples that were out of range of 
the standard curve were appropriately diluted before protein concentrations were determined 
by the procedure. 
 
 
Figure 4. Biorad calibration curve determined from the absorbance of standard solutions of BSA at 
595 nm, and used to estimate the protein concentrations at each stage of Mtr purification 
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4.5 Results  
4.5.1 Cloning and Expression of Mtr 
 
The heat-shock promotor Hsp60 containing the Mtr gene was cloned into the plasmid 
pMV261 (donated by Annelise Williamson, UCT Division of Medical Virology).  In keeping 
with the published procedure of Patel and Blanchard,1 M. smegmatis was used as the 
bacterial expression system, and cells were successfully transformed with the plasmid by 
electroporation, followed by spreading on LB-agar plates containing kanamycin (15 g/ml), 
to yield successfully-transformed colonies.   
 
A selected colony was inoculated into 200 ml of Middlebrook/ADS medium under aseptic 
conditions and was incubated with shaking at 37 C for 3 days, then 30 C for 2 days, after 
which 20 ml of this inoculum was added to each 10 x 1 L flasks containing 400 ml of 
Middlebrook/ADS medium per flask.  The lower temperature of 30 °C was used for growth of 
the cells to create a large temperature jump for the heat-shock induction step.  Once the 
flasks had reached an OD600 = 1.2, the temperature in the incubator was increased to 42 C.  
It took approximately 1.5 h for the internal temperature of the medium to reach the required 
42 C.  Incubation was continued for a further 3.5 h until the OD600 = 1.8.  Cells were then 
collected by centrifugation at 8000 g at 4 C for 15 min (wet weight of expressed cells = 9.22 
g), and resuspended in 40 ml of 20 mM KH2PO4, 50 mM NaCl buffer (pH 7.6) containing 
DNAse (final concentration = 20 g/ml) and 200 L EDTA-free protease inhibitor cocktail 
(set III, Calbiochem).  The resuspended cells were sonicated (Branson Sonifier 250) on ice 
for 10 x 2 min bursts, such that the temperature of the solution did not exceed 10 C.  The 
cell extract was then clarified by centrifugation (Beckman J2-21 centrifuge, JA14 rotor) at 
22,000 rpm, 4 C, for 45 min.   
 
4.5.2 Chromatographic Purification 
 
 
Purification of the expressed protein was envisioned to proceed via a similar method to that 
of Patel and Blanchard,5 namely, immobilised metal ion affinity chromatography (IMAC) 
utilising the His6 tag on the carboxyl terminus.  However, binding of the enzyme to the IMAC 
resin was weak and minor traces of imidazole were sufficient to induce elution of the bound 
protein.  This suggested that the His6-tag was not present, or that it was truncated (through 
protease activity or irregular transcription), or otherwise had folded in such an orientation 
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that it had restricted access to the resin (possibly as a result of post-translational 
modification).  The partially purified enzyme solution was concentrated in an Amicon® 
pressure filtration cell at 400 kPa using a 30 kDa cut-off membrane.  The volume was 
reduced from 900 ml to 20 ml, and a 100 l sample run on a 10 % acrylamide gel.  The 
resulting gel indicated some degree of purification, despite the presence of numerous 
impurities.  Consequently, focus was then switched to a procedure that had been 
successfully employed to purify non-His-tagged Mtr.1  The reported procedure used a 
combination of anion exchange chromatography, 2’,5’-adenosine diphosphate (ADP)-
sepharose affinity chromatography, and gel filtration chromatography, to isolate a single 
band of purified Mtr.  In a parting from the reported procedure, the 2’,5’-ADP-sepharose 
column was employed first.  This affinity resin binds enzymes that use NADPH as a cofactor 
(2’,5’-ADP is a structural analogue of NADP), and it proved to be an effective means of 
purifying the Mtr extract, although the yield of purified enzyme tended to be low (8 %) due to 
a large proportion (92 %) of the extract not binding to the resin.  Three active fractions were 
obtained, each eluting at a different NaCl concentration.  The 75 mM NaCl fraction contained 
minor impurities, however, the 0.2 M and 1.0 M NaCl fractions were found to be pure by 
SDS-PAGE analysis (Figure 5).  Protein concentrations of each fraction were determined by 
the Bradford dye-binding assay (Bio-Rad) using bovine serum albumin (BSA) as a standard. 
 
 
Figure 5. SDS-PAGE of ADP-Sepharose purification of Mtr. (M) Marker; (1) Crude cell extracts after 
expression of Mtr; (2) partially purified fraction obtained from the IMAC column; (3) active fraction of 
Mtr with minor impurities eluting in 75 mM NaCl from ADP-sepharose column; (4) pure, active fraction 
of Mtr eluting in 0.2 M NaCl from ADP-Sepharose column; (5) pure, active fraction of Mtr eluting in 1 
M NaCl from ADP-Sepharose column. 
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Despite the high degree of purity, the ADP-sepharose method had a low yield of protein.  
Anion exchange chromatography (Q-Sepharose High Performance column) was therefore 
used as an alternate means of purification of the eluted IMAC enzyme fractions in the hope 
that it would achieve higher yields.  The sample was dialysed against 20 mM Tris-HCl, pH 
7.6, containing 300 mM NaCl.  According to the results of Patel and Blanchard1 the enzyme 
eluted at 0.45 and 0.5 M NaCl (for the constitutively expressed M. smegmatis and 
recombinant M. tuberculosis Mtr, respectively) in 20 mM triethylamine hydrochloride (TEA-
HCl) (pH 7.6).  However, it was discovered that this buffer system does not act as a buffer at 
pH 7.6.  Consequently, Tris-HCl was instead used at the same concentration and pH.  The 
sample was loaded onto the pre-equilibrated column, and cycled three times in order to 
increase enzyme interaction with the resin.  Thereafter, the column was washed with binding 
buffer (20 mM Tris-HCl, 300 mM NaCl, pH 7.6) and once the A280 < 0.05, a gradient elution 
was run (300 mM to 1 M NaCl).  SDS-PAGE analysis (Figure 6) revealed poor purification of 
the desired protein.  It was noted that the mobile phase buffer was different to that used by 
Patel and Blanchard1 in their purification procedure, and the different buffer system with 
different ionic properties might alter the NaCl concentration required for protein elution to 
that which was reported.  However, the presence of n extended gradient of eluted enzyme 
between test tubes 6 and 24 suggested that there was a degree of binding to the stationary 
phase.  This negates the possibility that the initial NaCl concentration was above the 
threshold level for binding, since this would have resulted in the entire enzyme fraction 
eluting in the first few tubes.  In the selection of an alternate purification strategy, it was 
decided not to proceed to gel filtration as this is generally a polishing step in purification 
protocols.   
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Figure 6. SDS-PAGE analysis of anion exchange chromatography fractions. (M) Marker; (1) fraction 
unretained by column; (2) – (14) collected fractions eluted in test tubes 6 and every second tube up to 
and including 30.  
 
Rather than using gel filtration, the ADP-sepharose technique was revisited with an 
alteration to the protocol that was hoped would increase the yield of purified protein.  The 
active samples from the anion exchange method (tubes 6-24) were pooled, concentrated in 
an Amicon® apparatus, and dialysed against 20 mM KH2PO4, pH 7.6 buffer.  This sample 
was then stirred overnight in a suspension of the 2’,5’-ADP-sepharose resin at 4 °C, before 
being poured into a column and purified in the manner described above.  By this stage, a 
significant proportion of the enzyme had become inactive and precipitated, and the quantity 
of purified, active protein obtained from the ADP-sepharose column was negligible.  A likely 
reason for this loss was the handling of the enzyme samples, which were run, stored during 
the run, and transported from the anion exchange apparatus, all at room temperature.  This 
elevated temperature is likely to have denatured a significant proportion of the sample over 
this period of time.  Extended interaction with the resin could also have been a contributing 
factor to the loss of activity. 
 
4.6 Discussion and Conclusion 
 
Mycothiol disulfide reductase was purified 4.7-fold in a combined yield of 2.68 %, for the 
combined ADP-sepharose fractions (yield based on total activity of the fraction relative to the 
extract, see Table 3).  Sequential chromatography on Ni2+ IMAC and ADP-sepharose 
columns yielded two solutions that contained a single band at 50 kDa (indicative of the target 
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protein monomer) and a third solution with a predominant band at 50 kDa and minor protein 
impurities of lower molecular weight.  A considerable amount of activity was lost after the 
IMAC column with a yield of just 17 % being recovered.  The subsequent purification step 
resulted in further loss of activity with a combined yield of just 5.98 % for the fractions 
collected from the ADP-sepharose column.  The purified fraction with the greatest specific 
activity (41.4 µmoles.min-1.mg-1) eluted in 75 mM NaCl, yet contained containing minor 
impurities.  Interestingly, the specific activity decreased by almost an order of magnitude for 
each subsequent fraction eluting from the ADP-sepharose column, from 75 mM NaCl to 200 
mM to 1 M, despite similar protein concentrations for each of the solutions.  This is likely due 
to inactivation of a considerable amount of protein over the course of the chromatography.  It 
is also likely that as a result of handling and several concentration steps in the Amicon 
apparatus, a substantial amount of enzyme activity was lost.  The sensitive nature of Mtr 
was already established during the attempted purification by anion exchange 
chromatography when a considerable portion of the enzyme became inactive. 
 
 
Table 3. Purification of recombinant M. tuberculosis mycothiol disulfide reductase 
Purification 
Stage 
Protein 
Conc 
(mg/ml) 
Vol of 
Fraction 
(ml) 
Total 
Protein 
Content 
(mg) 
Specific 
Activity 
(SA) 
(µmols/mg/
min) 
Total Activity 
(nmols/min) 
Yield (%) Purification 
Factor 
SA/SA-
extract 
Extract 7.68 55 422.4 9.99 4219.77 100 1 
IMAC 3.45 55 189.5 3.78 716.31 17 0.378 
ADP-Ua 7.66 18 137.9 1.01 139.28 3.3 0.101 
ADP-1b 0.21 10 2.1 41.4 86.94 2 4.14 
ADP-2c 0.48 10 4.8 5.02 24.1 0.6 0.50 
ADP-3d 0.52 10 5.2 0.67 3.48 0.08 0.35 
a Pooled fraction unretained by the ADP-sepharose column 
b Pooled fraction eluting from the ADP-sepharose column in 75 mM NaCl 
c Pooled fraction eluting from the ADP-sepharose column in 200 mM NaCl 
d Pooled fraction eluting from the ADP-sepharose column in 1.0 M NaCl 
 
 
The separation of active enzyme into different fractions during the ADP-sepharose 
purification step was surprising and suggested that post-translational modification of the 
protein structure may have taken place.  This could give rise to a variety of protein 
morphologies with divergent ionic properties resulting in differing degrees of adsorption to 
the stationary phase.  In particular, the lack of binding of the major fraction of protein (12.1 
mg retained vs 137.9 mg unretained) suggested that this particular affinity chromatography 
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technique is inefficient for this enzyme and an alternate method will have to be employed for 
larger scale preparations.  The poor adhesion of the enzyme to the IMAC stationary phase 
could be explained by a possible mutation having occurred in the gene that give rise to a 
truncated His6-tag with a lower affinity for the bound Ni2+.  Alternatively, it is possible that 
protease activity resulted in different degrees of protein cleavage, giving rise to a range of 
protein sizes.   An attempt to establish the molecular weight of each eluted protein fraction 
by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry 
was carried out on a purified Mtr fraction.  The analysis gave inconclusive results, however, 
since it appeared that the protein and matrix did not co-crystallise.  This precluded a 
satisfactory analysis being carried out, and a molecular ion signal was not obtained.   
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Chapter 5 
Cloning and Expression of 
Mycobacterium tuberculosis 
Glyoxalase I 
 
5.1 Introduction 
 
The glyoxalase system (GlxI and GlxII)i (Scheme 1) has been promoted as a potential drug 
target for a number of diseases, including malaria,1,2 leishmaniasis and trypanosomiasis,3,4,5 
bacterial infections,6 and cancer, for which the greatest body of literature has been 
published.7,8,9,10,11,12  Inhibition of this enzyme system as a means of generating cell death is 
based upon the associated accumulation of the toxic by-product of glycolysis, methyl glyoxal 
(MG).  MG is toxic because its high reactivity allows is to form adducts with numerous 
biological targets, including proteins and nucleic acids, forming glycation end-products such 
as hydroimidazolones and imidazopurinones.13  In general, it is the first glyoxalase enzyme 
that is targeted for drug development since it is involved in isomerising the glutathione (GSH) 
conjugate of MG (Scheme 1), and therefore its inhibition would have a direct result on the 
accumulation of MG, whereas inhibition of GlxII would result largely in the accumulation of S-
D-lactoyl glutathione.  It is, however, also likely that there would be overlapping activity 
between the two enzymes since the substrate structures are so similar, which has in fact 
been reported.14  Within the context of cancer research, GlxII activity has been shown to be 
substantially lower than GlxI in some types of cancer cells, which has also contributed to the 
focus being on GlxI.15 
 
 
                                               
i The abbreviations for glyoxalase, Glx and Glo, are used interchangeably in the literature 
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Scheme 1.  The glutathione-dependent glyoxalase enzyme system, comprising GlxI and GlxII, 
responsible for the detoxification of MG 
 
Several polyphenols and flavonoids have been shown to display inhibitory activity against 
GlxI, including curcumin and derivatives thereof,9,16 10-ethylisoalloxazine,17 kojic acid,18 the 
naphthoquinone, lapachol,18,19 quercetin,19 delphinidin,20 and a thiazole developed from 
computational modelling of the enediolate intermediate and termed TLSC702.21 (Figure 1).   
 
OHO
OH
OH
OH
OH
OH
Deliphinidin
N
S
O
OH
OTLSC702
H3CO
HO
OO
OCH3
OH
curcumin
NO
HN
O
N
N
10-ethylisoalloxazine
O
O
OH
Lapachol
O
OH
O
HO
kojic acid  
Figure 1.  Chemical structures of selected polyphenols and flavonoids with inhibitory activity against 
GlxI 
 
In addition to these classes of active compounds, several glutathione S-conjugates have 
been shown to be good inhibitors of GlxI, with the most active derivatives being (i) S-p-
bromobenzyl glutathione (5.1),22,23,24,25 and (ii) S-hydroxamic acid glutathione (5.2)15 (see 
Figure 2), with the combination of these two pharmacophores (5.3) shown to generate a 
nanomolar inhibitor of yeast GlxI.14,26,27  
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Figure 2.  Chemical structures of S-conjugate glutathione illustrating the two most active 
pharmacophores, S-p-bromobenzyl (5.1) and S-(N-methyl-N-hydroxycarbamoyl) glutathione (5.2), 
and the combination of the two into a single molecule (5.3) 
 
Within the context of Mycobacterium tuberculosis, although the presence of a mycobacterial 
glyoxalase system has been suggested, to date there has not been a published report of its 
identification, although the production of S-lactoylmycothiol, the hypothetical reaction product 
of the enzyme, in extracts of M. smegmatis, was noted but not published by Nobel lauteate, 
Irwin Rose.28  However, it does seem to be likely that this enzyme system exists, and that 
instead of GSH-mediated detoxification of MG, this process would be carried out instead by 
a MSH-dependent glyoxalase system.  Such a MSH-dependent GlxI system is worthwhile 
investigating as a potential drug target due to the importance of detoxification of MG to the 
integrity of a cell.  Also, the large structural difference that exists between GSH and MSH 
creates the possibility of generating an inhibitor that is selective for the mycobacterial protein 
over the mammalian one.  Based on the reported activity of the flavonoid-type inhibitors 
described above, and the reported activity derived from S-conjugation of GSH, it seemed 
plausible that the naphthoquinone and carbazole-1,4-quinone conjugates described in 
Chapters 2 and 3 might display inhibitory activity against the hypothetical mycobacterial GlxI, 
since they consist of a MSH-type functionality substituted with a quinone at a similar position 
to the thiol of MSH.  This could potentially increase the number of enzymes targeted by the 
synthesised derivatives and thus increase their overall activity against TB. 
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5.2 Glyoxalase I: Cloning, Transformation and Expression Methods 
   
The first step in the planned process towards identifying and then cloning and expressing a 
potential mycobacterial GlxI protein involved performing a sequence homology search of the 
M. tuberculosis genome to identify the gene candidate.  This was followed by PCR 
amplification of the putative gene and then cloning into a suitable vector, in this case, 
pET17b (Novagen), to generate the expression vector.  This construct was then used to 
transform the bacterial expression system, namely, BL21(DE3) Rosetta pLysS E. coli cells 
(Novagen), in which the protein was expressed.  Precedent for this approach was given by 
the published work of Fairlamb and co-workers29,30 who cloned, expressed and 
characterised the related trypanothione-dependent Leishmania Major and Trypanosoma 
cruzi GlxI enzymes from BL21(DE3)pLysS E. coli cells transformed with a pET15b construct.  
Induction was carried out by treatment of the transformed cells with IPTG. 
 
5.2.1 Material Suppliers 
 
M. tuberculosis H37Rv, was obtained as a gift from Dr Ian Wiid at the Department of Medical 
Biochemistry at the University of Stellenbosch, South Africa.  Blue/Orange Loading Dye 
(Agarose Gel), 1kb DNA ladder and Pfu DNA polymerase were obtained from Promega.  
pET17b vector and BL21 (DE3) Rosetta, pLysS competent E. coli cells were obtained from 
Novagen.  Fastdigest® BamHI and Fastdigest® NdeI restriction enzymes, isopropyl β-D-1-
thiogalactopyranoside (IPTG), agarose, and T4 DNA ligase (as part of a “Rapid DNA ligation 
kit”) were all purchased from Fermentas.  The antibiotics, carbenicillin and kanamycin were 
obtained from Calbiochem, whereas chloramphenicol was obtained from Boehringer 
Mannheim.  Protease Inhibitor Cocktail set III was also obtained from Calbiochem.  One 
Shot Top 10™ competent E. coli cells and Zero Blunt® PCR cloning kit were obtained from 
Invitrogen.  QiAprep® Spin Miniprep kits were acquired from Qiagen.  DNA extraction from 
agarose gel was employed utilising a number of kits from different suppliers: DNA Gel 
Extraction Kit (Fermentas), NucleoSpin® Extract II (Macherey-Nagel), GELase™ Agarose 
Gel Digesting Preparation (Epicentre Biotechnologies), Zymoclean Gel DNA Recovery 
(Zymo Research Corporation) and TaKaRa RECOCHIP (Takara Bio Inc.).  Methyl glyoxal 
and 4,4’-dithiodipyridine were purchased from Sigma Aldrich.  N,N’-methylenebisacrylamide 
was purchased from Fluka.  Ammonium persulfate, sodium dodecyl sulphate and TEMED 
were acquired from BDH.  Tryptone, yeast extract and agar were purchased either from 
Difco, Biolab, Fluka or Oxoid. 
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5.2.2 Identification of M. tuberculosis GlxI Gene Candidate  
 
The search for a mycobacterial glxI gene product in the M. tuberculosis H37Rv genome 
(NCBI Protein database)31 using the functionally homologous E. coli GlxI (accession number 
U57363.1)32 as a protein database query, resulted in a match with 88 % sequence 
homology, and with 78 % sequence homology with both the related trypanothione-
dependent GlxI of Trypanosoma cruzi CL Brener (accession no. XP_810268) and 
Leishmania major Friedlin (accession no. XP_843406). There was little detectable overlap 
with the glutathione-dependent human GlxI (accession no. AAH11365). 
 
The amino acid sequence of the putative M. tuberculosis GlxI protein is indicated below: 
MEILASRMLL RPADYQRSLS FYRDQIGLAI AREYGAGTVF FAGQSLLELA GYGEPDHSRG 
PFPGALWLQV RDLEATQTEL VSRGVSIARE PRREPWGLHE MHVTDPDGIT LIFVEVPEGH 
PLRTDTRA   
Mol Wt: 14.35 kDa 
 
The nucleotide sequence of the identified gene Rv0546c was obtained from the BioCyc33 M. 
tuberculosis genome database as:  
 
ATGGAAATCC TGGCCAGCCG GATGCTACTT CGGCCGGCGG ACTATCAGCG GTCGCTGAGC 
TTCTACCGTG ACCAGATCGG GCTGGCGATT GCCCGTGAAT ACGGGGCCGG CACAGTGTTT 
TTCGCCGGTC AGTCACTGCT CGAACTGGCC GGTTACGGCG AGCCGGACCA TTCGCGGGGA 
CCTTTTCCCG GCGCGCTGTG GCTGCAGGTG CGCGACCTCG AGGCTACCCA GACCGAGCTG 
GTCAGCCGAG GCGTGTCGAT CGCTCGCGAG CCCCGCCGCG AACCGTGGGG CCTGCACGAG 
ATGCATGTGA CCGACCCAGA CGGGATCACA CTGATATTCG TCGAGGTTCC CGAGGGTCAC 
CCGCTGCGTA CAGACACCCG GGCGTGA 
 
The identified open reading frame was used to design oligonucleotide primers containing 
restriction enzyme sites for NdeI (forward primer) and BamHI (reverse primer).  The gene 
was amplified by PCR from M. tuberculosis H37Rv template DNA using the forward primer: 5’ 
cacagggcatatgaaatcctg 3’ with the NdeI site underlined, and the reverse primer: 5’ 
ggatccgcgttttgcggagttcacgcccg 3’ with the BamHI site underlined.  The expected PCR 
product with restriction sites underlined is indicated below:   
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CACAGGGCAT ATGGAAATCC TGGCCAGCCG GATGCTACTT CGGCCGGCGG ACTATCAGCG 
GTCGCTGAGC TTCTACCGTG ACCAGATCGG GCTGGCGATT GCCCGTGAAT ACGGGGCCGG 
CACAGTGTTT TTCGCCGGTC AGTCACTGCT CGAACTGGCC GGTTACGGCG AGCCGGACCA 
TTCGCGGGGA CCTTTTCCCG GCGCGCTGTG GCTGCAGGTG CGCGACCTCG AGGCTACCCA 
GACCGAGCTG GTCAGCCGAG GCGTGTCGAT CGCTCGCGAG CCCCGCCGCG AACCGTGGGG 
CCTGCACGAG ATGCATGTGA CCGACCCAGA CGGGATCACA CTGATATTCG TCGAGGTTCC 
CGAGGGTCAC CCGCTGCGTA CAGACACCCG GGCGTGAACT CCGCAAAACG CGGATCC 
 
5.2.3 PCR Conditions 
 
The putative gene identified from the BLAST search of the mycobacterial genome was 
amplified by PCR from M. tuberculosis H37Rv template DNA using the forward primer: 5’ 
ggatccgcgttttgcggagttcacgcccg 3’ which contained a BamHI restriction site (underlined), and 
the reverse primer:  5’ cacagggcatatgaaatcctg 3’ with an incorporated NdeI restriction site 
incorporated (underlined).  The PCR conditions employed are given below in Table 1. 
 
Table 1.  PCR conditions employed for the amplification of the putative M. tuberculosis GlxI gene 
Time (min) Temperature (°C) 
5 98 
1 98 
1 50 
2 72 
10 72 
Store at 4 °C 
 
The PCR mixture contained the following components: 
Pfu buffer (5 µl), dNTP mix (2 mM, 5 µl), primers (100-fold diluted, 2 µl), template DNA (M. 
tuberculosis H37Rv; 2 µl), pfu DNA polymerase (1.25 µl), water (32 µl). 
 
5.2.4 DNA Digestion 
 
Fastdigest® BamHI and NdeI restriction enzymes (Fermentas) were used for digestion of 
the pET-17b plasmid (Novagen).  According to the manufacturer, 1 µl of each enzyme is 
capable of digesting 1 µg of plasmid DNA in 5 – 15 min.  A typical reaction involved 
35 cycles 
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combining the following reagents (in the order indicated) in a 1.5 ml microcentrifuge tube in 
ice: 
    Vol (µl) 
Nuclease-free water  15 
10x Fastdigest® buffer 2 
DNA    2 
Fastdigest® BamHI  1 
Fastdigest® NdeI  1 
Total volume   21 
After mixing, the contents of the tube was spun down and incubated at 37 °C for 15 min in a 
thermostated waterbath.  Upon completion of the reaction, the restriction enzymes were 
inactivated by incubating at 80 °C for 5 min.  Successful plasmid digestion was confirmed by 
agarose gel electrophoresis. 
 
5.2.5 Agarose Gel Electrophoresis 
 
TAE Buffer: A working solution of 1x TAE (Tris-acetate, EDTA) was prepared by diluting an 
aliquot of 50x stock solution with deionised water.  The final solute concentration was 40 mM 
Tris-acetate and 1 mM EDTA. 
Agarose Gel Preparation: The 1 % agarose gel was prepared by mixing 500 mg agarose gel 
powder in 50 ml TAE buffer, and heat ng in a microwave until complete dissolution.  Ethidium 
bromide (0.5 µg/ml) was added and the liquid gel poured into a mould containing a sample 
comb and left to set at room temperature.  Once set, the sample comb was removed and the 
gels submerged in TAE buffer in the electrophoresis apparatus in preparation for sample 
loading.   
 
Sample Preparation: DNA products of restriction enzyme digest reactions were typically 
loaded in 5 µl aliquots and combined with 1 µl blue/orange loading dye.  DNA products from 
PCR or large scale plasmid digestion reactions, which required purification by 
electrophoresis, were loaded in 50 µl aliquots and combined with 5 µl blue/orange loading 
dye.  An additional end lane containing a low concentration of the product was also prepared 
in order to identify the position of the bulk DNA band during visualisation (see description 
below).  The prepared samples were then added to the sample wells and the gel run at 80 – 
100 mA until the dye front was approximately 2 cm from the end of the gel.   
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Visualisation:  For small-scale restriction enzyme digest products, the gel was placed on a 
transilluminator (UV light at 254 nm) after completion of the run and photographed.  In order 
to prevent exposure of purified PCR or large-scale plasmid digestion products to harmful UV 
light, which can damage DNA and negatively influence subsequent ligation reactions, the 
end lane was cut off and visualised under UV (Figure 3).  The DNA band was marked, and 
the excised lane aligned with the remainder of the gel.  The position of the bulk DNA product 
band was estimated using the marked band, and excised without exposure to the UV lamp.   
   
 
Figure 3. Diagram indicating method of identification of agarose gel product band 
 
5.2.6 DNA Purification and Recovery 
 
DNA was extracted from the agarose gel using one of three methods: Nucleospin® Extract 
II, Zymoclean Gel DNA Recovery kit, or TaKaRa Recochip. 
 
5.2.6.1 NucleoSpin® Extract II (Macherey-Nagel) 
 
The published protocol for DNA purification using NucleoSpin Extract II was used.34 
Briefly, DNA was bound to a silica membrane in the presence of a chaotropic salt solution, 
which was added to the sample as a binding buffer (buffer NT).  The mixture was added to a 
Nucleospin® column and centrifuged on a bench-top microcentrifuge (11,000 x g; 30 s).  
Contaminants (including salts and macromolecular components) were removed by elution 
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with an ethanolic buffer (buffer NT3) (11,000 x g; 30 s).  Finally, pure DNA was obtained by 
eluting with an alkaline, low ionic strength buffer (buffer NE) (11,000 x g; 1 min).  
 
Small fragments of DNA can be removed from a sample by diluting an aliquot of buffer NT 
with sterile water.  Diluting buffer NT in a specified range lowers the binding efficiency of 
small DNA fragments without compromising the recovery of larger DNA strands.  The degree 
of dilution depends on the size of the DNA fragment to be purified, i.e. the smaller the 
fragment, the less buffer NT has to be diluted.  This method was used particularly for 
purifying linearised pET17b vector in preparation for ligation with a sticky ended insert.  
Since the fragment of pET17b to be removed was 63 bp in size, a dilution of 5 volumes of 
water was used (calculation based on the manufacturer’s agarose gel result showing size of 
fragment removed at each level of dilution).  
 
5.2.6.2 Zymoclean Gel DNA Recovery Kit 
 
This agarose gel DNA recovery kit provided a method of extraction of DNA from agarose gel 
slices excised after electrophoresis.  The system used a single buffer system (Agarose 
Dissolving Buffer - ADB™) to dissolve the agarose gel slice, which was then passed through 
the Zymo-Spin I™ column by spinning on a microcentrifuge allowing adsorption of the DNA 
onto the column matrix.  After washing, the DNA was eluted in a small volume of water (6-10 
μl).  According to the manufacturers, DNA purified by this method is suited for use in DNA 
ligation reactions, sequencing and PCR.  The protocol is available online.35 
 
5.2.6.3 TaKaRa RECOCHIP 
 
The protocol is available online from the manufacturer.36  The technology involves binding 
DNA to a cellulose membrane during electrophoresis.  The band of interest is identified by 
UV illumination after the gel has been run, and the chip containing the cellulose membrane 
is inserted into the agarose gel directly in front of the band of interest.  Electrophoresis is 
then continued and the DNA is trapped by the membrane as it travels along the electrical 
gradient.  The DNA is removed from the chip by centrifugation on a benchtop 
microcentrifuge. 
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Figure 4. Diagram indicating collection of DNA by RECOCHIP during electrophoresis36 
 
5.2.7 Determination of DNA Concentration 
 
The concentration of DNA in solution was determined by a NanoDrop (Thermo Scientific) 
spectrophotometer.  Typically 1-2 µl samples were measured at A260 to give a DNA 
concentration in ng/µl, which was used to calculate the quantities of vector and insert for 
ligation reactions, and the amount of DNA product from miniprep extractions.    
 
5.2.8 Ligation of PCR Product into ZeroBlunt Vector and Transformation of 
Top10 Cells 
 
Ligation of the PCR product into a pCR-Blunt® vector was carried out using T4 DNA ligase 
(1 µl; 4U/µl) in a solution of ligation buffer (total volume 10 µl).  The mixture was incubated at 
16 °C (optimal temperature for ligation) for 1 h.  A 2 µL aliquot was added to an ice-thawed 
50 µl vial of One Shot® TOP10 cells and the mixture gently stirred with the pipette tip and 
incubated on ice for 30 min, before being subjected to a 45 sec heat shock at 45 °C followed 
by cooling on ice for 2 min.  SOC medium (250 µl) was added and the vials shaken at 225 
rpm at 37 °C for 1 h.  The transformation mix was then spread on 1 % LB agar plates 
containing 50 µg/ml kanamycin and incubated overnight at 37 °C. 
 
5.2.9 Preparation of plates 
 
LB medium (200 ml) was added to 2 x 500 ml Schott bottles (labelled “1” and “2”) containing 
bactoagar (2.00 g).  The bottles were autoclaved at 121 °C and 15 psi for 20 min.  Upon 
cooling to 45 °C, chloramphenicol (final concentration 30 μg/ml) was added to each bottle 
and carbenicillin (final concentration 50 μg/ml) added to bottle “1”.  After mixing, 20 ml agar 
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plates of each solution were poured, covered, labelled and left to set in a laminar flow 
cabinet.   
 
5.2.10 Preparation of Luria-Bertani (LB) Medium 
 
A 1 L solution of LB medium was prepared by mixing tryptone powder (10 g), yeast extract 
(5 g) and NaCl (10 g) in deionised water (1 L) and autoclaving at 121 °C and 15 psi for 20 
min.  Upon cooling, appropriate antibiotic was added. 
 
5.2.11 Miniprep 
 
Harvesting of plasmids was achieved using the QIAprep Spin Miniprep kit according to the 
manufacturer’s protocol.37 
 
5.2.12 Transformation of BL21 (DE3) Rosetta, pLysS Cells 
 
The vial of BL21 (DE3) Rosetta, pLysS cells was thawed on ice before 4 µl of ligation mix 
was added and the mixture gently stirred with the pipette tip.  The vial was then incubated on 
ice for 20 min before being subjected to a 30 sec heat shock at 42 °C, and then returned to 
the ice.  250 µl of room temperature SOC medium was added and the mixture shaken 
horizontally at 37 °C for 1 h at 225 rpm.  The mixture was then plated on a 1 % LB agar plate 
containing carbenicillin (50 µg/ml) and chloramphenicol (34 µg/ml), and incubated overnight 
at 37 °C. 
 
5.2.13 Induction with IPTG 
 
Into each of two 2 L conical flasks was placed 500 ml of freshly autoclaved LB medium 
containing chloramphenicol (34 g/ml) and carbenicillin (50 g/ml).  Each flask was 
inoculated with a portions of the same colony and incubated and shaken at 37 C until each 
flask had an OD600 = 0.5.  A 10 ml sample from each flask was removed, prior to the addition 
of IPTG to a final concentration of 0.4 mM, and incubation and shaking was continued at 25 
C.  Subsequent 10 ml samples were removed from each flask after 1 h, 2.5 h and 3.5 h.  
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Samples from equivalent times were combined and centrifuged at 4000 rpm for 15 min at 4 
C.  The cells in the bulk medium after 3.5 h were collected by centrifugation under the same 
conditions, and stored at -80 C.   The supernatant of each sample was then discarded and 
the cells resuspended in Tris-HCl buffer (2 ml, 0.75 M, pH 8.8).  DNAse (final conc. 20 
g/ml), to reduce viscosity due to DNA, and a protease inhibitor tablet, to prevent protease 
digestion of the expressed enzyme, was added to each sample.  The samples were then 
successively frozen in liquid N2 and thawed 3 times in order to break open the cells (the 
BL21 pLysS cells contain T7 lysozyme which leaks out during freeze/thaw cycles and 
digests the cell wall).  This approach was employed in an attempt to maintain a low sample 
temperature and reduce loss of enzyme activity, however, several additional mild sonication 
cycles were required to complete cell lysis. Samples were then clarified by centrifugation at 
5000 rpm and 4 C in preparation for SDS-PAGE. 
 
5.2.14 Glyoxalase I Assay 
 
The assay used for the determination of glyoxalase I activity measured the rate of formation 
of the isomerised thiohemiacetal-MSH adduct, which has an absorbance peak at 240 nm.38  
The assay protocol employed was adapted from a published procedure that was used for a 
trypanothione-dependent glyoxalase I from Leishmania major.29  The first step involved 
preparation of lactoylmycothiol by combining 3.2 µl of 55.5 mM methyl glyoxal (final conc. 
200 µM) with 26 µl of 5.2 mM MSH (final conc. 150 mM) in 870 µl of 100 mM Na2HPO4 (pH 
7.0) and incubating at 27 °C for 10 min.  This provided the substrate for glyoxalase I.  The 
second step involved the addition of 5 µl of enzyme sample, and recording the time-
dependent increase of absorbance at A240 as the isomerised thiohemiacetal-MSH product 
was formed.  
 
5.2.15 Recovery of MSH from MSSNaph 
 
Pure MSH was obtained for the GlxI assay from MSSNaph after reduction of the disulphide 
by 2-mercaptoethanol using the following procedure:   
The required amount of MSSNaph (typically ~1 mg) was suspended in a 2:1:1 mixture of 
water: acetonitrile: EtOAc.  A slight excess of 2-mercaptoethanol was added to reduce 
MSSNaph to its constituent thiols, and the mixture vortexed.  Under these conditions, 
mycothiol will partition into the aqueous phase, while 2-thio-6-hydoxynaphthalene and most 
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of the 2-mercaptoethanol will partition into the organic phase.  The pH was lowered to <5.0 
by the addition of glacial acetic acid to stabilize the protonated forms of the thiols. This 
improved the extraction of 2-thio-6-hydroxynaphthalene and 2-mercaptoethanol into the 
organic phase.  The residual 2-mercaptoethanol was removed by repeated extraction of the 
aqueous phase using water saturated EtOAc.  
  
5.2.16 Absorbance Spectrophotometry 
 
To determine the mycothiol content of a sample resulting from the reduction of MSSNaph, a 
5 µl aliquot was added to a solution containing 10 µl of 19.27 mM DTDP and 985 µl Hepes 
buffer (50 mM; pH 7).  The absorbance change, due to the formation of pyridine-4-thione 
(Δε325 = 19800 M-1cm-1), at 325 nm was recorded on an Ocean Optics USB2000 
spectrophotometer and was used to calculate the MSH concentration.    
 
5.3 Results  
 
DNA amplification by PCR was carried out under the conditions described above.  The PCR 
product was run on a 1 % agarose gel in TAE buffer to confirm that it was the predicted size, 
416 bp (Figure 5) 
 
 
Figure 5. Agarose gel indicating required size of PCR product at 416 bp. (M) Marker; (1) PCR 
product. 
 
1000 bp 
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The plasmid into which the PCR product was cloned was Novagen’s pET17b.  This vector is 
3,306 base pairs (bp) in length, contains an ampicillin resistance gene, and in the multiple 
cloning region has BamHI and NdeI restriction sites.  pET plasmids have been used to clone 
a wide range of enzymes, including many found in mycobacteria,39,40 and their ease of use 
and wide-spread application rendered pET17b a suitable candidate for the cloning 
experiment.  Linearisation of the vector with BamHI and NdeI restriction enzymes removed a 
63 bp section of the cloning region (Figure 6).   
 
Figure 6. (M) Marker; (1) pET17b plasmid linearised by digestion with BamHI and NdeI to give a 
product consistent with the expected length of 3243 bp. 
 
Several gel extraction kits were unsuccessfully employed in attempts to extract pure pET17b 
digestion and PCR products from agarose gels run by electrophoresis.  These included the 
DNA Gel Extraction Kit (Fermentas), the NucleoSpin® Extract II (Macherey-Nagel) kit and 
the GELase™ Agarose Gel Digesting Preparation (Epicentre Biotechnologies).  In all cases, 
and regardless of the scale-up, insufficient plasmid DNA (<20 ng/ml) was obtained to 
proceed with the ligation.   
 
The Zymoclean Gel DNA Recovery kit was then used to purify the PCR product.  From an 
initial 50 L of product (conc. = 427 ng/L), 10 L of 50 ng/L pure PCR product were 
obtained from the excised agarose gel band.   
 
Ligation of the purified blunt-ended PCR product into the ZeroBlunt® vector containing the 
lethal control of cell death B (ccdB) gene was then attempted by incubating the ligation mix 
at 16 C for 2 h.41  This gene reduces non-recombinant background clones since ligation of a 
blunt PCR fragment disrupts expression of the ccdB gene permitting exclusive growth of 
positive recombinants during transformation.  Cells containing non-recombinant vector die 
due to expression of the ccdB protein, which interferes with bacterial topoisomerase II, an 
essential enzyme catalysing negative supercoiling of DNA. Inhibition of topoisomerase II 
results in DNA breakage and ultimately cell death.42 
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Transformation of Top10™ cells was then attempted using the manufacturer’s protocol, and 
followed by spreading on 1 % LB agar plates containing kanamycin (50 g/ml).  After 
overnight incubation at 37 C, no colonies were formed. 
 
The ligation procedure was then repeated with a modified incubation time of 5 min at 16 C 
(as proposed in the manufacturer’s manual) for the ligation experiment.  Transformation of 
Top10™ cells was then attempted, and followed by spreading on 1 % LB agar plates 
containing kanamycin (50 g/ml).  Once again, after overnight incubation at 37 C, no 
colonies were formed. 
  
In order to rule out the possibility that the lack of successful transformation was due to poor 
cell competency, transformation of the Top10™ cells was attempted with undigested 
pET17b vector.  After following the same protocol, and spreading on 1 % LB agar plates 
containing carbenicillin (50 g/ml), several colonies were formed, although a “lawn” of 
colonies was not obtained.  The cells appeared to be moderately competent.   
 
The ligation of the PCR product into the ZeroBlunt® vector was then repeated, with a 
modification to the incubation conditions.  The incubation time was extended from 5 min to 
overnight, and the incubation temperature was raised from 16 C to room temperature.  
Transformation of Top10 cells was then performed utilising the same procedure as in 
previous attempts, and was followed b  spreading of the mixture on 1 % LB agar plates 
containing kanamycin (50 g/ml).  After overnight incubation at 37 C, 3 colonies were 
obtained.  These were inoculated into 5 ml LB medium containing kanamycin (50 g/ml) and 
incubated overnight at 37 C with shaking.  The plasmids in each sample were harvested by 
miniprep, with good yields ranging from 261 – 311 ng/l (as determined by Nanodrop 
spectrophotometry), and digested with BamHI and NdeI restriction enzymes at 37 C for 90 
min.  The presence of the desired insert in the plasmids was confirmed by agarose gel (1 % 
in TAE buffer) electrophoresis.  The gel indicated the presence of a band of the required size 
at 404 bp, as indicated in Figure 7 below. 
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Figure 7. Digested plasmid from TOPO transformation.  (M) Marker; (1), (3), (5) undigested plasmid 
isolated by miniprep from three different colonies 1,2,3 respectively.  The two bands correspond to the 
supercoiled and non-supercoiled circular plasmids.  (2), (4), (6) Plasmid samples isolated from 
colonies 1,2,3, respectively, digested by BamHI and NdeI restriction enzymes.  The gene can be seen 
faintly appearing at 404 bp.  
 
A large-scale digestion (13.5 g) of the ZeroBlunt plasmid was then performed to isolate the 
insert in bulk.  The Fastdigest™ BamHI and NdeI restriction enzymes were used as before, 
and the reaction mixture incubated at 37 C for 2 h.  The insert was purified by agarose gel 
electrophoresis, and extracted using the Zymoclean gel DNA recovery kit. 
 
In preparation for ligation with the insert, 5 g of the pET17b vector was digested with the 
Fastdigest™ BamHI and NdeI restriction enzymes at 37 C for 2 h, and purified by agarose 
gel electrophoresis, with extraction by means of the Zymoclean kit.  The amount of linearized 
pET17b vector isolated from the agarose gel was 680 ng (14 % yield), and the amount of 
insert obtained was 960 ng (5 % yield from an initial volume of 45 L at a concentration of 
427 ng/L). 
 
Once the purified, correctly digested insert and plasmid were obtained, ligation was once 
again attempted.  The two components were combined with ligation buffer and T4 DNA 
ligase, and incubated at room temperature overnight.  Transformation was attempted with 
both Top10 cells and pLysS BL21 cells utilising the same protocol for each as outlined 
above.  The transformation mixes were spread on 1 % LB agar plates containing 
carbenicillin (50 g/ml), in the case of the Top10 cells, and chloramphenicol (34 g/ml) and 
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carbenicillin (50 g/ml) in the case of the pLysS BL21 cells.  After overnight incubation at 37 
C, only colonies of transformed Top10 cells had formed.  Several of these colonies were 
inoculated into 5 ml aliquots of LB medium containing carbenicillin (50 g/ml), and incubated 
overnight at 37 C with shaking.  The plasmids of each of the samples were harvested by 
miniprep, and digested with the previously-used restriction enzymes to confirm the presence 
of the insert.  The digested samples were analysed by 1 % agarose gel electrophoresis.  As 
indicated by Figure 8, all but one sample contained a band of the required insert length.   
 
 
Figure 8. Successful transformation as indicated by presence of insert at 404 bp. (M) Marker; (1) 
undigested plasmid isolated from colony of transformed Top10 cells; (2) – (7) plasmid samples 
isolated from colonies of transformed Top10 cells after culturing and miniprep.  Digested by BamHI 
and NdeI restriction enzymes.  The presence of the insert at 404 bp in all but sample (2) indicates 
successful transformation of samples (3) – (7). 
 
Plasmid isolated from one of the samples containing the correctly-sized insert band, was 
used for transformation of BL21 (DE3) Rosetta, pLysS cells.  These cells are designed to 
enhance the expression of proteins that contain codons rarely used in E. coli, and provide 
the tRNAs for the 6 rare codons, AUA, AGG, AGA, CUA, CCC, GGA, on a chloramphenicol-
resistant plasmid that also codes for T7 lysozyme.43  This is of importance since 
Mycobacteria are rich in guanine and cytosine,44,45 whereas E. coli is not, and this difference 
could impact on its ability to express mycobacterial proteins.  Rosetta cells have been used 
to express various mycobacterial enzymes.46,47,48  The protocol described above was used to 
effect the transformation, which was followed by plating of the cell mixture on 1 % LB agar 
plates containing chloramphenicol (34 g/ml) and carbenicillin (50 g/ml).  Colonies were 
successfully grown, and several were inoculated into 5 ml aliquots of LB medium containing 
chloramphenicol (34 g/ml) and carbenicillin (50 g/ml).  The plasmids of the grown colonies 
were extracted by miniprep and samples digested (BamHI and NdeI) in order to confirm the 
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presence of the insert.  The digested samples were run on a 1 % agarose gel, which when 
visualised, indicated the presence of the insert at 404 bp (Figure 9). 
 
   
Figure 9. A: Digest of plasmids isolated from transformed Rosetta cells.  (M) Marker; (1) – (3) three 
different colonies that were cultured, cells collected and plasmids isolated and digested by restriction 
enzymes BamHI and NdeI.  The multiple bands correspond to the ligated plasmid and the resident 
pLysS plasmid that were both cleaved by the restriction enzymes.  The gene of interest corresponds 
to the faint band at 404 bp.  The bands corresponding to the pLysS plasmid are identified in B: (M) 
Marker; (1) Resident pLysS plasmid isolated by miniprep of untransformed Rosetta cells and digested 
by BamHI and NdeI restriction enzymes. 
 
Since the gel indicated that the insert was present, expression of the enzyme was attempted 
next.  Colony 1 (see above gel image) was inoculated into 500 ml of freshly autoclaved LB 
medium containing chloramphenicol (34 g/ml) and carbenicillin (50 g/ml) in a 2 L conical 
flask, and incubated with shaking at 37 C until the medium had an OD600 = 0.6.  At that 
point, a 10 ml sample was removed (to provide a pre-induction sample for SDS-PAGE), and 
IPTG added to the bulk mixture to a final concentration of 0.4 mM.  Incubation and shaking 
was then continued at 25 C.  Subsequent 10 ml samples were removed from the flask 1 h, 
2 h, 3 h and 4 h post-induction.  Samples were centrifuged at 4000 rpm for 15 min at 4 C, 
the supernatant discarded, and the cell pellet resuspended in 2 ml lysis buffer (50 mM NaCl 
in 50 mM Hepes, pH 7.5).  A protease inhibitor cocktail (set III, Calbiochem) was added to 
each sample, followed by DNAse (final conc. 20 g/ml) to reduce viscosity due to DNA, 
before being sonicated on ice for 10 min (5 x 2 min; 30 % duty cycle).  The mixture was 
clarified at 15,000 g for 30 min at 4 C, and the supernatant removed for analysis by SDS-
PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis). 
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The running and stacking gels were prepared as outlined in Chapter 4, with the running gel 
being composed of 15 % acrylamide.  The small size (14.35 kDa) of the target protein, which 
would cause it to run rapidly near the gel front, necessitated a high acrylamide percentage in 
the gel.  100 L of each sample was treated with 10 l of sample treatment buffer and 
heated at 80 C for 5 min in order to denature and linearise the protein prior to loading, as 
well as increase the density of the sample so that it would sink in the gel sample well. 
Samples were loaded into the wells, the buffer poured into the reservoir, and the gel run at 
30 mA for 5 h.  The visualised gel is given in Figure 10 below: 
 
 
Figure 10. SDS-PAGE of first attempted expression. (M) Marker; (U) uninduced cells; 1 h, 2 h, 3.5 h = 
time after addition of IPTG at 25 C. 
 
The lack of an increase in intensity in any of the protein bands in the gel indicated that either 
expression was too low to be observed on the gel, or was unsuccessful.  Consequently, the 
plasmid used for the expression was sequenced and analysed for errors.  The sequence is 
given below:  
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Score =  728 bits (394),  Expect = 0.0  Identities = 399/401 (99%), Gaps = 
1/401 (0%) Strand=Plus/Minus 
 
Query  45      ATGGAAATTCTGGCCAGCCGGATGCTACTTCGGCCGGCGGACTATCAGCGGTCGCTGAGC  
104            |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  296062  ATGGAAATCCTGGCCAGCCGGATGCTACTTCGGCCGGCGGACTATCAGCGGTCGCTGAGC  
296003 
 
Query  105     TTCTACCGTGACCAGATCGGGCTGGCGATTGCCCGTGAATACGGGGCCGGCACAGTGTTT  
164            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  296002  TTCTACCGTGACCAGATCGGGCTGGCGATTGCCCGTGAATACGGGGCCGGCACAGTGTTT  
295943 
 
Query  165     TTCGCCGGTCAGTCACTGCTCGAACTGGCCGGTTACGGCGAGCCGGACCATTCGCGGGGA  
224            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  295942  TTCGCCGGTCAGTCACTGCTCGAACTGGCCGGTTACGGCGAGCCGGACCATTCGCGGGGA  
295883 
 
Query  225     CCTTT-CCCGGCGCGCTGTGGCTGCAGGTGCGCGACCTCGAGGCTACCCAGACCGAGCTG  
283            ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  295882  CCTTTTCCCGGCGCGCTGTGGCTGCAGGTGCGCGACCTCGAGGCTACCCAGACCGAGCTG  
295823 
 
Query  284     GTCAGCCGAGGCGTGTCGATCGCTCGCGAGCCCCGCCGCGAACCGTGGGGCCTGCACGAG  
343            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  295822  GTCAGCCGAGGCGTGTCGATCGCTCGCGAGCCCCGCCGCGAACCGTGGGGCCTGCACGAG  
295763 
 
Query  344     ATGCATGTGACCGACCCAGACGGGATCACACTGATATTCGTCGAGGTTCCCGAGGGTCAC  
403            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  295762  ATGCATGTGACCGACCCAGACGGGATCACACTGATATTCGTCGAGGTTCCCGAGGGTCAC  
295703 
 
Query  404     CCGCTGCGTACAGACACCCGGGCGTGAACTCCGCAAAACGC  444 
               ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  295702  CCGCTGCGTACAGACACCCGGGCGTGAACTCCGCAAAACGC  295662 
 
Two errors were found in the sequence, namely a mutation at position 9 of the gene from a 
C to a T, as well as a single nucleotide deletion at position 230.  The mutation of the wobble 
base as position 9 is not significant, since the resulting ATT codon will code for the same 
amino acid as ATC (isoleucine).  However, the deletion at position 230 is likely to have a 
dramatic effect on the sequence, since each three consecutive nucleotides in the DNA 
sequence comprise a codon, which codes for a single, specific amino acid.  Consequently, 
the deletion of one nucleotide (a frameshift mutation) would disrupt each subsequent codon, 
thereby preventing the correct amino acids from being inserted.  In addition, the stop codon 
will be misread resulting in a different stop codon being used and a different sized protein 
being produced.  The deletion is therefore a possible reason for the protein not being 
expressed. 
 
In order to remove any doubt that the error had occurred at the PCR stage, the PCR product 
was also sequenced, and was found to be correct.  It was then decided to repeat the entire 
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process from the PCR ligation stage since it was known that the PCR product was correct 
and unmutated.  Consequently, ligation into the ZeroBlunt plasmid was carried out by 
incubation of 4 l of the PCR product with 1 l of ZeroBlunt vector at 16 C for 1 h in a 
reaction mix containing 1 l of 10X ligation buffer, 1 l T4 DNA ligase and 3 l of water.  
Top10 cells were then transformed according to the protocol described above, before being 
spread on LB-agar plates containing kanamycin (50 g/ml).  After incubation overnight at 37 
C, colonies were obtained, 6 of which were inoculated into 5 ml LB medium containing 
kanamycin (50 g/ml) and incubated with shaking overnight at 37 C.  The plasmids in each 
sample were isolated by miniprep using the Qiaprep kit (Qiagen).  2 l Samples of each 
were digested (Fastdigest BamHI and NdeI) and run on a 1 % agarose gel to check for the 
presence of the insert.  The gel image (Figure 11) confirmed that all of the colonies but one 
contained the insert. 
 
 
Figure 11. Digest of ligated Zeroblunt plasmid to confirm presence of insert.  (M): ladder; (1) – (6): six 
colonies that were cultured in LB medium, cells collected, plasmids isolated by miniprep and digested 
by restriction enzymes BamHI and NdeI.  The absence of the insert in colony (1) and its presence in 
colonies (2) – (6) is noted. 
 
Miniprep 3 was selected and digested in large scale (45 l, 242 ng/l, 10.8 g), to liberate 
the sticky ended insert, in a mix containing 12 l each of BamHI, NdeI and 10X Fastdigest 
buffer.  The digestion mix was incubated at 37 C for 1 h, before being run on a 1 % agarose 
gel.  The DNA was extracted using the Takara chip extraction kit, to yield 50 l of 13 ng/l 
purified sticky ended insert.  Ligation was performed using 1 l of the linearized pET17b 
vector previously prepared with 15 l of the insert in 2 l of 5X rapid ligation buffer and 2 l 
T4 DNA ligase (Fermentas, “Rapid DNA ligation kit”).  4 l of the ligation product was used 
to transform Rosetta cells, which were subsequently spread on LB-agar plates containing 
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carbenicillin (50 g/ml) and chloramphenicol (34 g/ml).  After overnight incubation at 37 C, 
many colonies were obtained, 7 of which were inoculated into LB medium containing the 
above antibiotics and cultured at 37 C overnight with shaking.  The plasmids in each 
sample were isolated by miniprep and aliquots of each digested with BamHI and NdeI to 
confirm the presence of the insert, following the protocol described above.  Agarose gel 
electrophoresis identified colonies 2, 4, 6 and 7 to have bands of equivalent size to that of 
the desired insert, as depicted in Figure 12 below.  Because Rosetta cells contain a resident 
pLysS plasmid with restriction sites that are digested by the enzymes, a reference agarose 
gel of untransformed, digested Rosetta cells was required to unambiguously identify the 
band corresponding to the insert.  To do this, untransformed Rosetta cells were inoculated 
into 5 ml of LB broth and grown up overnight at 37 C.  The plasmid was then isolated by 
miniprep and digested with the same enzymes and run on a 1 % agarose gel to provide a 
comparison to the transformed cells’ digested plasmids.  The gel is indicated below: 
 
             
Figure 12. A: Digest of plasmid from transformed Rosetta cells. (M) Marker; (1) – (7) seven colonies 
of transformed Rosetta cells that were cultured in LB medium, plasmids isolated by miniprep and 
digested by restriction enzymes BamHI and NdeI.  The absence of the insert in colonies (1) and (5) 
and its presence in colonies (2), (4), (6) and (7) is noted.  Colony (3) appears to be lacking the 
resident pLysS plasmid.  B: (M) Marker; (1) resident pLysS plasmid isolated from cultured Rosetta 
cells, digested by BamHI and NdeI restriction enzymes.  The corresponding four plasmid fragment 
bands can be assigned in lanes (1) – (7) of A to the pLysS plasmid, and by deduction the remaining 
two bands assigned to the recombinant pET17b vector containing the GlxI gene.  
 
The gel confirmed that the insert of appropriate length was still present in the cells, and so 
expression of the enzyme was attempted next.  This was carried out according to the 
protocol described previously in section 5.2.12.   
 
A 13 % polyacrylamide gel was prepared for the electrophoresis in order to evaluate whether 
expression had been successfully achieved.  This gel concentration was chosen after 
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evaluating the pattern of the previously-run polyacrylamide gel.  To this end, 17.3 ml of the 
30 % acrylamide/bis-acrylamide solution was diluted with 2.7 ml water, and mixed with 20 ml 
of running gel buffer, 15 l TEMED and 15 mg (NH4)2S2O8, to produce the running gel.  The 
stacking gel consisted of 1.5 ml 30 % acrylamide/bis-acrylamide, 3.75 ml stacking gel buffer, 
9.6 ml water, 12 l TEMED and 9.5 mg (NH4)2S2O8 (Figure 13). 
 
 
Figure 13. SDS-PAGE gel indicating successful expression. (M) Protein marker; (U) uninduced cells; 
1 h – 3.5 h: time after addition of IPTG.  The increase in concentration of the protein band at 14.35 
kDa indicates successful expression of the protein. 
 
The gel indicated that expression was successful.  This was an encouraging result, and the 
bulk cells were retrieved from the -80 C storage, defrosted on ice, and lysed by sonication 
(10 x 2 min, 30 % duty cycle).  The mixture was then clarified by centrifugation at 30,000 g 
for 30 min at 4 C.  The supernatant containing the expressed protein was then stored at -20 
C in preparation for assaying to determine activity.  
 
The assay was carried out according to the protocol described in section 5.2.13, and 
surprisingly it was revealed that there was no change in absorption at 240 nm, suggesting a 
lack of enzyme activity.   
 
In order to confirm the validity of the assay, clarified cell extracts of E. coli (BL21, pLysS) 
were assayed as a positive control, using glutathione instead of MSH. Since E. coli has been 
proven to possess a glutathione-dependent glyoxalase system, which also generates an 
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isomerised thiohemiacetal product with an absorbance peak at 240 nm, it seemed 
reasonable to assume that it would be able to validate the MSH-based assay.49  
Unfortunately, the results were inconclusive and no obvious peak at 240 nm was generated 
during the reaction.  This could be due to the presence of GlxII in the clarified cell extracts 
which may have converted the S-D-lactoyl glutathione to D-lactate and GSH immediately it 
was formed, thus preventing its visualisation on the spectrophotometer.  Similar difficulties 
were reported in a previous study using this approach.50 
 
The plasmid was then sequenced and found to contain two mutations: a C to T (position 9) 
and a C to A (position 344).  The mutation at position 9 resulted in a codon for the same 
amino acid, isoleucine, whereas the mutation at 344 would have altered the amino acid 
coded for from asparagine to histidine, which may have affected activity.  The positions of 
these mutations are indicated below. 
 
 
Score =  730 bits (395),  Expect = 0.0 Identities = 399/401 (99%), Gaps = 
0/401 (0%) Strand=Plus/Minus 
 
Query  50      ATGGAAATTCTGGCCAGCCGGATGCTACTTCGGCCGGCGGACTATCAGCGGTCGCTGAGC  
109            |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637969  ATGGAAATCCTGGCCAGCCGGATGCTACTTCGGCCGGCGGACTATCAGCGGTCGCTGAGC  
637910 
 
Query  110     TTCTACCGTGACCAGATCGGGCTGGCGATTGCCCGTGAATACGGGGCCGGCACAGTGTTT  
169            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637909  TTCTACCGTGACCAGATCGGGCTGGCGATTGCCCGTGAATACGGGGCCGGCACAGTGTTT  
637850 
 
Query  170     TTCGCCGGTCAGTCACTGCTCGAACTGGCCGGTTACGGCGAGCCGGACCATTCGCGGGGA  
229            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637849  TTCGCCGGTCAGTCACTGCTCGAACTGGCCGGTTACGGCGAGCCGGACCATTCGCGGGGA  
637790 
 
Query  230     CCTTTTCCCGGCGCGCTGTGGCTGCAGGTGCGCGACCTCGAGGCTACCCAGACCGAGCTG  
289            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637789  CCTTTTCCCGGCGCGCTGTGGCTGCAGGTGCGCGACCTCGAGGCTACCCAGACCGAGCTG  
637730 
 
Query  290     GTCAGCCGAGGCGTGTCGATCGCTCGCGAGCCCCGCCGCGAACCGTGGGGCCTGAACGAG  
349            |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  637729  GTCAGCCGAGGCGTGTCGATCGCTCGCGAGCCCCGCCGCGAACCGTGGGGCCTGCACGAG  
637670 
 
Query  350     ATGCATGTGACCGACCCAGACGGGATCACACTGATATTCGTCGAGGTTCCCGAGGGTCAC  
409            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637669  ATGCATGTGACCGACCCAGACGGGATCACACTGATATTCGTCGAGGTTCCCGAGGGTCAC  
637610 
 
Query  410     CCGCTGCGTACAGACACCCGGGCGTGAACTCCGCAAAACGC  450 
               ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  637609  CCGCTGCGTACAGACACCCGGGCGTGAACTCCGCAAAACGC  637569 
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5.4 Discussion and Conclusion 
 
It is surprising that the mutations occurred and the poor degree of transformation of the 
Rosetta cells with the ligated plasmid seems to suggest that perhaps the expressed protein 
is toxic to E. coli, and/or perhaps the selected gene from the BLAST search did not, in fact, 
code for GlxI.  Low expression levels could be indicative of inherent toxicity of the expressed 
protein to the host bacterium.51  This phenomenon has been reported in relation to the 
expression of a range of proteins including membrane proteins,52 cytoplasmic proteins,53 cell 
division proteins,54,55 and other toxic proteins such as DNAse.56  Since few colonies were 
obtained it is possible that the only viable cells were those that did not express active 
enzyme, with those that did succumbing to the associated toxicity.  This would result in the 
formation of mutated, inactive enzyme in the post-induction clarified cell extract. 
 
A final possibility is that the gene selected from the BLAST search was not the mycobacterial 
Glx I.  Glyoxalase is a member of the vicinal oxygen chelate (VOC) metalloenzyme 
superfamily.57  VOC proteins can be difficult to differentiat  from one another as they have 
similar amino acid sequences despite having differing enzymatic functions.58,59  Diverse 
members of this group include the fosfomycin resistance protein FosA, several extradiol 
dioxygenases and methylmalonyl-CoA epimerase, among others.60 Consequently it is 
possible that the incorrect gene, possibly another VOC protein, was selected for cloning and 
expression, and as a result did not display glyoxalase I activity. 
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Chapter 6 
Biological Evaluation of Synthetic 
Conjugates 
 
6.1 Naphthoquinone Conjugates 
 
As noted previously, completion of the synthesis of the naphthoquinone conjugates was not 
achieved within the time-frame of this study, and since the advanced intermediates bearing a 
structural resemblance to the designed target molecules were also not obtained, evaluation 
of the inhibitory/subversive substrate activity of this class of molecules against Mtr or one of 
the other mycothiol enzymes was not possible.   
 
6.2 Carbazole Quinone Conjugates  
 
The successful synthesis of the carbazole quinone conjugates afforded three target 
molecules for biological evaluation. Through a collaboration with Prof Hans-Joachim Knölker 
(TU Dresden, Germany) the compounds were analysed for their anti-tuberculosis activity 
using the same assays applied to the parent carbazole quinone derivatives as reported in a 
published study,1 with assays being performed in the lab of  Prof Scott Franzblau (Institute 
for Tuberculosis Research, University of Illinois at Chicago). Activity was evaluated against 
M. tuberculosis strain H37Rv in in vitro assays to determine minimum inhibitory 
concentration (MIC) using the microplate alamar blue assay (MABA).2,3,4  Conjugates 3.35, 
3.36 and 3.37 were tested and found to be inactive, with MIC values >128 µm (see Table 1), 
and with Rifampicin used as a positive control.   
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Table 1. Anti-TB Results obtained from MABA assay 
† Prepared and assayed in a prior study by Knölker and co-workers1 
 
The results suggest that addition of the linker and phenylthioglucosamine unit to the 
carbazole quinone 3.9 significantly reduces the anti-TB activity of the parent carbazole 
quinone. This is consistent with the earlier findings of Knölker et al. that further substitution 
of the carbazole-quinone nucleus tends to dampen the anti-TB activity. While the 
mechanism of action of the carbazole-1,4-quinones is not known, these results seem to 
disprove our initial hypothesis, that they may target enzymes involved in the mycothiol 
biosynthetic pathway, or be subversive substrates for the enzyme Mtr and therefore that 
coupling to substrate mimics in this pathway may deliver them to their target. However, it 
remained important to test the compounds for inhibitory activity against the enzymes, or for 
activity as subversive substrates of Mtr.    The low activity of the Mtr prepared during this 
study necessitated finding alternative assays, and samples were submitted to the group of 
Dr Chris Hamilton (University of East Anglia, UK). Unforeseen problems in his lab have 
delayed the assays, and the results are not available at this time.  In addition, it was decided 
to evaluate the conjugates as inhibitors of the MSH biosynthetic enzyme, MshB, since 
Compound code Structure MABA Results 
3.35 
 
>128 µM 
3.36 
 
>128 µM 
3.37 
 
>128 µM 
3.9
†
 
 
9 µM 
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similar plumbagin-derived analogues (described in Chapter 2 and prepared in a previous 
study)5 displayed good activity against the enzyme.  The compounds were submitted to the 
group of Prof Trevor Sewell at the University of Cape Town but similar delays have been 
encountered, with results of these assays not yet available. 
 
6.3 Discussion and Conclusion 
 
Although the enzyme assay results were not obtained within the timeframe of the project, the 
valuable anti-TB results provided a useful indication of the likelihood of this class of inhibitors 
eventually being developed into active pharmaceutical agents.  It appears that addition of 
the elaborate substituents on either the nitrogen or C-3 of the carbazole-quinone shuts down 
the anti-TB activity, while the effect on the enzyme-inhibitory activity is yet to be determined.  
Since the carbazole quinone 3.9 displayed the best activity in the assay, it is clear that 
further systematic study of the structure-activity of analogues of this needs to be carried out, 
and is indeed under investigation in on-going studies. Some possible variations in the 
structure of the conjugate in relation to the carbohydrate and linker functionalities are as 
suggested at the end of Chapters 2 and 3.   
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Chapter 7 
Experimental 
 
7.1 General 
 
All commercial chemicals were purchased from Merck (South Africa) or Sigma-Aldrich.  All 
solvents were freshly distilled and dried by appropriate techniques with the exception of 
analytical grade absolute ethanol (EtOH), methanol, methylene chloride and acetone.  
Reactions were monitored by thin layer chromatography (TLC) using Merck F254 silica gel 
plates and were visualised by ultraviolet light or staining with acidic ethanolic solutions of 
anisaldehyde, ceric ammonium sulfate or ninhydrin, or ferric chl ride ethanol/water. Silica 
gel chromatography was performed using Merck silicagel 60.  Automated flash 
chromatography was performed on a Biotage Isolera system, using prepacked columns, or 
in the case of the carbazole quinone derivatives, on a Buchi Sepacore flash chromatography 
system using self-packed silica gel columns.  Melting points were determined on a Reichert-
Jung Thermovar hot-stage microscope and are uncorrected.  Infrared spectra were recorded 
on a Perkin-Elmer Spectrum 100 FT-IR spectrometer in the range 4000 – 600 cm-1 using 
thin films of compound on NaCl disks.  Microanalyses were determined using a Fisons EA 
1108 CHNS-O instrument.  GC/MS results for the carbazole quinone derivatives were 
obtained using an Agilent 6890N GC/5973N MSD gas chromatography/mass spectrometry 
system.  HRMS data were obtained using a Waters Synapt G2 with direct injection (1 µl) into 
a stream into a stream of 80% acetonitrile, 0.1% formic acid using a Waters UPLC at flow 
rate of 0.1ml/min.  Source: Electrospray positive/negative, Capillary voltage 3 kV, Cone 
Voltage 25 V.  1H, 13C and 2D NMR spectra were recorded on a Varian Mercury 300 MHz 
Spectrometer, a Varian Unity 400 MHz Spectrometer or a Bruker Advance III with 
Ultra Shield 400 Plus magnet.  In the case of the carbazole quinone derivatives, 1H, 13C and 
2D spectra were recorded on an Avance 300 or 400 MHz, or DRX-500 spectrometer.  All 
spectra were recorded in deuterochloroform, deuterodimethylsulfoxide, deuteroacetone, 
deuteromethanol or deuterium oxide.  All chemical shifts were recorded in ppm with 
reference to TMS as internal standard. 
The numbering scheme given for each compound is for assignment purposes only and not 
necessarily consistent with the IUPAC naming convention used in the title.  1H NMR spectra 
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are provided as mark of purity, in accordance with Journal of Organic Chemistry Guidelines 
for Authors,1 and are attached in the appendix.   
 
7.2 Synthesis of the Glucosamine-Derived Thioglycoside 
Trifluoromethanesulfonyl azide, 2.2 
F3C
S
N3
O O
 
Sodium azide (39.00 g; 600 mmol) was dissolved in water (100 ml) before toluene (100 ml) 
was added and the mixture stirred at 0 °C.  Triflic anhydride (40 ml; 238 mmol) was added 
drop-wise and stirring continued for 30 min, after which the temperature was raised to 10 °C 
and the biphasic mixture stirred for a further 2 h.  Saturated NaHCO3 was added until 
effervescence ceased.  The organic phase was separated and the aqueous phase extracted 
with toluene (2 x 50 ml).  The extracts were combined to form the stock solution of triflic 
azide (maximum possible concentration ~ 1.15 M). Note: this reagent is shock-sensitive and 
should be handled with care. 
 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-β-D-glucopyranoside,2,3 2.5 
O
AcO
AcO
N3
OAc
1
2
3
4 5
6
OAc
 
Protocol adapted from a reported procedure.4  Glucosamine hydrochloride (30.00 g; 139 
mmol), NaHCO3 (46.71 g; 556 mmol) and CuSO4.5H2O (1.40 g; 5.6 mmol) were dissolved in 
H2O (92.4 ml).  Triflic azide 2.2 stock solution (157 ml) was added, followed by the addition 
of MeOH (609.5 ml) to yield a homogeneous mixture that was stirred at room temperature 
for 15 h.  Over the course of the reaction, the colour of the solution changed from blue to 
green.  The solvents were removed under reduced pressure, and the residue left to dry on a 
high vacuum pump for 3 days.  The residue was then dissolved in dry pyridine (100 ml) and 
cooled to 0 °C.  Acetic anhydride (100 ml) was added drop-wise to the solution, which was 
stirred for 30 min at 0 °C before being warmed to room temperature and left to stir for a 
further 17 h until complete consumption of the starting material.  The solvents were removed 
under reduced pressure, and the crude residue dissolved in EtOAc (1 L) and washed with 
H2O (2 x 500 ml).  The aqueous fractions were extracted with EtOAc (2 x 500 ml), and the 
combined organic fractions were dried (Na2SO4) and reduced under reduced pressure.  The 
syrupy residue was purified by column chromatography (silica gel, eluting in 
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EtOAc:petroleum ether, 3:7) to obtain the product as a white precipitate of α/β isomers 
(46.28 g; 124 mmol; 89 %).  The β isomer was obtained by recrystallisation of the purified 
product mixture in EtOAc/Pet Ether and used for analysis.  Rf (EtOAc:Petroleum Ether, 3:7) 
0.25; m.p. 93-94 °C (β-isomer); lit.5 m.p. 96-97 °C; IR (NaCl, dry film) νmax (cm-1): 2115 (N3), 
1756 (C=O).  
 
1H NMR (300 MHz, CDCl3) β-isomer: δ 5.55 (d, J = 8.6, 1H, H1), 5.06 (m, 2H, H3, H4), 4.29 
(dd, J = 4.6, 12.5, 1H, H6a), 4.08 (dd, J = 2.2, 12.5, 1H, H6b), 3.83 – 3.77 (m, 1H, H5), 3.70 – 
3.61 (m, 1H, H2), 2.18 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.01 (s, 3H, CH3). 
 
13C NMR (75 MHz, CDCl3) β-isomer: δ 170.5 (C=O), 169.7 (C=O), 169.6 (C=O), 168.5 
(C=O), 92.6, 72.8, 72.7, 67.8, 62.6, 61.4, 20.8 (CH3), 20.6 (CH3), 20.6 (CH3), 20.5 (CH3). 
 
Anal. Calcd for C14H19N3O9: C, 45.04; H, 5.13; N, 11.26.  Found: C, 45.33; H, 5.26; N, 10.91. 
 
Phenyl 3,4,6-Tri-O-acetyl-2-azido-2-deoxy-1-thio-α-D-glucopyranoside,6 2.6a 
O
AcO
AcO
N3
OAc
1
2
3
4 5
6
1'
2'
3'
4'
S
 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranoside 2.5 (10.003 g; 26.80 mmol) was 
dissolved in dry CH2Cl2 (40 ml) and cooled to 0 °C.  To this solution, BF3.OEt2 (15.28 ml; 
120.60 mmol) was added drop-wise and the solution left stirring for 30 minutes to form the 
oxocarbenium ion intermediate.  Thiophenol (4.13 ml; 40.20 mmol) was then added drop-
wise and the solution allowed to warm to room temperature, before the temperature was 
increased and the solution refluxed for 14 hours until the reaction was complete (determined 
by TLC).  After cooling to room temperature, crushed ice was added and the reaction 
mixture extracted with CH2Cl2 (2 x 150 ml).  The CH2Cl2 extract was washed with water (150 
ml), dried (Na2SO4), and purified by column chromatography (EtOAc:Pet Ether, 2:8) to yield 
the product as a mixture of isomers (9.029 g; 21.32 mmol; 80 %).  Pure crops of the α-
thioglycoside were isolated by crystallisation from EtOH and obtained as white needles 
(5.185 g; 12.24 mmol; 46  %), however, further separation of the isomers was not possible 
and the mother liquor remained as a mixture.  Rf (EtOAc:Pet Ether, 3:7) 0.45; m.p. 93-95 °C;  
IR (NaCl, dry film) νmax (cm-1): 3440, 2111 (N3), 1750 (C=O). 
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1H NMR (400 MHz, CDCl3) δ 7.45 – 7.40 (m, 2H, Ph), 7.28 – 7.21 (m, 3H, Ph), 5.56 (d, J = 
5.6, 1H, H1), 5.26 (dd, J = 9.2, 10.6, 1H, H3), 4.96 (dd, J = 9.2, 10.3, 1H, H4), 4.52 (ddd, J = 
2.2, 5.0, 10.3, 1H, H5), 4.21 (dd, J = 5.2, 12.4, 1H, H6a), 3.99 (dd, J = 5.6, 10.6, 1H, H2), 3.96 
(dd, J = 2.3, 12.3, 1H, H6b), 2.02 (s, 3H, CH3), 1.98 (s, 3H, CH3), 1.95 (s, 3H, CH3). 
 
13C NMR (101 MHz, CDCl3) δ 170.4 (C=O), 169.7 (2 x C=O), 132.5 (C1’), 132.2 (2 x C2’3’), 
129.2 (2 x C2’3’), 128.1 (C4’), 86.6 (C1), 72.1 (C3), 68.9 (C4), 68.6 (C5), 62.0 (C6), 61.7 (C2), 
20.6 (2 x CH3), 20.6 (CH3). 
 
EI-MS m/z: Calcd for C18H21N3O7S, 423.11; Found 423.06 [M]. 
 
Anal.Calcd for C18H21N3O7S: C, 51.06; H, 5.00; N, 9.92; S, 7.57. Found: C, 52.08; H, 5.07; N, 
9.78; S, 7.56.   
 
Phenyl 3,4,6-Tri-O-acetyl-2-amino-2-deoxy-1-thio-α-D-glucopyranoside, 2.7  
 
Ethanol (50 ml) was added to a round-bottomed flask, followed by 10 wt % palladium on 
carbon (0.499 g).  The walls of the flask were washed with a further 250 ml of ethanol to 
ensure full wetting of the palladium.  Phenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-1-thio-D-
glucopyranoside 2.4 (4.751 g; 11.22 mmol) was dissolved in this mixture before the flask 
was subjected to successive purging and filling with hydrogen.  The flask was then fitted with 
a hydrogen-filled balloon, and the mixture stirred for 16 h at room temperature until complete 
consumption of the starting material.  The mixture was then filtered through a celite plug, 
evaporated to dryness, and the residue purified by silica gel chromatography (eluting in 
EtOAc:petroleum ether, 6:4).  The purified product was then crystallised from EtOAc/Pet 
Ether and obtained as colourless needles (3.368 g; 8.47 mmol; 75 %).  Rf (EtOAc/Petroleum 
Ether, 6:4) 0.40; m.p. 83-85 °C; IR (NaCl, dry film) νmax (cm-1): 3392 (NH), 1742 (C=O), 1632 
(C=C). 
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Alternate synthesis: 
Pd/C (10 wt %; 125 mg) was added to a round-bottomed flask before the sides of the flask 
were washed down with Et2O (5 ml).  2.4 (500 mg; 1.181 mmol) was added to the 
suspension, and the atmosphere of the flask flushed with H2 gas.  The solution was stirred at 
room temperature under a H2 atmosphere (provided by a balloon) for 24 h.  The mixture was 
filtered through a plug of Celite and the solvent removed at room temperature under reduced 
pressure.  The product (482 mg; 1.212 mmol) was obtained in quantitative yield as a syrup, 
which was then crystallised from EtOAc/Pet Ether and obtained as colourless needles. 
 
1H NMR (300 MHz, CDCl3) δ 7.60 – 7.43 (m, 2H, Ph), 7.38 – 7.20 (m, 3H, Ph), 5.56 (d, J = 
5.2, 1H, H1), 5.10 – 4.95 (m, 2H, H3, H4), 4.56 (ddd, J = 2.2, 5.0, 9.7, 1H, H5), 4.32 (dd, J = 
5.1, 12.3, 1H, H6a), 4.07 (dd, J = 2.3, 12.3, 1H, H6b), 3.32 (dd, J = 5.2, 10.2, 1H, H2), 2.09 (s, 
3H, CH3), 2.04 (s, 6H, 2 x CH3). 
 
13C NMR (75 MHz, CDCl3) δ 170.7 (C=O), 170.6 (C=O), 169.8 (C=O), 133.5 (C1’), 131.9 
(2C, C2’), 129.1 (2C, C3’), 127.8 (C4’), 91.3 (C1), 74.7 (C3), 69.0 (2C, C4C5), 62.3 (C6), 55.2 
(C2), 20.8 (CH3), 20.7 (2 x CH3). 
 
EI-MS m/z: [M+] Calcd for C18H23NO7S, 397.12; Found 397.14 
HRMS (ESI-TOF): Calcd for C18H23NO7S, 397.1195; Found 398.1265 [M+H], 420.1087 
[M+Na]. 
 
7.3 Attempts Toward the Synthesis of a Glycerol Glycoside 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose,7 2.18 
O
AcO
AcO
OAc
OHN3
1
23
4
5
6
 
Using a method adapted from Zhang and Kováč,8 glacial acetic acid (1.50 ml; 26.03 mmol) 
was added drop-wise to a stirring solution of ethylene diamine (1.50 ml; 22.31 mmol) in THF 
(400 ml) at 0 °C.  A solution of 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose 
2.5 (6.942 g; 18.595 mmol) in THF (64 ml) was added drop-wise to the protonated ethylene 
diamine solution, and the reaction continued for 24 h.  Upon consumption of the starting 
material (as indicated by TLC), water (200 ml) was added and the product extracted into 
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CH2Cl2.  The organic layer was washed sequentially with 1 M HCl (3x 100 ml), saturated 
aqueous NaHCO3 (2 x 100 ml) and brine (100 ml), and dried (Na2SO4).  The solvent was 
removed under reduced pressure and the crude syrup purified by silica gel chromatography 
(EtOAc:hexane, 3:7 – 1:1) to afford the product (6.2045 g) in quantitative yield as an 
inseparable mixture of anomers (α:β = 1.59:1 by 1H NMR) and as a colourless syrup.  Rf 
(EtOAc:hexane, 4:6) 0.18. 
 
α Anomer:  
1H NMR (400 MHz, CDCl3) δ 5.50 (dd, J = 10.5, 9.3 Hz, 1H, H3), 5.37 (d, J = 3.4 Hz, 1H, H1), 
5.07 – 5.01 (m, 1H, H4), 4.32 – 4.18 (m, 2H, H5, H6a), 4.16 – 4.07 (m, 2H, H6b), 3.93 (bs, 1H, 
OH), 3.41 (dd, J = 10.5, 3.4 Hz, 1H, H2), 2.07 (s, 3H, CH3COO), 2.07 (s, 3H, CH3COO), 2.02 
(s, 3H, CH3COO). 
  
13C NMR (101 MHz, CDCl3) δ 171.0 (C=O), 170.2 (C=O), 169.9 (C=O), 92.1 (C1), 70.6 (C3), 
68.7 (C4), 67.6 (C5), 62.1 (C6), 61.6 (C2), 20.7 (2C, 2 x CH3COO), 20.6 (CH3COO). 
 
β Anomer:  
1H NMR (400 MHz, CDCl3) δ 5.01 – 4.96 (m, 2H, H3, H4), 4.71 (d, J = 8.0 Hz, 1H, H1), 4.42 
(bs, 1H, OH), 4.32 – 4.18 (m, 1H, H6a), 4.16 – 4.07 (m, 1H, H6b), 3.74 – 3.65 (m, 1H, H5), 
3.51 – 3.43 (m, 1H, H2), 2.07 (s, 3H, CH3COO), 2.07 (s, 3H, CH3COO), 2.00 (s, 3H, 
CH3COO). 
 
13C NMR (101 MHz, CDCl3) δ 171.0 (C=O), 170.2 (C=O), 169.9 (C=O), 96.3 (C1), 72.7 (C3 or 
C4), 72.0 (C5), 68.5 (C4 or C3), 65.0 (C2), 62.1 (C6), 20.7 (2C, 2 x CH3COO), 20.6 (CH3COO). 
 
HRMS (ESI-TOF): Calcd for C12H17N3O8, 331.1016; Found 354.0909 [M+Na].  
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranosyl trichloroacetimidate, 2.19 
O
AcO
AcO
OAc
ON3
1
23
4
5
6
CCl3
NH
7
8
9  
A suspension of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose 2.18 (1.50 g; 4.53 
mmol) and furnace-dried K2CO3 (2.56 g; 18.52 mmol) in anhydrous CH2Cl2 (15 ml) was 
stirred at r.t. before trichloroacetonitrile (2.31 ml; 3.26 g; 22.58 mmol) was added and the 
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mixture stirred for 2 h.  Upon completion of the reaction, as determined by TLC, the reaction 
mixture was diluted with CH2Cl2, filtered through a plug of celite, and concentrated.  The oily 
residue was purified by automated flash chromatography (EtOAc:hexane, 3:7 – 4:6) to afford 
the product (1.64 g; 3.45 mmol) as a mixture of anomers in 76 % yield.  Rf (EtOAc:hexane, 
4:6) 0.77. 
α-Anomer:  
1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H, H9), 6.47 (d, J = 3.6 Hz, 1H, H1), 5.49 (dd, J = 
10.5, 9.4 Hz, 1H, H3), 5.12 (dd, J = 10.2, 9.4 Hz, 1H, H4), 4.25 (dd, J = 12.2, 4.3 Hz, 1H, 
H6a), 4.19 (ddd, J = 10.3, 4.4, 2.0 Hz, 1H, H5), 4.08 (dd, J = 12.2, 2.1 Hz, 1H, H6b), 3.75 (dd, 
J = 10.5, 3.6 Hz, 1H, H2), 2.08 (s, 3H, CH3COO), 2.03 (s, 3H, CH3COO), 2.03 (s, 3H, 
CH3COO). 
 
13C NMR (101 MHz, CDCl3) δ 170.4 (C=O), 169.8 (C=O), 169.6 (C=O), 160.6 (C7), 94.0 (C1), 
90.5 (C8), 70.7 (C5), 70.2 (C3), 68.0 (C4), 61.4 (C6), 60.7 (C2), 20.6 (CH3COO), 20.6 
(CH3COO), 20.5 (CH3COO). 
 
β-Anomer:  
1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H, H9), 5.69 (d, J = 8.4 Hz, 1H, H1), 5.12 – 5.03 (m, 
2H, H3, H4), 4.28 (dd, J = 12.5, 4.5 Hz, 1H, H6a), 4.09 (dd, J = 12.9, 2.8 Hz, 1H, H6b), 3.83 – 
3.76 (m, 1H, H5), 3.77 (dd, J = 9.9, 8.5 Hz, 1H, H2), 2.06 (s, 3H, CH3COO), 2.03 (s, 3H, 
CH3COO), 1.99 (s, 3H, CH3COO). 
 
13C NMR (101 MHz, CDCl3) δ 170.5 (C=O), 169.8 (C=O), 169.5 (C=O), 160.7 (C7), 96.4 (C1), 
90.2 (C8), 72.7 (C3 or C5), 72.7 (C5 or C3), 68.0 (C4), 63.3 (C2), 61.5 (C6), 20.6 (CH3COO), 
20.6 (CH3COO), 20.5 (CH3COO). 
 
Attempt to Convert the Protecting Groups of 5.28 From Acetates to Benzyl Ethers 
2.19
X
O
BnO
BnO
OBn
ON3 CCl3
NH
2.20
O
AcO
AcO
OAc
ON3 CCl3
NH  
A suspension of 2.19 (662 mg, 1.39 mmol), TBAI (100 mg; 0.27 mmol) and powdered NaOH 
(757 mg; 18.92 mmol) in THF (12 ml) was stirred for 30 min at r.t. before BnBr (2.206 g; 3.17 
ml; 12.9 mmol) was added and the mixture stirred for an additional 1 h.  At this stage it was 
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clear that decomposition was taken place (based on TLC analysis) and the reaction was not 
continued. 
 
Glycosylation Attempts with Trichloroacetimidate 2.28 
O
AcO
AcO
N3
OAc
O
2.21
O
O
O
AcO
AcO
OAc
ON3 CCl3
NH
2.19
X
 
 
i) A solution of 2.19 (75 mg; 0.157 mmol), isopropylidene glycerol 2.15 (14.5 mg; 0.110 
mmol) and TMSOTf (2.9 mg; 23 µl; 0.129 mmol)) in anhydrous Et2O (5 ml) was 
stirred at r.t. for 1h15min, by which time there was no discernible reaction product (as 
determined by TLC). 
 
ii) A solution of 2.19 (602 mg; 1.274 mmol) and 2.15 (811 mg; 6.137 mmol) in 
anhydrous CH2Cl2 (10 ml) containing furnace-dried 4 Å powdered molecular sieves 
was stirred under nitrogen at 0 °C before a 46.5% solution of BF3 in Et2O (2.089 ml; 
6.128 mmol) was added.  The reaction was continued for  3 h by which stage the 
starting material had been consumed (according to TLC).  The reaction was 
quenched by the addition of solid NaHCO3 and then filtered through a plug of Celite.  
After concentration under reduced pressure, the residue was purified by automated 
flash chromatography (MeOH:CH2Cl2, 1:20 – 1:4) to afford a pure fraction of the 
product, which was subsequently analysed by 1H NMR spectroscopy and found to be 
the starting material 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose 2.18. 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranosyl fluoride,9 2.30 
O
AcO
AcO
OAc
FN3
1
23
4
5
6
 
Using a protocol adapted from Posner and Haines,10 a solution of 3,4,6-tri-O-acetyl-2-azido-
2-deoxy-α/β-D-glucopyranose 2.18 (0.8953 g; 2.702 mmol) in anhydrous THF (20 ml) under 
argon was cooled to 0 °C before diethylaminosulfur trifluoride (DAST) (1.00 ml; 8.106 mmol) 
was added drop-wise over a period of 5 minutes.  The solution was allowed to warm to room 
temperature and gradually turned yellow with time.  After 45 min the starting material had 
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been consumed (according to TLC) and MeOH (1 ml) was added to quench the DAST.  After 
removal of the solvents under reduced pressure, the residue was purified by silica gel 
chromatography (eluting in EtOAc:hexane, 2:8 – 4:6) to afford the glycosyl fluoride (768 mg; 
2.304 mmol) as an inseparable mixture of anomers (α:β = 1:2.2 by 1H NMR) and as a 
colourless syrup in 85 % yield.  Rf (EtOAc:hexane, 4:6) 0.39. 
 
α-Anomer: 1H NMR (400 MHz, CDCl3) δ 5.72 (dd, J = 51.9, 2.7 Hz, 1H, H1), 5.45 (dd, J = 
10.5, 9.4 Hz, 1H, H3), 5.10 (t, J = 9.72 Hz, 1H, H4), 4.31 (dd, J = 11.8, 3.6 Hz, 1H, H6a), 4.23 
– 4.20 (m, 1H, H5), 4.14 (dd, J = 12.5, 2.2 Hz, 1H, H6b), 3.51 (ddd, J = 25.5, 10.5, 2.7 Hz, 1H, 
H2), 2.10 (s, 3H, CH3COO), 2.09 (s, 3H, CH3COO), 2.05 (s, 3H, CH3COO). 
 
β-Anomer: 1H NMR (400 MHz, CDCl3) δ 5.14 (dd, J = 51.5, 7.3 Hz, 1H, H1), 5.12 – 5.03 (m, 
2H, H3, H4), 4.28 (dd, J = 11.8, 4.5 Hz, 1H, H6a), 4.18 (dd, J = 12.1, 2.3 Hz, 1H, H6b), 3.85 – 
3.76 (m, 1H, H5), 3.71 – 3.61 (m, 1H, H2), 2.10 (s, 3H, CH3COO), 2.09 (s, 3H, CH3COO), 
2.03 (s, 3H, CH3COO). 
 
HRMS (ESI-TOF): Calcd for C12H16FN3O7, 333.0972; Found 356.0866 [M+Na].  
 
Glycosylation Attempts with Glycosyl Fluoride 
O
AcO
AcO
N3
OAc
O
O
AcO
AcO
N3
OAc
F
X
O
O
 
i) A solution of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranosyl fluoride 2.30 
(67 mg; 0.201 mmol) and (S)-O-isopropylidene glycerol 2.15 (40 mg; 0.302 mmol) in 
anhydrous THF (3 ml) containing powdered, furnace-dried molecular sieves (4 Å) 
was stirred under argon at room temperature for 30 min (to ensure anhydrous 
conditions) before BF3.OEt2 (29 mg; 25 µl; 0.201 mmol) was added drop-wise.  
Stirring was continued for 2 h, by which stage no product spot was visible by TLC.  
Consequently, additional BF3.OEt2 (0.1 ml; 4 equiv.) was added.  The reaction was 
left to stir overnight, but there was still no evidence for formation of any product.  
Consequently the reaction was quenched with Et3N (1 ml), filtered through Celite and 
extracted into EtOAc.  The work up yielded the unreacted starting material. 
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ii)  A solution of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranosyl fluoride 2.30 
(254 mg; 0.762 mmol) and 2.15 (67 mg; 0.508 mmol) in anhydrous THF (6 ml) 
containing powdered, furnace-dried molecular sieves (4 Å) was stirred under argon at 
room temperature for 30 min (to ensure anhydrous conditions) before BF3.OEt2 (433 
mg; 368 µl; 3.049 mmol) was added drop-wise.  Stirring was continued for a further 2 
hours by which stage the colour had changed from light yellow to colourless.  No 
product was detectable by TLC, and the temperature was then raised to 40 °C.  After 
2.5 h at this temperature there was still no product evident from TLC, and the 
temperature was raised further to 50 °C and stirring continued overnight.  The 
starting material appeared to have been consumed (TLC), and the reaction was thus 
quenched with Et3N (0.4 ml), filtered though Celite, extracted into EtOAc and then 
washed sequentially with saturated aqueous NaHCO3 (2 x 30 ml), saturated aqueous 
NH4Cl (2 x 30 ml) and brine.  After drying (Na2SO4) and removal of the solvent under 
reduced pressure, the residue was purified by silica gel chromatography (eluting in 
MeOH:CH2Cl2, 0:100 – 5:95).  The chromatography yielded a thick colourless gel, 
which after 1H NMR analysis, was found to be polymerised THF (only two signals 
were present: a multiplet at 3.40 ppm and one at 1.60 ppm). 
 
iii) Change of solvent to CH2Cl2: A solution of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-
glucopyranosyl fluoride 2.30 (71 mg; 0.213 mmol) and 2.15 (29 mg; 0.219 mmol) in 
anhydrous CH2Cl2 (5 ml) containing powdered, furnace-dried molecular sieves (4 Å) 
was stirred under argon at room temperature for 30 min (to ensure anhydrous 
conditions) before BF3.OEt2 (120 mg; 0.l0 ml; 0.852 mmol) was added drop-wise and 
the solution stirred at r.t.  The solution turned from colourless to light orange after 20 
min.  After 5 h the reaction was incomplete, therefore additional (S)-O-isopropylidene 
glycerol (2 drops) was added.  The starting material was consumed after 22 h (by 
TLC) and the TLC evidence for a more polar product was noted (Rf 0.18 vs. Rf 0.38 
for the glycosyl fluoride).  The reaction was quenched by the addition of  Et3N (0.4 
ml) and stirred for 5 min.  After filtration through a plug of Celite, the reaction product 
was extracted into EtOAc, washed successively with saturated aqueous NaHCO3 (2 
x 30 ml), saturated aqueous NH4Cl (30 ml) and brine (30 ml), and dried (Na2SO4).  
The solvent was removed under reduced pressure and the residue purified by silica 
gel chromatography (eluting in EtOAc:hexane, 4:6).  A pure fraction (20 mg) of the 
reaction product was isolated and characterised (1H and 13C NMR spectroscopy) and 
shown to be 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose 2.18, in the ratio 
α:β = 2:1 (by 1H NMR).  Rf (EtOAc:hexane, 4:6) 0.18.    
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iv) Change of solvent to Et2O:  An anhydrous Et2O (10 ml; dried over CaH2) solution of 
3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranosyl fluoride 2.30 (140 mg; 0.420 
mmol) and 2.15 (94 mg; 0.711 mmol) containing furnace-dried molecular sieves was 
stirred under argon at room temperature for 30 minutes before BF3.OEt2 (144 mg; 
129 µl; 1.26 mmol) was added drop-wise and the solution stirred for 19 h.  By this 
stage a considerable amount of starting material remained although a component 
with a lower Rf was visible below it on the TLC.   The reaction was quenched by the 
addition of Et3N (0.3 ml), and after stirring for 5 minutes was filtered through a plug of 
Celite and washed with EtOAc.  The crude reaction mixture was washed 
successively with NaHCO3 (2 x 30 ml), NH4Cl (2 x 30 ml) and brine (30 ml), dried 
(Na2SO4) and solvent removed under reduced pressure.  The residue was purified by 
silica gel chromatography (eluting in EtOAc:hexane, 4:6) to afford the starting 
material (63 mg; 45 %) as a mixture of inseparable anomers (α:β = 1.8:1, by 1H 
NMR) and 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose 2.18 (33 mg; 
0.100 mmol; 24 %) also as a mixture of inseparable anomers (α:β = 1.7:1, by 1H 
NMR). 
 
Glycosylation Attempts by Activation of a Phenyl-thioglycoside 11 
O
AcO
AcO
OAc
SPhN3
1
23
4
5
6
O
AcO
AcO
OAc
ON3
1
23
4
5
6
O
O
X
 
A mixture of the acetylated phenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-1-thio-D-
glucopyranoside 2.6 (112 mg; 0.265 mmol), NIS (119 mg; 0.529 mmol) and molecular sieves 
(4 Å) in anhydrous CH2Cl2 (20 ml) was cooled to -40 °C (acetonitrile/liq. N2 slurry) under 
nitrogen before (S)-1,2-isopropylidene glycerol (52 mg; 0.397 mmol) was added.  The 
mixture was stirred for 4 h whilst being allowed to warm to 0 °C, whereafter there was no 
detectable product (TLC), and the temperature was raised to 50 °C and the reaction left 
overnight.  After this treatment, there was still no evidence for product formation, and the 
reaction was worked up and starting material recovered.  
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3,4,6-Tri-O-benzyl-2-azido-2-deoxy-α/β-D-glucopyranose, 2.34 
O
BnO
BnO
OBn
SN3
1
23
4
5
6
1''
2'' 3''
4''
 
Using an adapted from a literature procedure,12 a solution of phenyl 3,4,6-tri-O-acetyl-2-
azido-2-deoxy-1-thio-D-glucopyranoside 2.6 (440 mg; 1.039 mmol; α:β = 1:9) in MeOH (10 
ml) was cooled to 0 °C (ice bath) before a solution of 4.62 M NaOMe (0.07 ml; 0.312 mmol) 
in MeOH was added.  The solution was allowed to warm to r.t. before being left to stir 
overnight (16 h).  DOWEX (H+ form) ion exchange resin was added and the mixture stirred 
for 10 min.  The resin was removed by filtration and the solvent removed under reduced 
pressure, before the product mixture was purified by automated flash chromatography 
(MeOH:CH2Cl2, 0:100 – 1:4).  The deacetylated phenyl 2-azido-2-deoxy-1-thio-D-
glucopyranoside (297 mg; 0.999 mmol) was obtained in 96 % yield, and directly subjected to 
benzylation.  Thus, a solution of the phenyl 2-azido-2-deoxy-1-thi -D-glucopyranoside (297 
mg; 0.999 mmol), TBAI (74 mg; 0.200 mmol) and NaOH (544 mg;13.60 mmol) was stirred in 
THF (4 ml) for 30 min before BnBr (1.08 ml; 9.00 mmol) was added and the mixture stirred at 
r.t. for 2.5 h.  Water was added and the product extracted into CH2Cl2.  The organic layer 
was washed with water and dried (Na2SO4) before the solvent was removed under reduced 
pressure.  The residue was purified by automated flash chromatography (EtOAc:hexane, 
3:97 – 1:4) to obtain phenyl 3,4,6-tri-O-benzyl-2-azido-2-deoxy-1-thio-α/β-D-glucopyranose 
2.34 (448 mg; 0.789 mmol; α:β = 1:9) in 79 % yield as a colourless syrup which solidified 
upon standing to form a white solid.  Rf (EtOAc:hexane, 1:9) 0.37. 
 
β Anomer (in agreement with reported characterisation)13 
1H NMR (400 MHz, CDCl3) δ 7.64 – 7.59 (m, 2H), 7.39 – 7.18 (m, 18H), 4.87 (d, J = 10.6 Hz, 
1H), 4.83 (d, J = 10.6 Hz, 1H), 4.80 (d, J = 11.0 Hz, 1H), 4.62 (d, J = 11.9 Hz, 2H), 4.60 (d, J 
= 10.9 Hz, 2H), 4.55 (d, J = 11.9 Hz, 1H), 4.43 (d, J = 10.1 Hz, 1H), 3.79 (dd, J = 11.0, 2.2 
Hz, 1H), 3.74 (dd, J = 11.0, 4.0 Hz, 1H), 3.63 (t, J = 9.3 Hz, 1H), 3.52 (t, J = 9.1 Hz, 1H), 
3.48 (ddd, J = 9.7, 4.0, 2.0 Hz, 1H), 3.35 (dd, J = 10.1, 9.3 Hz, 1H). 
 
Literature: 1H NMR (500 MHz, CDCl3) δ 7.60 (m, 2H), 7.35-7.19 (m, 18H), 4.86 (d, J = 10.5, 
1H), 4.83 (d, J= 10.5, 1H), 4.79 (d, J= 11.0, 1H), 4.62 (d, J = 12.0, 1H), 4.58 (d, J= 10.5, 1H), 
4.54 (d, J = 12.0, 1H), 4.41 (d, J = 10.0, 1H), 3.78 (dd, J = 2.0, 11.0, 1H), 3.74 (dd, J = 4.0, 
11.0, 1H), 3.61 (dd, J = 9.5, 9.5, 1H), 3.51 (dd, J=  9.5, 9.5, 1H), 3.47 (ddd, J = 2.0, 4.0, 9.5, 
1H), 3.34 (dd, J = 9.5, 9.5, 1H). 
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HRMS (ESI-TOF): Calcd for C33H33N3O4S, 567.2192; Found 590.2092 [M+Na]. 
 
Glycosylation Attempt with Phenyl 3,4,6-tri-O-benzyl-2-azido-2-deoxy-1-thio-D-
glucopyranoside (2.34) as Donor  
O
BnO
BnO
OBn
SPhN3
1
23
4
5
6
O
BnO
BnO
OBn
ON3
1
23
4
5
6
O
O
X
 
A mixture of 2.34 (235 mg; 0.414 mmol), NIS (186 mg;0.828 mmol) and furnace-dried 
molecular sieves (4 Å) was stirred under vacuum for 30 min before being suspended in 
anhydrous CH2Cl2 (3 ml) and anhydrous Et2O (6 ml).  The suspension was cooled to -30 °C 
(acetonitrile/liq N2 slurry) and stirred for 30 min (to allow the molecular sieves to absorb any 
residual water), before a solution of (s)-isopropylidene glycerol (82 mg; 0.621 mmol) in 
anhydrous Et2O (6 ml) was added drop-wise over 10 min (to generate a solution of 0.03 M 
concentration with respect to the glycoside donor).  The solution was stirred under argon at 
between -40 and -30 °C for 1 h, then allowed to warm to 0 °C.  After 2 h, no product was 
detectable by TLC, and the reaction was therefore allowed to warm to r.t. and was left 
stirring overnight.  At this stage there was still no product detectable, and the reaction was 
worked up and starting material recovered. 
 
 
7.4 General Procedure for Oxidative Decarboxylation and Coupling of 
Carboxylic acids to Naphthoquinones 
 
The general synthesis is adapted from a reported procedure.14 A degassed 100 ml solution 
of 30 % acetonitrile in water containing naphthoquinone (1 eq), carboxylic acid (5 eq) and 
AgNO3 (0.3 eq) was stirred at 65 °C for 1 hr under an inert atmosphere (Ar or N2).  A second 
degassed solution of 30 % acetonitrile in water (50 ml) containing (NH4)2S2O8  (2.5 eq) under 
argon was added drop-wise to the first solution over a period of 2 h.  The reaction was 
allowed to stir for a further 2 h, by which time maximum conversion of the starting materials 
to product had taken place.  The reaction was removed from heat, evaporated under 
reduced pressure to remove the acetonitrile, and crude mixture partitioned between EtOAc 
and water.  The water layer was washed with EtOAc (3 x 50 ml), and the combined organic 
fractions dried (Na2SO4), concentrated under reduced pressure, and purified by column 
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chromatography (silica gel). Unreacted naphthoquinone was recovered and used in 
subsequent reactions. 
 
Benzyl (S)-2-(tert-butoxycarbonylamino)-3-(8-hydroxy-3-methyl-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)propanoate, 2.48 
OH
O
O
O
O
HN O
O
1
2
3
5'
6'
1'
2'
3'4'
7'
8'
4a'
8a'
1''
2''
3''
4''
4 5 6 7
9'
10'
8
 
Compound 2.48 was prepared from plumbagin (379 mg; 2.13 mmol) and (S)-benzyl 2-(tert-
butoxycarbonylamino)-3-(8-hydroxy-3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)butanoate (3.263 g; 10.65 mmol) using the general procedure described above.  
Purification by column chromatography (silica gel, eluting in EtOAc:pentane, 2:8) provided 
2.48 as an orange powder (355 mg; 0.763 mmol; 36 %).  Rf (EtOAc:pentane, 2:8) 0.47; m.p. 
139-142 °C; IR (NaCl, dry film) νmax (cm-1): 3435 (NH), 1744 (C=O), 1712 (C=O), 1660 
(C=O), 1635 (C=C). 
 
1H NMR (500 MHz, CDCl3) δ 12.01 (s, 1H, H9’), 7.60 – 7.53 (m, 2H, H5’, H6’), 7.29 – 7.25 (m, 
5H, H2’’, H3’’, H4’’), 7.20 (dd, J = 7.5, 1.6 Hz, 1H, H7’), 5.27 (d, J = 7.7 Hz, 1H, H4), 5.15 (d, J = 
12.2 Hz, 1H, H8a), 5.12 (d, J = 12.2 Hz, 1H, H8b), 4.64 – 4.54 (m, 1H, H2), 3.15 (dd, J = 12.9, 
6.6 Hz, 1H, H3a), 3.06 (dd, J = 12.9, 8.2 Hz, 1H, H3b), 2.22 (s, 3H, H10’), 1.35 (s, 9H, H7). 
 
13C NMR (126 MHz, CDCl3) δ 189.8 (C1’), 184.0 (C4’), 171.2 (C1), 161.2 (C8’), 155.0 (C5), 
147.0 (C2’ or C3’), 141.7 (C3’ or C2’), 136.0 (C6’), 134.8 (C1’’), 132.1, 128.6 (2C, C2’’ or C3’’), 
128.5 (C4’’), 128.2 (2C, C3’’ or C2’’), 123.9 (C7’), 119.0 (C5’), 114.7 (C8a’), 80.2 (C6), 67.5 (C8), 
52.7 (C2), 30.1 (C3), 28.2 (3C, C7), 13.2 (C10’). 
 
HRMS (ESI-TOF): Calcd for C26H27NO7, 465.1788; Found 465.1775 [M+]. 
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Benzyl (S)-2-(tert-butoxycarbonylamino)-4-(8-hydroxy-3-methyl-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)butanoate, 2.49 
OH
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O
O
O
HN O
O
12
3
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2'
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Compound 2.49 was prepared from plumbagin (300 mg; 1.59 mmol) and (S)-5-(benzyloxy)-
4-(tert-butoxycarbonylamino)-5-oxopentanoic acid (2.192 g; 7.97 mmol)  using the general 
procedure described above.  Purification by column chromatography (silica gel, eluting in 
EtOAc:toluene, 5:95) provided 2.49 as an orange powder (390 mg; 0.813 mmol; 51%).  Rf 
(EtOAc:toluene, 5:95) 0.19; m.p. 101-103 °C; IR (NaCl, dry film) νmax (cm-1): 3401 (NH), 1740 
(C=O),1716 (C=O), 1660 (C=O), 1632 (C=C). 
 
1H NMR (500 MHz, CDCl3) δ 12.08 (s, 1H, H9’), 7.58 (dd, J = 7.5, 1.4, 1H, H5’), 7.54 (t, J = 
7.8, 1H, H6’), 7.40 – 7.30 (m, 5H, H2’’, H3’’, H4’’), 7.20 (dd, J = 8.1, 1.3, 1H, H7’), 5.33 (bs, 1H, 
NH5), 5.24 (d, J = 12.2, 1H, H9), 5.16 (d, J = 12.2, 1H, H9), 4.44 (bs, 1H, H2), 2.68-2.58 (m, 
2H, H4), 2.08 (s, 3H, H10’), 2.08 – 2.00 (m, 1H, H3), 1.90 - 1.82 (m, 1H, H3), 1.45 (s, 9H, H8). 
 
13C NMR (126 MHz, CDCl3) δ 189.6 (C1’), 184.1 (C4’), 171.9 (C1), 161.2 (C8’),155.3 (C6), 
145.5 (C2’ or C3’), 145.2 (C3’ or C2’), 136.0 (C6’), 135.2 (C1’’), 132.0 (C4a’), 128.6 (2C, C2’’ or 
C3’’), 128.6 (C4’’), 128.5 (2C, C3’’ or C2’’), 123.8 (C7’), 118.9 (C5’), 114.9 (C8a’), 80.1 (C7), 67.3 
(C9), 53.5 (C2), 30.8 (C3), 28.3 (3C, C8), 22.2 (C4), 12.5 (C10’).   
 
HRMS (ESI-TOF): Calcd for C27H29NO7, 479.1944; Found 502.1823 [M+Na]. 
 
(S)-2-(tert-butoxycarbonylamino)-3-(8-hydroxy-3-methyl-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)propanoic acid, 2.54 
OH
O
O
OH
O
HN O
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9'  
A solution of 2.48 (115 mg; 0.247 mmol) in THF (4 ml) and H2O (2 ml) was stirred at r.t., 
before adding LiOH.H2O (31 mg; 0.741 mmol).  There was an instantaneous colour change 
from yellow to purple due to deprotonation of the phenolic OH.  The reaction mixture was 
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stirred for 4 h before being diluted with EtOAc (40 ml), washed with saturated aqueous 
NH4Cl (2 x 30 ml) and brine (30 ml).  The aqueous layer was extracted with EtOAc (2 x 10 
ml) and the combined organic layers dried (Na2SO4) and concentrated under reduced 
pressure.  The residue was purified by silica gel chromatography (eluting in EtOAc:hexane, 
1:1, 1 % AcOH), to afford the product (83 mg; 0.221 mmol) as a yellow film in 89 % yield.  Rf 
(MeOH:CH2Cl2, 1:9) 0.34; m.p. 93-95 °C; IR (NaCl, dry film) νmax (cm-1): 3431 (NH), 1635 
(C=O, C=C). 
 
1H NMR (400 MHz, CDCl3) δ 12.05 (s, 1H, H9’), 7.65 – 7.54 (m, 2H, H5’, H6’), 7.26 – 7.18 (m, 
1H, H7’), 5.35 – 5.26 (m, 1H, H4), 4.55 (bs, 1H, H2), 3.30 – 3.17 (m, 1H, H3a), 3.14 – 2.99 (m, 
1H, H3b), 2.26 (s, 3H, H10’), 1.33 (s, 9H, H7). 
 
13C NMR (100 MHz, CDCl3) δ 189.9 (C1’), 184.1 (C4’), 175.0 (C1), 161.3 (C8’), 155.4 (C5), 
147.2 (C2’ or C3’), 141.9 (C3’or C2’), 136.1 (C6’), 132.2 (C4a’), 123.9 (C7’), 119.1 (C5’), 114.8 
(C8a’), 80.5 (C6), 52.8 (C2), 29.9 (C3), 28.1 (C7), 13.3 (C10’). 
 
HRMS (ESI-TOF): Calcd for C19H21NO7, 375.1318; Found 376.1395 [M+H], 398.1212 
[M+Na]. 
 
 
(S)-2-(tert-butoxycarbonylamino)-4-(8-hydroxy-3-methyl-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)butanoic acid, 2.55 
OH
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O
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A solution of 2.49 (582; 1.22 mmol) in THF (10 ml) and H2O (3.5 ml) was stirred at r.t. before 
adding LiOH.H2O (153 mg; 3.64 mmol).  The reaction mixture was stirred for 4 h and then 
extracted into EtOAc and the EtOAc extract washed with saturated aqueous NH4Cl (2 x 50 
ml) and brine (30 ml).  After drying (Na2SO4) and removal of the solvent under reduced 
pressure, the residue was purified by column chromatography (silica gel, eluting in 
EtOAc:hexane, 1:1, 1 % AcOH) to give the product as a yellow precipitate (431 mg; 1.108 
mmol; 91 %).  Rf (MeOH:CH2Cl2, 1:9) 0.40; m.p. 66-68 °C; IR (NaCl, dry film) νmax (cm-1): 
3414 (NH), 1635 (C=O, C=C). 
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1H NMR (500 MHz, CD3OD) δ 7.56 (1H, dd, J = 8.2, 7.7 Hz, H6’), 7.47 (d, J = 7.5 Hz, 1H, 
H5’), 7.15 (dd, J = 8.4, 0.9 Hz, 1H, H7’), 4.20 – 4.11 (m, 1H, H2), 2.75 – 2.65 (m, 2H, H4), 2.13 
(s, 3H, H10’), 2.11 – 2.00 (m, 1H, H3a), 1.91 – 1.80 (m, 1H, H3b), 1.44 (s, 9H, H8). 
 
13C NMR (126 MHz, CD3OD) δ 189.5 (C1’), 183.9 (C4’), 174.5 (C1), 160.8 (C8’), 156.6 (C6), 
145.6 (C2’ or C3’), 145.0 (C3’or C2’), 135.7 (C6’), 132.1 (C4a’), 123.2 (C7’), 118.2 (C5’), 114.7 
(C8a’), 79.2 (C7), 53.6 (C2), 30.0 (C3), 27.4 (3C, C8), 22.6 (C4), 11.4 (C10’). 
 
HRMS (ESI-TOF), Calcd for C20H23NO7Na, 412.1372; Found 412.1393 [M+Na]. 
 
Phenyl-3,4,6-tri-O-acetyl-2-deoxy-2-[(S)-2’-(tert-butoxycarbonyamino)-3'-(8''-hydroxy-3''-
methyl-1'',4''-dioxo-1'',4''-dihydronaphthalen-2''-yl)propanamido]-1-thio-α-D-
glucopyranoside, 2.56 
O
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A solution of 2.54 (60 mg; 0.160 mmol), EDC.HCl (34 mg; 0.176 mmol) and HOBt.H2O (24 
mg; 0.176 mmol) in anhydrous THF (10 ml) was cooled to 0 °C.  To this was added a 
solution of 2.7 (100 mg; 0.252 mmol) in dry THF (10 ml), drop-wise over 15 min, followed by 
DIEA (0.1 ml; 0.574 mmol).  There was an instantaneous colour change from dark orange to 
dark red due to deprotonation of the phenolic OH.  The reaction was allowed to warm to 
room temperature and stirring was continued for 18 h.  By this stage TLC showed the 
reaction to be incomplete, and a spatula tip of EDC.HCl was therefore added and stirring 
continued for a further 24 h.  The reaction mixture was then partitioned between EtOAc (40 
ml) and saturated aqueous NH4Cl (40 ml).  The organic layer was washed once again with 
saturated aqueous NH4Cl (30 ml) and brine (30 ml).  The combined aqueous layers were 
extracted with EtOAc (3 x 20 ml), and the combined organic layers dried (Na2SO4).  After 
removal of the solvent under reduced pressure, the crude residue was purified by column 
chromatography (silica gel, eluting in EtOAc:petroleum ether, 6:4) to yield the product (40 
mg; 0.053 mmol) in 33 % yield.  Rf (EtOAc:petroleum ether, 6:4) 0.60; m.p. 210-212 °C; IR 
(NaCl, dry film) νmax (cm-1): 3435 (NH), 1746 (C=O), 1664 (C=O), 1635 (C=C). 
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Alternate Synthesis Using EEDQ as Coupling Reagent: 
 
Portions of 2.54 (91 mg; 0.242 mmol), phenyl 3,4,6-tri-O-acetyl-2-amino-2-deoxy-1-thio-D-
glucopyranoside 2.7 (200 mg; 0.503 mmol) and EEDQ (2-ethoxy-1-ethoxycarbonyl-1,2-
dihydroquinoline) (72 mg; 0.290 mmol) were dissolved in anhydrous THF (10 ml) under Ar, 
and stirred at 40 °C overnight (15 h).  The solvent was removed under reduced pressure, 
and the residue purified by automated flash chromatography (EtOAc:petroleum ether, 1:9 – 
1:1 containing 1 % AcOH) to afford the product (179 mg; 0.237 mmol) as a yellow powder in 
98 % yield.    
 
1H NMR (400 MHz, CDCl3) δ 12.00 (s, 1H, H9’), 7.62 – 7.53 (m, 2H, H5’, H6’), 7.49 – 7.42 (m, 
2H, H2’’), 7.35 – 7.25 (m, 3H, H3’’, H4’’), 7.23 (dd, J = 7.2, 2.1 Hz, 1H, H7’), 6.80 (d, J = 8.3 Hz, 
1H, NH7), 5.74 (d, J = 5.2 Hz, 1H, H1), 5.28 – 5.20 (m, 2H, H3 or H4, NH11), 5.17 (t, J = 9.6 
Hz, 1H, H4 or H3), 4.60 – 4.49 (m, 2H, H2, H5), 4.40 – 4.32 (m, 1H, H9), 4.29 (dd, J = 12.3, 5.0 
Hz, 1H, H6a), 4.09 (broad dd, J = 12.4, 1.9 Hz, 1H, H6b), 3.07 (dd, J = 13.5, 3.5 Hz, 1H, H10a), 
2.92 (dd, J = 13.4, 10.0 Hz, 1H, H10b), 2.23 (s, 3H, H10’), 2.06 (s, 3H, CH3COO), 2.05 (s, 3H, 
CH3COO), 2.04 (s, 3H, CH3COO), 1.30 (s, 9H, H14).   
 
13C NMR (101 MHz, CDCl3) δ 190.4 (C1’), 183.9 (C4’), 171.4 (C=O), 171.0 (C=O), 170.6 
(C=O), 169.3 (C=O), 161.4 (C8’), 155.3 (C12), 147.2 (C2’ or C3’), 142.3 (C3’ or C2’), 136.3 (C6’), 
132.8 (C1’’), 132.1 (C4a’), 131.6 (2C, C2’’), 129.2 (2C, C3’’), 127.9 (C4’’), 124.0 (C7’), 119.2 (C5’), 
114.8 (C8a’), 87.3 (C1), 80.5 (C13), 71.1 (C3), 69.0 (C5), 68.2 (C4), 62.0 (C6), 54.1 (C9), 53.0 
(C2), 30.4 (C10), 28.1 (3C, C14), 20.6 (2 x CH3COO), 20.6 (CH3COO), 13.3 (C10’) .  
 
HRMS (ESI-TOF), Calcd for C37H42N2O13S, 754.2408; Found 755.2495 [M+H], 777.2307 
[M+Na]. 
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Phenyl-3,4,6-tri-O-acetyl-2-deoxy-2-[(S)-2’-(tert-butoxycarbonyamino)-4'-(8''-hydroxy-3''-
methyl-1'',4''-dioxo-1'',4''-dihydronaphthalen-2''-yl)butanamido]-1-thio-α-D-
glucopyranoside, 2.57 
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Portions of 2.55 (129 mg; 0.331 mmol) and EEDQ (86 mg; 0.348 mmol) were combined and 
first placed under reduced pressure for 20 min, then purged with Ar before adding anhydrous 
THF (5 ml).  The resulting solution was stirred for 10 min at r.t. before adding a solution of 
2.7 (158 mg; 0.398 mmol) in anhydrous THF (5 ml).  The mixture was stirred at r.t. under Ar 
for 39 h.  The reaction mixture was then partitioned between EtOAc and sat. aq. NH4Cl, and 
the organic layer washed with additional NH4Cl (2 x 30 ml) and brine (30 ml).  The combined 
aqueous layers were extracted with additional EtOAc until the yellow product colour was no 
longer evident.  The combined organic fractions were dried (Na2SO4), the solvent removed 
under reduced pressure, and the residue purified by silica gel chromatography (eluting in 
EtOAc:petroleum ether, 3:7).  The purified product was obtained as a yellow solid (217 mg; 
0.282 mmol, 85 %).  Rf (EtOAc:petroleum ether,1:1) 0.50; m.p. 173-174 °C; IR (NaCl, dry 
film) νmax (cm-1): 3431 (NH), 1746 (C=O), 1660 (C=O), 1633 (C=C). 
 
 1H NMR (400 MHz, CDCl3) δ 12.02 (s, 1H, H9’), 7.58 (dd, J = 7.5, 1.6 Hz, 1H, H5’), 7.57 – 
7.52 (m, 1H, H6’), 7.42 – 7.37 (m, 2H, H2’’), 7.25 – 7.17 (m, 4H, H3’’H4’’H7’), 6.79 (d, J = 8.1 
Hz, 1H, NH7), 5.73 (d, J = 5.3 Hz, 1H, H1), 5.19 (dd, J = 10.7, 9.2 Hz, 1H, H3 or H4), 5.16 – 
5.10 (m, 2H, H4 or H3, NH12), 4.57 – 4.47 (m, 2H, H2, H5), 4.26 (dd, J = 12.4, 5.0 Hz, 1H, H6a), 
4.14 – 4.09 (m, 1H, H9), 4.06 (dd, J = 12.4, 2.3 Hz, 1H, H6b), 2.68 – 2.53 (m, 2H, H11), 2.09 
(s, 3H, H10’), 2.03 (s, 3H, CH3COO), 2.02 (s, 3H, CH3COO), 2.01 (s, 3H, CH3COO), 1.98 – 
1.88 (m, 1H, H10a), 1.82 – 1.69 (m, 1H, H10b), 1.44 (s, 9H, H15).  
 
13C NMR (101 MHz, CDCl3) δ 189.9 (C1’), 184.1 (C4’), 171.7 (C=O), 171.4 (C=O), 170.6 
(C=O), 169.3 (C=O), 161.3 (C8’), 155.6 (C13), 145.6 (C2’ or C3’), 145.3 (C3’ or C2’), 136.2 (C6’), 
133.0 (C1’’), 132.1 (C4a’), 131.5 (2C, C2’’), 129.2 (2C, C3’’), 127.8 (C4’’), 123.9 (C7’), 119.1 (C5’), 
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114.9 (C8a’), 87.4 (C1), 80.6 (C14), 70.8 (C3), 69.0 (C5), 68.3 (C4), 62.0 (C6), 54.6 (C9), 53.0 
(C2), 30.7 (C10), 28.3 (3C, C15), 20.6 (2 x CH3COO), 20.6 (CH3COO), 12.7 (C10’).  
 
HRMS (ESI-TOF), Calcd for C38H44N2O13S, 768.2564; Found 769.2648  [M+H]. 
 
Attempted Removal of Boc Protecting Group in 5.56: Formation of Phenyl-3,4,6-tri-O-acetyl-
2-deoxy-2-[(s)-2’-(trifluoroacetamido)-3'-(8''-hydroxy-3''-methyl-1'',4''-dioxo-1'',4''-
dihydronaphthalen-2''-yl)propanamido]-1-thio-α-D-glucopyranoside, 2.65 
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A solution of 2.56 (24 mg; 0.032 mmol) and anisole (7 mg; 0.064 mmol) in CH2Cl2 (2 ml) was 
stirred at r.t. before drop-wise addition of TFA containing TFAA (0.4 ml).  The solution was 
stirred for 4 h at r.t., by which stage the starting material had been consumed (by TLC), and 
the excess reagents and solvents were then removed by evaporation under a stream of air.  
The residue was diluted with EtOAc (30 ml) and washed with NaHCO3 (2 x 20 ml) then 
NH4Cl (20 ml) before drying (Na2SO4) and removing the solvent under reduced pressure, 
and the residue purified by automated flash chromatography (gradient elution with 
EtOAc:hexane mixtures, 2:8 – 6:4).  The product was obtained as a yellow powder (36.5 mg; 
0.049 mmol; 70 %).  Rf (EtOAc:hexane, 4:6) 0.35; m.p. 234-236 °C; IR (NaCl, dry film) νmax 
(cm-1): 3440 (NH), 1725 (C=O), 1635 (C=C). 
 
1H NMR (400 MHz, CDCl3) δ 11.84 (s, 1H, H9’), 7.59 – 7.53 (m, 3H, H11, H5’, H6’), 7.41 – 7.34 
(m, 2H, H2’’), 7.31 – 7.25 (m, 3H, H3’’, H4’’), 7.23 – 7.19 (m, 1H, H7’), 6.86 (d, J = 7.8 Hz, 1H, 
H7), 5.77 (d, J = 5.4 Hz, 1H, H1), 5.22 (dd, J = 10.5, 9.3 Hz, 1H, H3 or H4), 5.17 (t, J = 9.4 Hz, 
1H, H4 or H3), 4.59 (td, J = 7.6, 4.7 Hz, 1H, H9), 4.54 – 4.44 (m, 2H, H2, H5), 4.27 (dd, J = 
12.4, 5.1 Hz, 1H, H6a), 4.05 (dd, J = 12.4, 2.3 Hz, 1H, H6b), 3.10 – 2.98 (m, 2H, H10), 2.19 (s, 
3H, H10’), 2.04 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.02 (s, 3H, CH3).   
 
13C NMR (101 MHz, CDCl3) δ 191.0 (C1’), 183.5 (C4’), 172.3 (C=O), 170.7 (C=O), 169.4 
(C=O), 169.1, 161.8 (C8’), 157.5 (q, 1C, J = 37.9 Hz, C12), 148.3, 141.1, 136.9 (C6’), 132.5, 
132.1, 131.7 (2C, C2’’), 129.5 (2C, C3’’), 128.1 (C4’’), 124.4 (C7’), 119.8 (C5’), 115.5 (q, 1C, J = 
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287.7 Hz, C13), 114.7, 86.8 (C1), 71.4 (C3 or C4), 69.2 (C2 or C5), 68.1 (C4 or C3), 62.1 (C6), 
53.8 (C5 or C2), 53.3 (C9), 30.6 (C10), 20.8 (CH3COO), 20.8 (CH3COO), 20.7 (CH3COO), 13.5 
(C10’).  
 
HRMS (ESI-TOF), Calcd for C34H33F3N2O12S, 750.1706; Found 751.1776 [M+H], 773.1596 
[M+Na]. 
 
Phenyl 2-deoxy-2-[(s)-2’-(trifluoroacetamido)-3'-(8''-hydroxy-3''-methyl-1'',4''-dioxo-1'',4''-
dihydronaphthalen-2''-yl)propanamido]-1-thio-α-D-glucopyranoside, 2.66 
O
HO
HO
SNH
OH
O
NH
OH
O
O
O
F3C
8
9
10
5'
6'
1'
2'
3'4'
7' 8'
11
12
9'
10'
1
23
4
5
6
1''
2''
3''
4''
7
13
 
A solution of 2.65 (36.5 mg; 0.049 mmol) in CH2Cl2 (5 ml) and MeOH (4 ml) was stirred at r.t. 
before a solution of NaOMe (0.52 mg; 0.010 mmol) in MeOH (0.26 ml) was added and the 
solution stirred for 8.5 h.  Two product spots were visible by TLC and after 8.5 h they had not 
converged to a single spot.  The starting material had, however, not been completely 
consumed at this stage, and degradation was evident from products detectable on the 
baseline of the TLC.  Consequ ntly, the reaction was neutralised by the addition of DOWEX 
ion exchange resin (H+ form), filtered and the solvent removed under reduced pressure.  
Purification of the residue was attempted by automated flash chromatography using 
MeOH:CH2Cl2 mixtures (0:100 - 10:90), but the product appeared to adhere to the silica, and 
1 % AcOH was added to the mobile phase to encourage elution.  However, considerable 
material was lost during chromatography due to adherence to the silica and due to 
degradation.  Two minor fractions were obtained (3 mg and 7 mg), neither of which had 
spectroscopic features (1H or 13C NMR) consistent with the desired product. 
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Phenyl-3,4,6-tri-O-acetyl-2-deoxy-2-[2’-carboxamido-5’-methyl-6’,10’-dihydroxy-
benzo[h]quinolinyl)-1-thio-α-D-glucopyranoside, 2.67 
O
AcO
AcO
S
OAc
NHO
N OH
OH
1
23
4 5
6
7
2'
3'
4'
5'
11'
8'
7'6'
9'
10'
8
1'
1''
2''
3''
4''
12'
13'
4a'
10a'
6a'
          
A solution of 2.57 (196 mg; 0.255 mmol) and anisole (55 mg; 0.510 mmol) in CH2Cl2 (5 ml) 
was cooled to 0 °C (ice slurry) before trifluoroacetic acid (1.5 ml) was added drop-wise.  The 
solution was stirred at 0 °C for 2h 30min by which stage the starting material was completely 
consumed (TLC).  The acid was neutralised by drop-wise addition f saturated aq. NaHCO3, 
and the product extracted into CH2Cl2, then the organic phase washed with saturated 
aqueous NH4Cl, dried (Na2SO4) and the solvent removed under reduced pressure.  The 
residue was purified by silica gel chromatography (EtOAc: hexane, 2:5) to yield the cyclised 
product as a yellow solid (141 mg; 0.217 mmol; 85 %).  Rf (EtOAc:hexane, 6:4) 0.37; m.p. 
217-219 °C; IR (NaCl, dry film) νmax (cm-1): 3444 (NH), 1746 (C=O), 1635 (C=C). 
 
1H NMR (400 MHz, CDCl3) δ 13.75 (s, 1H, H13’), 8.20 (d, J = 8.6 Hz, 1H, H3’ or H4’), 8.14 (d, J 
= 8.6 Hz, 1H, H4’ or H3’), 7.63 (1H, bs, H7), 7.61 – 7.53 (m, 2H, H2’’), 7.48 (dd, J = 8.2, 1.6 Hz, 
1H, H7’ or H9’), 7.44 (t, J = 8.0 Hz, 1H, H8’), 7.30 – 7.24 (m, 3H, H3’’, H4’’), 7.17 (dd, J = 7.47, 
1.45 Hz, 1H, H9’ or H7’), 6.13 (bs, 1H, H12’), 5.91 (d, J = 5.4 Hz, 1H, H1), 5.49 (dd, J = 11.1, 
9.2 Hz, 1H, H3), 5.29 (t, J = 9.6 Hz, 1H, H4), 4.89 (ddd, J = 11.1, 8.7, 5.4 Hz, 1H, H2), 4.68 
(ddd, J = 10.1, 4.9, 2.2 Hz, 1H, H5), 4.37 (dd, J = 12.3, 5.0 Hz, 1H, H6a), 4.17 (dd, J = 12.3, 
2.3 Hz, 1H, H6b), 2.52 (s, 3H, H11’), 2.11 (s, 3H, CH3COO), 2.10 (s, 3H, CH3COO), 2.08 (s, 
3H, CH3COO).   
 
13C NMR (75 MHz, CDCl3) δ 172.6 (C=O), 170.7 (C=O), 169.4 (C=O), 165.3 (C=O), 158.7, 
149.1, 143.1, 142.4, 133.1, 132.2 (C3’ or C4’), 132.0 (2C, C2’’), 129.9 (C8’), 129.4, 129.2 (2C, 
C3’’), 128.3, 128.0 (C4’’), 120.0 (C4’ or C3’), 114.4, 114.0 (C7’ or C9’), 111.4 (C9’ or C7’), 109.3, 
88.0 (C1), 71.8 (C3), 69.0 (C5), 68.5 (C4), 62.2 (C6), 53.2 (C2), 20.9 (CH3COO), 20.7 
(CH3COO), 20.6 (CH3COO), 10.6 (C11’).   
 
HRMS (ESI-TOF), Calcd for C33H32N2O10S, 648.1778; Found 649.1850 [M+H]. 
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Attempted Removal of Boc Protecting Group in 5.48: Formation of Benzyl (S)-2-
(trifluoroacetamido)-3-(8-acetoxy-3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)propanoate, 2.68 
 
O
O
O
O
O
HN
1
2
3
5'
6'
1'
2'
3'4'
7'
8'
4a'
8a' 1'' 2''
3''
4''4
5
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10'
O
11'
CF3
O
6
7
 
A solution of 2.48 (165 mg; 0.353 mmol) and anisole (76 mg; 0.707 mmol) in CH2Cl2 (9 ml) 
was stirred at room temperature before trifluoroacetic acid (2 ml) was added.  The solution 
was stirred for 3.5 h by which stage the starting material was completely consumed (TLC, 
staining with ferric chloride).  The mixture was then neutralised with saturated aqueous 
NaHCO3, washed with saturated aqueous NH4Cl, and the organic fraction dried (Na2SO4) 
before removing the solvent under reduced pressure.  The crude mixture was purified by 
silica gel chromatography (eluting with EtOAc:petroleum ether, 1:9 – 3:17) to afford the 
deprotected product (146 mg) as a yellow powder in quantitative yield.  After confirmation of 
the disappearance of the t-Bu signal in the 1H NMR spectrum, the free amine was subjected 
to acetylation.  A solution of the amine (100 mg; 0.274 mmol) in Ac2O (1 ml) and anhydrous 
pyridine (2 ml) was stirred overnight (17 h) at room temperature.  The solution was diluted 
with EtOAc, washed sequentially with 1M HCl (2 x 30 ml), saturated aqueous NaHCO3 (2 x 
30 ml) and saturated aqueous NH4Cl (30 ml), and the organic layer dried (Na2SO4).  After 
removal of the solvent removed under reduced pressure, the resulting residue was purified 
by silica gel chromatography (EtOAc:petroleum ether, 1:5) to afford the acetylated product  
as a yellow powder (81 mg; 0.161 mmol; 59 %).  Rf (EtOAc:hexane, 3:7) 0.35; m.p. 151-152 
°C; IR (NaCl, dry film) νmax (cm-1): 3470 (NH), 1746 (C=O), 1725 (C=O), 1660 (C=C). 
 
1H NMR (400 MHz, CDCl3) δ 7.98 (dd, J = 7.8, 1.3 Hz, 1H, H5’), 7.73 – 7.65 (t, J = 7.90 Hz, 
1H, H6’), 7.46 (d, J = 6.7 Hz, 1H, H4), 7.31 (dd, J = 8.1, 1.2 Hz, 1H, H7’), 7.27 – 7.21 (m, 5H, 
H2’’, H3’’, H4’’), 5.17 (d, J = 12.1 Hz, 1H, H7a), 5.08 (d, J = 12.1 Hz, 1H, H7b), 4.74 – 4.67 (m, 
1H, H2), 3.19 – 3.07 (m, 2H, H3), 2.39 (s, 3H, CH3), 2.15 (s, 3H, CH3). 
 
13C NMR (101 MHz, CDCl3) δ 184.1 (C1’), 183.6 (C4’), 169.4 (C=O), 169.3 (C=O), 157.1 (q, J 
= 38.0 Hz, C5), 149.6, 145.6, 141.8, 134.8 (C6’), 134.5, 133.7, 129.6 (C7’), 128.7 (C4’’), 128.7 
(C2’’ or C3’’), 128.4 (C3’’ or C2’’), 125.1 (C5’), 123.1, 115.6 (q, J = 287.6 Hz, C6), 68.1 (C7), 51.9 
(C2), 29.2 (C3), 21.0 (CH3), 12.9 (CH3).  
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Benzyl 5,9-dihydroxy-4-methyl-1H-benzo[g]indole-2-carboxylate, 2.69 
HNOH
OH
O
O
3
4
1
56
7
8
9
10
11
12
13 1''
2''
2
3a
3''
4''
9a
 
A solution of 2.48 (197 mg; 0.423 mmol) and anisole (few drops) in CH2Cl2 (10 ml) and TFA 
(1ml) was stirred at r.t. for 4 h, by which time the starting material had been consumed.  The 
acid was neutralised with NaHCO3, diluted with additional CH2Cl2 (20 ml) and the organic 
layer washed sequentially with saturated aqueous NH4Cl and brine.  The solvent was 
removed under reduced pressure and the residue purified by automated flash 
chromatography (eluting in EtOAc:hexane, 1:4 – 2:3) to afford the cyclised product as a pale 
yellow solid (73 mg; 0.211 mmol; 50 %).  Rf (EtOAc:hexane, 1:4) 0.15; m.p. 191-192 °C. 
 
1H NMR (400 MHz, MeOD) δ 7.73 (dd, J = 8.3, 0.9 Hz, 1H, H6 or H8), 7.51 – 7.44 (m, 2H, 
H2’’), 7.42 – 7.35 (m, 2H, H3’’), 7.34 – 7.27 (m, 2H, H4’’, H7), 7.28 (s, 1H, H3), 6.91 (dd, J = 7.7, 
0.8 Hz, 1H, H8 or H6), 5.38 (s, 2H, H13), 2.49 (s, 3H, H11).  
 
HRMS (ESI-TOF), Calcd for C21H17NO4, 347.1158; Found 348.1241 [M+H], 370.1115 
[M+Na]. 
 
Benzyl 5,9-diacetoxy-4-methyl-1H-benzo[g]indole-2-carboxylate , 2.70 
HNO
O
O
O
3
4
1
56
7
8
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11
12
13 1''
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2
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3''
4''
9a
O
O  
A solution of 2.69 (18 mg; 0.052 mmol) in acetic anhydride (2 ml) and anhydrous pyridine 
(1.5 ml) was stirred at r.t. under argon for 24 h to allow for complete acetylation.  The 
solution was then diluted with CHCl3 (30 ml) and washed sequentially with 1 M HCl (2 x 50 
ml), saturated aqueous NaHCO3 (2 x 50 ml) and saturated aqueous NH4Cl (20 ml).  After 
drying (Na2SO4) and removal of the solvent under reduced pressure, the crude product 
residue was purified by automated flash chromatography (eluting in EtOAc:hexane, 1:4 – 
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2:5).  The purified product was obtained as an off-white powder (11 mg; 0.025 mmol; 48 %).  
Rf (EtOAc:hexane, 2:3) 0.64; m.p. 164-166 °C. 
 
1H NMR (400 MHz, CDCl3) δ 10.00 (s, 1H, H1), 7.65 (dd, J = 8.0, 1.3 Hz, 1H, H6 or H8), 7.48 
(dd, J = 8.0, 7.9 Hz, 1H, H7), 7.48-7.33 (m, 7H, H8 or H6, H3, H2’’, H3’’, H4’’), 5.39 (s, 2H, H13), 
2.48 (s, 3H, CH3COO), 2.45 (s, 3H, CH3COO), 2.43 (s, 3H, H11). 
 
13C NMR (101 MHz, CDCl3) δ 169.1 (C=O), 167.6 (C=O), 161.0 (C=O), 145.7, 138.5, 135.6, 
128.6 (ArBn), 128.4 (ArBn), 128.3 (ArBn), 128.1, 127.8, 125.6, 125.5 (C7), 125.2, 122.2, 119.4 
(C6 or C8), 118.4 (C6 or C8), 114.0, 108.6 (C3), 66.7 (C13), 21.5 (CH3COO), 20.4 (CH3COO), 
12.8 (C11). 
 
HRMS (ESI-TOF), Calcd for C25H21NO6, 431.1369; Found 432.1448 [M+H], 454.1263 
[M+Na]. 
 
Benzyl 6-acetoxy-10-hydroxy-5-methylbenzo[h]quinoline-2-carboxylate, 2.77 
O
NOH
O
O
O
3
4
1
5
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A solution of 2.49 (156 mg; 0.325 mmol) and anisole (70 mg; 0.651 mmol) in CH2Cl2 (5 ml) 
was cooled to 0 °C before TFA (1.5 ml) was added drop-wise.  The solution was stirred at 0 
°C for 3h 10min at which stage the starting material was completely consumed (according to 
TLC) and the acid neutralised with saturated aqueous NaHCO3.  The mixture was diluted 
with additional CH2Cl2 (20 ml) and the organic layer washed sequentially with saturated 
aqueous NH4Cl and brine.  The solvent was removed under reduced pressure and the 
residue dissolved in dry THF (8 ml), pyridine (0.5 ml) and Ac2O (0.5 ml), and stirred at room 
temperature for 24 h.  The reaction was found to be incomplete after this period, and the 
temperature was therefore raised to 50 °C, additional Ac2O (1.2 eq) added and stirring 
continued for a further 24 h.  Reaction was then found to be complete by TLC and the 
reaction mixture was then diluted with EtOAc, washed successively with 1 M HCl (2 x 90 ml), 
saturated aqueous NaHCO3 (2 x 100 ml), saturated aqueous NH4Cl (100 ml) and brine (100 
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ml).  After drying (Na2SO4), the organic layer was concentrated under reduced pressure and 
the residue purified by silica gel chromatography (CH2Cl2:EtOAc:hexane, 2:1:7) to afford the 
product as yellow needles (116 mg; 0.275 mmol; 85 %).  Rf (EtOAc:hexane, 3:7) 0.46; m.p. 
181-182 °C; IR (NaCl, dry film) νmax (cm-1): 3427 (OH), 1766 (C=O), 1727 (C=O), 1628 
(C=C). 
 
1H NMR (400 MHz, CDCl3) δ 14.70 (s, 1H, H11), 8.51 (d, J = 8.5 Hz, 1H, H3 or H4), 8.36 (d, J 
= 8.5 Hz, 1H, H4 or H3), 7.66 (t, J = 8.1 Hz, 1H, H8), 7.58 – 7.54 (m, 2H, H2’’), 7.46 – 7.40 (m, 
2H, H3’’), 7.39 – 7.33 (m, 1H, H4’’), 7.35 (dd, J = 8.07, 1.01 Hz, 1H, H7 or H9) 7.30 (dd, J = 
8.0, 1.0 Hz, 1H, H9 or H7), 5.55 (s, 2H, H16), 2.53 (s, 3H, H14), 2.51 (s, 3H, H12).  
 
13C NMR (101 MHz, CDCl3) δ 168.5 (C13), 163.9 (C15), 159.7 (C10), 146.4, 145.8, 141.9, 
135.6, 133.6 (C3 or C4), 131.0 (C8), 129.8, 128.7 (2C, C3’’), 128.7, 128.5 (C4’’), 128.2 (2C, 
C2’’), 121.4 (C4 or C3), 121.3, 115.5 (C7 or C9), 115.4, 111.7 (C9 or C7), 67.7 (C16), 20.6 (C14), 
12.0 (C12). 
 
HRMS (ESI-TOF), Calcd for C24H19NO5, 401.1263; Found 402.1335 [M+H]. 
 
Towards the Preparation of an N-Acetylated Amino Acid 
O
O
HN
HO
O
Boc
O
O
HN
HO
O
O 2.852.46
X
 
A solution of 2.46 (244 mg; 0.755 mmol), TFA (1 ml) and anisole (few drops) in CH2Cl2 (5 ml) 
was stirred at r.t. for 4 h before the solvent was removed under reduced pressure and the 
residue redissolved in CH2Cl2 (3 ml), Ac2O (1 ml) and pyridine (2 ml), before stirring at r.t. 
overnight (17 h).  The crude mixture was then diluted in CH2Cl2 (40 ml) and washed 
sequentially with 1 M HCl (2 x 30 ml), saturated aqueous NaHCO3 (30 ml), and saturated 
aqueous NH4Cl (30 ml).  The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure before purification by automated flash chromatography (MeOH:CH2Cl2, 
1:9).  The eluted column fractions all contained multiple components suggesting 
decomposition had taken place. 
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Attempts Towards the Synthesis of an Acetylated Boc-Protected Amine: Formation of Benzyl 
(S)-2’-(tert-butoxycarbonyamino)-3'-(8''-acetoxy-3''-methyl-1'',4''-dioxo-1'',4''-
dihydronaphthalen-2''-yl)propanoate, 2.86 
2.86
(i) or (ii)
O
O
HN
Boc
O
O
OH
O
O
N
O
O
O
OBoc
O
O
HN
O
O
O
O
O
X
(ii)
2.48 2.87
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2'
3'4'
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i) A solution of 2.48 (24 mg; 0.516 mmol) in Ac2O (0.5 ml) and pyridine (0.5 ml) was 
stirred at r.t. under Ar for 2 days.  The product was extracted into CH2Cl2 (20 ml), 
washed sequentially with 1 M HCl (2 x 20 ml), saturated aqueous NaHCO3 (20 ml) 
and saturated aqueous NH4Cl (20 ml), and dried (Na2SO4).  After concentration 
under reduced pressure, purification of the residue was attempted by automated 
flash chromatography (EtOAc:hexane, 1:9), however, TLC analysis of the eluted 
fractions indicated that mulitiple components were present in each, suggesting that 
decomposition had taken place. 
 
ii) A solution of 2.48 (24 mg; 0.051 mmol) in anhydrous CH2Cl2 (5 ml) was stirred at 0 
°C (ice bath) before Et3N (18 µl; 0.128 mmol) and acetyl chloride (9 µl; 0.128 mmol) 
were added drop-wise.  The ice bath was removed and the solution allowed to warm 
to r.t. and stirred for 24 h.  After this extended reaction time no detectable product 
had formed (TLC) and additional AcCl (0.1 ml) and Et3N (0.1 ml) were added and 
stirring continued for an additional 15 min, by which stage the starting material had 
been consumed.  The reaction mixture was diluted with CH2Cl2 and the organic layer 
washed sequentially with saturated aqueous NaHCO3 and saturated aqueous NH4Cl, 
and dried (Na2SO4).  After removal of the solvent under reduced pressure, the 
residue was purified by automated flash chromatography (EtOAc:hexane, 1:4) to 
afford a fraction that was analysed by 1H NMR spectroscopy and found to be the 
phenolic acetate derivative 2.86. Rf (EtOAc:hexane, 1:4) 0.19. 
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1H NMR (400 MHz, CDCl3) δ 8.00 (dd, J = 7.8, 1.2 Hz, 1H, H5’ or H7’), 7.68 (t, J = 7.9 
Hz, 1H, H6’), 7.31 (dd, J = 8.1, 1.1 Hz, 1H, H7’ or H5’), 7.28 (bs, 5H, H2’’, H3’’, H4’’), 5.24 
(s, 1H, H4), 5.15 (d, J = 12.2 Hz, 1H, H8a), 5.09 (d, J = 12.2 Hz, 1H, H8b), 4.57 – 4.44 
(m, 1H, H2), 3.16 – 2.99 (m, 2H, H3), 2.41 (s, 3H, H11’), 2.20 (s, 3H, H10’), 1.35 (s, 9H, 
H7). 
 
7.5 Carbazole Quinone Derivatives 
 
7.5.1 3-Substituted Carbazole Quinones 
 
2,3-dihydro-3-dioxolanyl-2-methyl-9H-carbazole-1,4-quinone, 3.13 
N
H
O
O
Me
O
O
9'
5'
6'
1'
2'
3'4'
7'
8' 10'
11'
12'
13'
H
 
i) A solution of 3-methoxy-2-methyl-9H-carbazole-1,4-quinone (53 mg; 0.220 mmol) 
and NaH (21 mg; 0.880 mmol) in ethane-1,2-diol (7.3 ml) was heated under Ar at 50 
°C overnight (17 h).  By this time the starting material had been consumed and the 
reaction mixture was extracted into EtOAc (50 ml), washed with NH4Cl (2 x 30 ml) 
and brine (2 x 30 ml) and the organic layer dried (Na2SO4).  After removal of the 
solvent under reduced pressure, the residue was purified by automated flash 
chromatography (A: pentane, B: CH2Cl2:EtOAc 5:1; 45 – 50 % B).  The purified 
product was obtained as a yellow solid (44 mg; 0.162 mmol; 74 %).   
 
ii) The reaction was repeated and the procedure modified such that a solution of NaH 
(30 mg; 1.24 mmol) in ethane-1,2-diol (5 ml) was added dropwise to a solution of the 
carbazole quinone (100 mg; 0.414 mmol) in ethane-1,2-diol (5 ml) and the mixture 
stirred under Ar at r.t. for 3h15min.  After purification by automated flash 
chromatography using a less polar mobile phase (30-35 % B), the product was 
recovered (78 mg; 0.288 mmol; 69 %) and the unreacted carbazole quinone starting 
material (13 mg; 0.054 mmol; 13 %) recovered for further reaction.  Rf 
(pentane:EtOAc:CH2Cl2, 10:5:1) 0.20. 
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1H NMR (600 MHz, Acetone) δ 11.79 (s, 1H, H9’), 8.24 (d, J = 8.1 Hz, 1H, H5’), 7.71 (d, J = 
8.3 Hz, 1H, H8’), 7.52 (t, J = 7.7 Hz, 1H, H7’), 7.41 (t, J = 7.5 Hz, 1H, H6’), 4.39 (td, J = 7.2, 
6.1 Hz, 1H, H12’ or H13’), 4.24 – 4.20 (m, 1H, H13’ or H12’), 4.13 (qt, J = 13.6, 6.8 Hz, 2H, H13’ 
or H12’), 3.52 (q, J = 6.9 Hz, 1H, H11’), 1.33 (d, J = 6.9 Hz, 3H, H10’). 
 
GC/MS m/z: Calcd for C15H13NO4, 271.1; Found 271.1 [M]  
 
3-(3-Hydroxypropoxy)-2-methyl-9H-carbazole-1,4-quinone, 3.14 
9'
5'6'
1'
2'
3'4'
7'
8' N
H
O
O
O
10'
11'
OH12' 13'
14'
 
A solution of NaH (15 mg; 0.625 mmol) in propane-1,3-diol (3.9 ml) was added drop-wise 
over 15 min to a solution of 3-methoxy-2-methyl-9H-carbazole-1,4-quinone (52 mg; 0.216 
mmol) in propane-1,3-diol (3.2 ml).  The reaction mixture was stirred at 40 °C under Ar for 42 
h.  EtOAc (50 ml) was then added and the solution washed extensively with saturated 
aqueous NH4Cl (3 x 30 ml), water (30 ml) and brine (30 ml), and the organic layer dried 
(Na2SO4) and solvent removed under reduced pressure.  The crude residue was purified on 
silica gel by automated flash chromatography (EtOAc:pentane, 3:7 – 4:6) to recover 
unreacted carbazole quinone (10 mg; 19 %) and the purified product as a solid (40 mg; 
0.141 mmol; 65 %).  Despite the work up and chromatography, a considerable amount of 
propane-1,3-diol were present as shown by the NMR spectrum.  This compound was not 
further pursued.  Rf (pentane:EtOAc:CH2Cl2, 10:4:1) 0.10.  
 
GC/MS m/z: Calcd C16H15NO4 285.1; Found 285.1.  
 
5-(5-Hydroxypentoxy)-2-methyl-9H-carbazole-1,4-quinone, 3.15 
9'
5'6'
1'
2'
3'4'
7'
8' N
H
O
O
O
10'
11'
12' 13'
OH14' 15'
16'
 
i) A solution of NaH (16 mg; 0.660 mmol) in pentane-1,5-diol (3.9 ml) was added drop-
wise over 15 min to a solution of 3-methoxy-2-methyl-9H-carbazole-1,4-quinone (53 
mg; 0.220 mmol) in pentane-1,5-diol (2.2 ml) and the mixture stirred under Ar at 50 
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°C overnight (18 h).  The reaction mixture was diluted with EtOAc (50 ml), washed 
with saturated aqueous NH4Cl (2 x 30 ml) and brine (2 x 30 ml), dried (Na2SO4) and 
solvent removed under reduced pressure.  The residue contained a significant 
amount of pentane-1,5-diol, necessitating two repetitions of the foregoing work up 
procedure.  However, after drying and removal of the solvent under reduced 
pressure, the product residue still contained a significant quantity of pentane-1,5-diol.  
This mixture was purified on silica gel by automated flash chromatography (A: 
pentane, B: CH2Cl2:EtOAc 5:1; 45 – 50 % B) to afford the product as an oil (44 mg; 
0.162 mmol; 74 %) with a considerable amount of diol starting material present (as 
evidenced in the 1H NMR spectrum). 
 
The reaction was repeated as follows: 
ii) A solution of NaH (90 mg; 3.731 mmol) in pentane-1,5-diol (15 ml) was added to a 
stirring solution of 3-methoxy-2-methyl-9H-carbazole-1,4-quinone (300 mg; 1.244 
mmol) in pentane-1,5-diol (12 ml) under Ar at 50 °C.  The mixture was stirred at this 
temperature for 12 h before being extracted into EtOAc (50 ml), washed with 
saturated aqueous K2CO3 (3 x 40 ml), saturated aqueous NH4Cl (2 x 30 ml) and brine 
(30 ml).  The organic layer was dried (Na2SO4) and evaporated before being purified 
by automated flash chromatography on silica gel (A: pentane, B: EtOAc).  After 
chromatography there still remained a significant amount of pentane-1,5-diol in the 
product fractions and this was mostly removed by repeatedly washing the organic 
layer with water (7 x 100 ml), leaving to separate overnight where necessary.  The 
organic layer was then concentrated under reduced pressure and the residue 
chromatographed once again under the conditions described above to afford the 
partially purified product (198 mg; 0.632 mmol; 51 %).  Rf (pentane:EtOAc:CH2Cl2, 
10:4:1) 0.10.  
 
ESI-MS m/z: Calcd C18H19NO4 313.1; Found 314.1 [M+H], 336.1 [M+Na] 
GC-MS m/z: Calcd C18H19NO4 313.1; Found 313.1 
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7.5.2 2-Substituted Carbazole Quinones 
 
4-(3-methoxy-9H-carbazole-1,4-quinone-2-yl)-butanoic acid, 3.18 
9'
5'6'
1'
2'
3'4'
7'
8'
1
23
N
H
4
O
O
O 10' O
OH
 
A solution of 3-methoxy-9H-carbazole-1,4-quinone (320 mg; 1.408 mmol) and glutaric acid 
(650 mg; 4.920 mmol) in 66 % CH3CN/H2O (20 ml) was heated to 70 °C.  Solid AgNO3 (111 
mg; 0.653 mmol) was then added and the solution degassed and placed under argon.  A 
degassed solution of K2S2O8 (576 mg; 2.131 mmol) in 30 % CH3CN/H2O (24 ml) was then 
added to the reaction mixture drop-wise over 2 h.  Once the addition was complete, the 
mixture was stirred at 70 °C for a further 2 h.  By this stage only partial conversion to the 
product had taken place (possibly due to the poor solubility of the starting material).  
Therefore, degassed CH3CN (12 ml) was added, followed by a solution of K2S2O8 (200 mg; 
0.740 mmol) in degassed H2O (5 ml) over 1 h, and stirring continued for a further 2 h.  The 
reaction was then stopped by removing the CH3CN under reduced pressure and extracting 
the crude aqueous suspension into EtOAc (50 ml).  The organic layer was washed with 
saturated aqueous NH4Cl (2 x 30 ml) and brine, and the combined aqueous layers extracted 
with additional EtOAc (3 x 20 ml).  The combined organic layers were dried (Na2SO4) and 
the solvent removed under reduced pressure.  The residue was purified by automated flash 
chromatography (silica gel, eluting in MeOH:CH2Cl2, 0:100 – 5:95) to recover the unreacted 
starting material (139 mg; 0.612 mmol; 43 %), and purified product as an orange solid (136 
mg; 0.434 mmol; 31 %). M.p. not determined due to presence of glutaric acid impurity. 
 
1H NMR (500 MHz, DMSO/CDCl3) δ 12.84 (s, 1H, H9’), 12.01 (s, 1H, COOH), 8.01 (d, J = 7.9 
Hz, 1H, H5’), 7.53 (d, J = 8.2 Hz, 1H, H8’), 7.39 – 7.33 (m, 1H, H7’), 7.30 (t, J = 7.1 Hz, 1H, 
H6’), 4.05 (s, 3H, H10’), 2.44 (t, J = 7.4 Hz, 2H, H2), 2.24 (t, J = 7.4 Hz, 2H, H4), 1.68 (p, J = 
7.4 Hz, 2H, H3). 
 
13C NMR (126 MHz, DMSO) δ 180.3 (C1’ or C4’), 178.5 (C4’ or C1’), 174.2 (COOH), 158.2 (C), 
137.5 (C), 136.1 (C), 129.3 (C), 125.9 (CH), 123.8 (CH) , 123.5 (C), 121.4 (CH), 113.9 (CH), 
113.8 (C), 61.4 (C10’), 33.3 (C2), 23.6 (C4), 22.1 (C3). 
 
ESI-MS m/z: Calcd for C17H15NO5 313.1; Found 314.1 [M+H], 336.1 [M+Na], 649.1 [2M+Na]. 
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HRMS m/z: Calcd for C17H15NO5 313.0950; Found 314.1019 [M+H], 336.0848 [M+Na]. 
 
5-(3-methoxy-9H-carbazole-1,4-quinone-2-yl)pentanoic acid, 3.19 
9'
5'6'
1'
2'
3'4'
7'
8'
1
2
3
N
H
4
O
O
O 10' OH
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A solution of 3-methoxy-9H-carbazole-1,4-quinone (241.5 mg; 1.063 mmol) and adipic acid 
(465.8 mg; 3.189 mmol) in 70 % CH3CN/H2O (10 ml) was degassed (by several cycles of 
evacuation followed by purging with argon) and heated to 70 °C.  AgNO3 (72 mg; 0.425 
mmol) was then added and the solution once again degassed.  A solution of K2S2O8 (374 
mg; 1.382 mmol) in degassed 50 % CH3CN/H2O (18 ml) was added drop-wise to the 
reaction mixture over 2 h.  After complete addition 10 ml of CH3CN was added to completely 
dissolve the starting material, and the reaction mixture maintained at 65 °C for a further 2 h.  
The product was then extracted into EtOAc (50 ml) and the EtOAc layer washed with 
saturated aqueous NH4Cl (3 x 25 ml) and brine.  The aqueous layer was extracted with 
further EtOAc (3 x 20 ml) and the combined organic layers dried (Na2SO4).  After removal of 
the solvent under reduced pressure, the residue was purified by automated flash 
chromatography (silica gel, eluting in MeOH:CH2Cl2, 0:100 – 5:95).  Unreacted starting 
material (117.5 mg; 49 %) was recovered, and the purified product obtained as an orange 
powder (131.5 mg; 0.402 mmol; 38 %).  Rf (MeOH:CH2Cl2, 5:95) 0.24; m.p. 210-212 °C. 
 
1H NMR (500 MHz, DMSO) δ 12.85 (s, 1H, H9’), 11.98 (s, 1H, COOH), 8.01 (d, J = 7.9 Hz, 
1H, H5’), 7.53 (d, J = 8.2 Hz, 1H, H8’), 7.36 (t, J = 7.5 Hz, 1H, H7’), 7.31 (t, J = 7.4 Hz, 1H, 
H6’), 4.05 (s, 3H, H10’), 2.41 (t, J = 7.4 Hz, 2H, H2), 2.24 (t, J = 7.2 Hz, 2H, H5), 1.57 – 1.48 
(m, 2H, H3 or H4), 1.48 – 1.40 (m, 2H, H4 or H3). 
 
13C NMR (126 MHz, DMSO) δ 180.4 (C1’ or C4’), 178.6 (C4’ or C1’), 174.4 (C1), 158.1 (C), 
137.6 (C), 136.1 (C), 130.1 (C), 126.1 (CH), 123.9 (CH), 123.5 (C), 121.5 (CH), 114.0 (CH), 
113.8 (C), 61.5 (C10’), 33.5 (CH2), 28.0 (CH2), 24.5 (CH2), 22.3 (CH2). 
 
HRMS m/z: Calcd for C18H17NO5 327.1107; Found 328.1194 [M+H], 350.1021 [M+Na]. 
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7.5.3 Substitution at the Carbazole Nitrogen 
 
Methyl 5-(3-methoxy-2-methyl-9H-carbazole-1,4-quinone-9-yl)-5-oxopentanoate, 3.22 
9'
5'6'
1'
2'
3'4'
7'
8'
1
2
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O
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To a stirring solution of 3-methoxy-2-methyl-9H-carbazole-1,4-quinone 3.11 (200.5 mg; 
0.831 mmol) in anhydrous THF (12 ml) was added Et3N (126.1 mg; 0.173 ml; 1.247 mmol) 
followed by glutaric acid monomethylester chloride (205.2 mg; 0.172 ml; 1.247 mmol).  The 
orange solution was left to stir at room temperature under an atmosphere of argon.  After 5 
min a precipitate had begun to form, and after 2 h the reaction was complete, accompanied 
by a colour change to red-orange. The crude product was extracted into EtOAc (20 ml), 
washed with sat. aqueous NH4Cl (2 x 25 ml) and brine (2 x 25 ml), dried (Na2SO4), and 
adsorbed onto silica gel.  Purified product was obtained by automated flash chromatography 
using a mobile phase gradient of 25 % A in pentane to 30 % A in pentane (A = 
CH2Cl2:EtOAc, 17:83).  Separation did prove to be difficult due to the starting material and 
product having almost identical Rf values.  However, a portion of pure product was obtained 
as a solid (225.8 mg; 0.611 mmol; 74 %).  Rf (CH2Cl2:EtOAc:pentane, 6:31:63) 0.33; m.p. 
unstable, decomposition back to carbazole quinone starting material. 
 
1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 7.9 Hz, 1H, H5’), 7.84 (d, J = 8.5 Hz, 1H, H8’), 7.50 
– 7.43 (m, 1H, H7’), 7.40 (t, J = 7.2 Hz, 1H, H6’), 4.14 (s, 3H, OCH3), 3.65 (s, 3H, OCH3), 3.03 
(t, J = 7.2 Hz, 2H, H2 or H4), 2.47 (t, J = 7.2 Hz, 2H, H4 or H2), 2.18 – 2.11 (m, 1H, H3), 2.02 
(s, 3H, H11’). 
 
13C NMR & DEPT (126 MHz, CDCl3) δ 180.1 (C1’ or C4’), 179.8 (C4’ or C1’), 175.0 (C=O), 
173.3 (C=O), 156.5 (C), 138.2 (C), 134.7 (C), 128.8 (CH), 128.2 (C), 125.7 (CH), 123.5 (C), 
122.9 (CH), 119.6 (C), 114.1 (CH), 61.3 (C10’), 51.7 (CH3), 38.7 (CH2), 32.6 (CH2), 20.4 
(CH2), 9.1 (CH3). 
 
ESI-MS m/z: Calcd for C20H19NO6 369.1; Found 370.2 [M+H], 392.2 [M+Na] 
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Methyl 6-(3-methoxy-2-methyl-9H-carbazole-1,4-quinone-9-yl)-6-oxohexanoate, 3.23 
9'
5'6'
1'
2'
3'4'
7'
8'
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To a stirring solution of 3-methoxy-2-methyl-9H-carbazole-1,4-quinone 3.11 (200 mg; 0.829 
mmol) in anhydrous THF (24 ml) was added Et3N (172 µl; 126 mg; 1.244 mmol), and after 5 
min of stirring at -10 °C, methyl adipoyl chloride (193 µl; 222 mg; 1.244 mmol) was added.  
Stirring was continued at this temperature for 1 h, followed by 4 h at room temperature.  
Similar Rf’s for the product and starting material made it difficult to determine by TLC 
whether the reaction had gone to completion.  Crude product was extracted into EtOAc (50 
ml), and the EtOAc solution washed with sat. NH4Cl (2 x 30 ml) and brine (2 x 30 ml), dried 
(Na2SO4) and evaporated under reduced pressure.  Purification of the residue was carried 
out by automated flash chromatography using a mobile phase gradient of 25 % A in pentane 
to 30 % A in pentane (A = CH2Cl2:EtOAc, 17:83) to afford the pure product as a red powder  
(129 mg; 0.363 mmol; 44 %). Rf (CH2Cl2:EtOAc:pentane, 6:31:63) 0.33; m.p. unstable, 
decomposition back to carbazole quinone starting material. 
 
1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 7.9 Hz, 1H, H5’), 7.84 (d, J = 8.5 Hz, 1H, H8’), 7.49 
– 7.44 (m, 1H, H7’), 7.42 – 7.37 (m, 1H, H6’), 4.14 (d, J = 2.2 Hz, 3H, OCH3), 3.65 (d, J = 5.9 
Hz, 3H, OCH3), 3.01 – 2.93 (m, 2H, H2 or H5), 2.34 (dd, J = 9.2, 5.6 Hz, 2H, H5 or H2), 2.03 
(s, 3H, H11’), 1.90 – 1.80 (m, 2H, H3 or H4), 1.75 – 1.66 (m, 2H, H4 or H3). 
 
13C NMR (126 MHz, CDCl3) δ 180.2 (C1’ or C4’), 179.8 (C4’ or C1’), 175.3 (C=O), 173.6 (C=O), 
156.5 (C), 138.2 (C), 134.7 (C), 128.8 (CH), 128.2 (C), 125.7 (CH), 123.5 (C), 122.9 (CH), 
119.5 (C), 114.2 (CH), 61.3 (C10’), 51.6 (CH3), 39.5 (CH2), 33.6 (CH2), 24.9 (CH2), 24.1 
(CH2), 9.1 (C11’). 
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Attempted Hydrolysis of Methyl Ester 6.5: Formation of 3-Hydroxy-2-methyl-9H-carbazole-
1,4-quinone, 3.25 
9'
5'6'
1'
2'
3'4'
7'
8' N
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11'
 
A solution of 3.22 (47 mg; 0.228 mmol) and LiOH (62 mg; 2.566 mmol) in THF (3 ml) and 
H2O (3 ml) was stirred at room temperature for 47 h.  The product was extracted into EtOAc 
(50 ml), washed with sat. NH4Cl (2 x 30 ml) and brine (2 x 30 ml), dried (Na2SO4) and 
evaporated under reduced pressure.  Purification was carried out by automated flash 
chromatography using a mobile phase gradient of 18 % A in pentane to 45 % A in pentane 
(A = CH2Cl2:EtOAc, 17:83) to afford the semi-purified carbazole-1,4-quinone 3.25 as a grey-
brown powder  (30 mg; 0.134 mmol; 59 %).   
1H NMR (300 MHz, DMSO) δ 12.88 (s, 1H, NH), 10.74 (s, 1H, OH), 7.98 (d, J = 7.1 Hz, 1H, 
H5’ or H8’), 7.53 (d, J = 7.3 Hz, 1H, H8’ or H5’), 7.40 – 7.27 (m, 2H, H6, H7), 1.86 (s, 3H, CH3). 
(No further characterisation performed – the side product is unwanted). 
 
Monobenzylglutarate, 3.27 
HO O
O O
1
2
3
4
5
6
1'
2'
3'
4'
 
A solution of glutaric anhydride (5.00 g; 43.82 mmol), benzyl alcohol (5.21 g; 4.992 ml; 48.20 
mmol), Et3N (4.877 g; 6.681 ml; 48.20 mmol) and DMAP (100 mg; 0.82 mmol) in dry CH2Cl2 
(50 ml) was stirred at room temperature under Ar.  Due to the exothermic nature of the 
reaction, the flask was initially immersed in a cold water bath.  The reaction was then 
allowed to stir overnight (20 h) by which time the glutaric anhydride was completely 
consumed.  The solvent was removed under reduced pressure and the residue dissolved in 
Et2O (50 ml) and then washed with saturated aqueous NaHCO3 (50 ml).  The water layer 
was acidified to pH 2 with 2 M HCl and extracted with Et2O (3 x 30 ml).  The organic layers 
were combined, dried (Na2SO4) and the solvent removed under reduced pressure to afford 
the benzylated glutaric acid as a colourless oil (9.855 g; 44.34 mmol) in quantitative yield. 
 
1H NMR (300 MHz, CDCl3) δ 7.44 – 7.32 (m, 5H, H2’, H3’, H4’), 5.15 (s, 2H, H6), 2.55 – 2.43 
(m, 4H, H2, H4), 2.08 – 1.95 (m, 2H, H3). 
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Literature15  1H NMR (200 MHz, DMSO-d6): 7.45 (5H, m, ArH); 5.09 (2H, s, CH2O); 2.39 
(2H, t, J = 6.9 Hz, ROOC-CH2); 2.25 (2H, t, J = 6.9 Hz, CH2COOH); 1.76 (2H, m, J = 6.9 Hz, 
CH2CH2CH2). 
 
Attempted Synthesis of 5-(3-methoxy-2-methyl-9H-carbazole-1,4-quinone-9-yl)-5-
oxopentanoic acid, 3.30 
9'
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A solution of 3.27 (143 mg; 0.643 mmol) in dry CH2Cl2 (2 ml) was stirred at room 
temperature before oxalyl chloride (2.0 M; 0.42 ml; 0.836 mmol) and a drop of dry DMF 
(which caused instantaneous effervescence) was added to the reaction mixture which was 
stirred for a further 2 h at room temperature.  This solution was then added dropwise to a 
solution of 3.11 (105.5 mg; 0.427 mmol) in anhydrous THF (12 ml) at 0 °C, followed by the 
addition of Et3N (89 µl; 65 mg; 0.643 mmol) at the same temperature.  The reaction was 
allowed to warm to room temperature and stirring continued for 1 h.  By this stage the 
reaction was complete, as determined by TLC, and the reaction mixture was diluted with 
EtOAc (40 ml), washed with saturated aqueous NH4Cl (3 x 20 ml) and brine (20 ml), and 
dried (Na2SO4).  The solvent was removed under reduced pressure and the residue purified 
by automated flash chromatography (A: pentane, B: CH2Cl2:MeOH 5:1; 25 – 35 % B).  The 
carbazole quinone (60 mg; 0.270 mmol) starting material was recovered from the column in 
60 % yield, suggesting the acylated product was unstable and was converted back to the 
starting material by interaction with the silica gel.  Fractions of the product (21 mg; 0.047 
mmol; 7 %) were isolated but found to be impure by 1H NMR. Hydrogenation of the benzyl 
protecting group was carried out on a crude fraction of the product (30 mg) using Pd(OH)2 
on carbon (10 mg) in EtOAc (15 ml).  The mixture was stirred at room temperature under a 
H2 atmosphere.  Upon complete reduction of the benzyl ester, the solution was filtered 
through a plug of Celite and the solvent removed under reduced pressure.  The initially 
colourless solution turned progressively orange as the reduced quinone was reoxidised in 
the presence of atmospheric oxygen.  An attempt to purify the residue by silica gel 
chromatography once again resulted in decomposition back to the starting carbazole 
quinone.   No reduction product was isolated. 
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7.5.4 Amide Coupling and Acetate Deprotection 
 
Phenyl-3,4,6-tri-O-acetyl-2-deoxy-2-[5’-(3’’-methoxy-9’’H-carbazole-1’’,4’’-quinone-2’’-yl)-
pentanamido]-1-thio-α-D-glucopyranoside, 3.32 
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A solution of 3.19 (72 mg; 0.219 mmol), 1-hydroxybenzotriazole (33 mg; 0.241 mmol) and 1-
(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl) (37 mg; 0.241 mmol) 
in dry THF was stirred at 0 °C for 30 min.  DIEA (41 µl; 31 mg; 0.241 mmol) was added, 
followed by a solution of 2.7 (87 mg; 0.219 mmol) in dry THF (8 ml). The solution was 
allowed to warm to r.t. and stirred for 22 h.  At this stage the reaction was still incomplete but 
with much of the amine having been consumed.  Additional amine (50 mg; 0.126 mmol) was 
therefore added and stirring continued for a further 20 h, then additional EDC.HCl (37 mg; 
0.241 mmol) and DIEA (41 µl; 0.241 mmol) added and the reaction continued for a further 2 
h (total reaction time 44 h).  The reaction mixture was then partitioned between EtOAc (50 
ml) and saturated aqueous NH4Cl (40 ml).  The organic layer was washed with additional 
NH4Cl (40 ml) and brine, and the combined aqueous layers extracted with EtOAc (3 x 30 
ml).  The combined organic layers were dried (Na2SO4) and the solvent removed under 
reduced pressure.  Purification of the residue was achieved by automated flash 
chromatography (silica gel, eluting in MeOH:CH2Cl2, 0:100 – 5:95) to afford the product as 
an orange solid (21 mg; 0.030 mmol; 14 %).  Rf (MeOH:CH2Cl2, 5:95) 0.57; m.p. 179-180 °C. 
 
1H NMR (500 MHz, CDCl3) δ 9.71 (s, 1H, H9’), 8.15 (d, J = 7.9 Hz, 1H, H5’), 7.47 (d, J = 8.2 
Hz, 1H, H8’), 7.39 – 7.28 (m, 4H, H6’, H7’, H2’’), 7.27 – 7.19 (m, 3H, H3’’, H4’’), 6.14 (d, J = 8.2 
Hz, 1H, H7), 5.76 (d, J = 5.3 Hz, 1H, H1), 5.22 – 5.15 (m, 1H, H3 or H4), 5.12 (t, J = 9.6 Hz, 
1H, H4 or H3), 4.60 – 4.53 (m, 1H, H2), 4.53 – 4.46 (m, 1H, H5), 4.26 (dd, J = 12.4, 4.9 Hz, 
1H, H6a), 4.15 (s, 3H, H10’), 4.06 (dd, J = 12.4, 2.2 Hz, 1H, H6b), 2.50 (t, J = 7.4 Hz, 2H, H9), 
2.38 – 2.18 (m, 2H, H12), 2.06 (s, 3H, CH3COO), 2.06 (s, 3H, CH3COO), 2.03 (s, 3H, 
CH3COO), 1.81 – 1.60 (m, 2H, H10 or H11), 1.60 – 1.45 (m, 2H, H11 or H10).  
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13C NMR (126 MHz, CDCl3) δ 181.2 (C1’ or C4’), 179.1 (C4’ or C1’), 173.3 (C=O), 172.0 (C=O), 
170.7 (C=O), 169.5 (C=O), 158.6 (C), 137.1 (C), 135.7 (C), 132.8 (C1’’), 131.5 (2C, C2’’), 
129.9 (C), 129.2 (2C, C3’’), 127.8 (C4’’), 126.6 (ArCH), 124.3 (ArCH), 124.2 (C), 122.6 
(ArCH), 114.9 (C), 113.0 (ArCH), 87.5 (C1), 71.1 (C3), 68.8 (C5), 68.5 (C4), 62.0 (C6), 61.8 
(C10’), 52.6 (C2), 36.0 (C9), 27.8 (C12), 25.4 (C10 or C11), 21.9 (C11 or C10), 20.8 (CH3), 20.7 
(CH3), 20.7 (CH3).  
 
ESI-MS m/z: Calcd for C36H38N2O11S 706.2; Found 707.3 [M+H], 729.3 [M+Na]. 
HRMS m/z: Calcd for C36H38N2O11S 706.2196; Found 707.2257 [M+H], 729.2105 [M+Na]. 
 
Phenyl-3,4,6-tri-O-acetyl-2-deoxy-2-[6’-(2’’-methyl-3’’-methoxy-9’’H-carbazole-1’’,4’’-
quinone-9’’-yl)-hexanamido]-1-thio-α-D-glucopyranoside, 3.34 
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A solution of 3.33 (125 mg; 0.352 mmol), EDC.HCl (82 mg; 0.527 mmol) and HOBt.H2O (71 
mg; 0.527 mmol) in dry THF (12 ml) was cooled to 0 °C.  DIEA (0.27 ml; 205 mg; 1.583 
mmol) was added followed by a solution of the amine (209 mg; 0.527 mmol) in dry THF (10 
ml), and the solution was allowed to warm to r.t.  Stirring was continued for 9 h before the 
reaction mixture was partitioned between EtOAc (50 ml) and sat. aqueous NH4Cl (30 ml).  
The organic layer was washed with additional sat. aqueous NH4Cl (30 ml) and brine (30 ml), 
and the combined aqueous layers extracted with EtOAc (4 x 20 ml).  The combined organic 
layers were dried (Na2SO4) and the solvent removed under reduced pressure, after which 
the residue was purified by automated flash chromatography (silica gel, eluting in 
EtOAc:pentane:AcOH, 40:59:1 – 45:54:1).  Of the initial acid starting material, 20 % (25 mg) 
was recovered, and the product obtained  as an orange solid (175 mg; 0.240 mmol; 68 %). 
M.p. 170-172 °C. 
 
1H NMR (500 MHz, CDCl3) δ 8.25 – 8.20 (m, 1H, H5’), 7.44 – 7.26 (m, 8H, H6’, H7’, H8’, H2’’, 
H3’’, H4’’), 5.86 (d, J = 8.5 Hz, 1H, H7), 5.71 (d, J = 5.4 Hz, 1H, H1), 5.18 – 5.09 (m, 2H, H3H4), 
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4.61 – 4.47 (m, 4H, H2, H5, H13), 4.27 (dd, J = 12.4, 5.0 Hz, 1H, H6a), 4.13 (s, 3H, H10’), 4.07 
(dd, J = 12.4, 2.2 Hz, 1H, H6b), 2.20 – 2.15 (m, 2H, H9), 2.05 (s, 3H, CH3COO), 2.05 (s, 3H, 
CH3COO), 2.03 (s, 3H, CH3COO), 2.00 (s, 3H, H11’), 1.86 – 1.77 (m, 2H, H10 or H12), 1.72 – 
1.60 (m, 2H, H12 or H10), 1.47 – 1.36 (m, 2H, H11). 
  
13C NMR (126 MHz, CDCl3) δ 181.9 (C1’ or C4’), 179.1 (C4’ or C1’), 172.6 (C=O), 171.7 (C=O), 
170.6 (C=O), 169.3 (C=O), 157.4 (C), 138.8 (C), 133.7 (C), 132.8 (C1’’), 131.5 (2C, C2’’), 
129.3 (2C, C3’’), 127.9 (C4’’), 127.6 (C), 126.3 (ArCH), 124.4 (ArCH), 123.7 (C), 122.9 
(ArCH), 115.3 (C), 111.0 (ArCH), 87.7 (C1), 71.3 (C3), 68.9 (C5), 68.0 (C4), 62.0 (C6), 61.3 
(C10’), 52.6 (C2), 44.7 (C13), 36.3 (C9), 29.6 (C10 or C11 or C12), 26.3 (C10 or C11 or C12), 25.0 
(C10 or C11 or C12), 20.8 (CH3), 20.7 (CH3), 20.6 (CH3), 8.7 (C11’).  
 
ESI-MS m/z: Calcd for C38H42N2O11S 734.3; Found 735.3 [M+H], 757.2 [M+Na]. 
HRMS m/z: Calcd for C38H42N2O11S 734.2509; Found 735.2587 [M+H], 757.2429 [M+Na]. 
 
Phenyl 2-deoxy-2-[4’-(3’’-methoxy-9’’H-carbazole-1’’,4’’-quinone-2’’-yl)-butanamido]-1-thio-
α-D-glucopyranoside, 3.35 
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A solution of 3.31 (49 mg; 0.071 mmol) in MeOH (10 ml) was stirred at r.t. before NaOMe 
(10 mg; 0.185 mmol) was added, causing a red suspension to form.  Stirring was continued 
for 45 min, after which the solution was filtered through a plug of Dowex 50wx2-200 ion 
exchange resin.  After removal of the solvent under reduced pressure, the residue was 
purified by flash chromatography (silica gel, eluting in CH2Cl2:MeOH:Acetone, 4:1:5) and 
recrystallisation from MeOH afforded the product as an orange solid (27 mg; 0.048 mmol; 68 
%).  M.p. 243-245 °C. 
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1H NMR (400 MHz, DMSO) δ 12.81 (m, 1H), 8.01 (dd, J = 7.7, 1.2 Hz, 1H, H5’), 7.95 (d, J = 
6.7 Hz, 1H, NH7), 7.54 (dd, J = 8.1, 1.0 Hz, 1H, H8’), 7.43 – 7.39 (m, 2H, H2’'), 7.35 (dd, J = 
8.2, 1.3 Hz, 1H, H8’), 7.33 – 7.29 (m, 1H, H7’), 7.30 – 7.24 (m, 2H, H3’’), 7.24 – 7.19 (m, 1H, 
H6’), 5.61 (d, J = 5.1 Hz, 1H, H1), 5.12 (d, J = 5.7 Hz, 1H, H13 or H14), 4.85 (d, J = 5.5 Hz, 1H, 
H14 or H13), 4.52 (t, J = 6.0 Hz, 1H, H12), 4.03 (s, 3H, H10’), 3.90 – 3.80 (m, 2H, H2, H5), 3.66 – 
3.51 (m, 2H, H6a, H6b), 3.48 – 3.39 (m, 1H, H3 or H4), 3.27 – 3.20 (m, 1H, H4 or H3), 2.44 (t, J 
= 7.5 Hz, 2H, H9 or H11), 2.25 – 2.11 (m, 2H, H11 or H9), 1.75 – 1.59 (m, 2H, H10).   
 
13C NMR (101 MHz, DMSO) δ 180.8 (C1’ or C4’), 179.0 (C4’ or C1’), 172.9 (C8), 158.7, 138.2, 
136.7, 135.5 (C), 131.8 (2C, C2’’), 130.2 (C), 129.4 (2C, C3’’), 127.4 (C4’’), 126.4 (C7’), 124.3 
(C6’), 124.0 (C), 121.9 (C5’), 114.4 (C8’), 114.3 (C), 88.3 (C1), 74.8 (C2 or C5), 71.2 (C3 or C4), 
71.1 (C4 or C3), 61.9 (C10’), 61.0 (C6), 55.2 (C5 or C2), 35.7 (C9 or C11), 25.3 (C10), 22.9 (C11 
or C9).    
 
HRMS m/z: Calcd for C29H30N2O8S 566.1723; Found 567.1820 [M+H], 589.1677 [M+Na]. 
 
Phenyl 2-deoxy-2-[5’-(3’’-methoxy-9’’H-carbazole-1’’,4’’-quinone-2’’-yl)-pentanamido]-1-
thio-α-D-glucopyranoside, 3.36 
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A red suspension of 3.32 (36 mg; 0.051 mmol) and NaOMe (0.8 mg; 0.015 mmol) in MeOH 
(20 ml) was stirred at room temperature for 24 h.  After this, due to poor conversion to the 
product, additional NaOMe (1.4 mg; 0.026 mmol) was added.  After 50 h, the temperature 
was raised to 50 °C, and stirring continued for a further 16 h.  The resultant precipitate was 
isolated by filtration and purified by flash chromatography (silica gel, eluting in 
EtOAc:MeOH:THF, 8:2:10), followed by recrystallisation from MeOH, to afford the product as 
an orange solid (11 mg; 0.019 mmol; 37 %).  M.p. 224-226 °C. 
 
1H NMR (400 MHz, DMSO) δ 12.74 (s, 1H, H9’), 7.95 (d, J = 7.7 Hz, 1H, H5’), 7.86 (d, J = 6.7 
Hz, 1H, NH7), 7.48 (d, J = 8.1 Hz, 1H, H8’), 7.35 – 7.29 (m, 3H, H2’’, H7’), 7.29 – 7.21 (m, 1H, 
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H6’), 7.20 – 7.14 (m, 2H, H3’’), 7.13 – 7.07 (m, 1H, H4’’), 5.54 (d, J = 5.2 Hz, 1H, H1), 5.06 (d, J 
= 5.7 Hz, 1H, H14 or H15), 4.79 (d, J = 5.6 Hz, 1H, H15 or H14), 4.46 (t, J = 5.9 Hz, 1H, H13), 
3.96 (s, 3H, H10’), 3.82 – 3.74 (m, 2H, H2, H5), 3.60 – 3.44 (m, 2H, H6a,b), 3.43 – 3.33 (m, 1H, 
H3 or H4), 3.21 – 3.15 (m, 1H, H4 or H3), 2.35 (t, J = 7.4 Hz, 2H, H9 or H12), 2.17 – 2.06 (m, 
2H, H12 or H9), 1.56 – 1.43 (m, 2H, H10 or H11), 1.44 – 1.32 (m, 2H, H11 or H10).  
 
13C NMR (101 MHz, DMSO) δ 180.9 (C1’ or C4’), 178.9 (C4’ or C1’), 173.1 (C8), 158.5 (C), 
138.1 (C), 136.6 (C), 135.5 (C), 131.7 (2C, C2’’), 130.7 (C), 129.4 (2C, C3’’), 127.3 (C4’’), 
126.3 (C6’ or C7’), 124.3 (C7’ or C6’), 124.1 (C), 121.9 (C5’ or C8’), 114.5 (C8’ or C5’), 114.3 (C), 
88.2 (C1), 74.8 (C2 or C5), 71.2 (C3 or C4), 71.0 (C4 or C3), 61.8 (C10’), 61.0 (C6), 55.2 (C5 or 
C2), 35.6 (C9 or C12), 28.7 (C10 or C11), 25.8 (C11 or C10), 23.0 (C12 or C9).  
 
HRMS m/z: Calcd for C30H32N2O8S 580.1879; 581.1972 [M+H], 603.1829 [M+Na]. 
 
Phenyl 2-deoxy-2-[6’-(2’’-methyl-3’’-methoxy-9’’H-carbazole-1’’,4’’-quinone-9’’-yl)-
hexanamido]-1-thio-α-D-glucopyranoside, 3.37 
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A solution of 3.34 (51 mg; 0.069 mmol) in MeOH (30 ml) was stirred at room temperature 
before NaOMe (0.8 mg; 0.014) was added, causing a red suspension to form.  Stirring was 
continued for 10 days, after which time the precipitate was filtered off and purified by flash 
chromatography (silica gel, eluting in EtOAc:Acetone:THF, 14:3:3).  Recrystallisation from 
MeOH afforded the product as an orange-red solid (20 mg; 0.033 mmol; 48 %).  M.p. 191-
192 °C. 
 
1H NMR (400 MHz, DMSO) δ 8.08 (d, J = 7.8 Hz, 1H, H5’), 7.94 (d, J = 6.6 Hz, 1H, H7), 7.69 
(d, J = 8.3 Hz, 1H, H8’), 7.44 – 7.38 (m, 3H, H2’’, H7’), 7.35 (t, J = 7.1 Hz, 1H, H6’), 7.32 – 7.25 
(m, 2H, H3’’), 7.25 – 7.20 (m, 1H, H4’’), 5.63 (d, J = 5.1 Hz, 1H, H1), 5.14 (d, J = 5.1 Hz, 1H, 
H15 or H16), 4.90 (d, J = 4.9 Hz, 1H, H16 or H15), 4.60 – 4.46 (m, 3H, H13, H14), 4.02 (s, 3H, 
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H10’), 3.89 – 3.78 (m, 2H, H2, H5), 3.66 – 3.50 (m, 2H, H6a,b), 3.49 – 3.35 (m, 1H, H3), 3.34 – 
3.23 (m, 1H, H4), 2.22 – 2.04 (m, 2H, H9), 1.91 (s, 3H, H11’), 1.79 – 1.65 (m, 2H, H12), 1.63 – 
1.47 (m, 2H, H10), 1.41 – 1.28 (m, 2H, H11). 
 
13C NMR (101 MHz, DMSO) δ 181.5 (C1’ or C4’), 178.8 (C4’ or C1’), 173.1 (C8), 157.4, 139.0, 
135.5, 131.7 (2C, C2’’), 129.4 (2C, C3’’), 127.6, 127.4 (C4’’), 126.6 (C7’), 124.9 (C6’), 123.3, 
122.2 (C5’), 112.7 (C8’), 88.2 (C1), 74.8 (C2 or C5), 71.2 (C3), 71.0 (C4), 61.4 (C10’), 61.0 (C6), 
55.2 (C5 or C2), 44.9 (C13), 35.5 (C9), 29.8 (C12), 26.3 (C11), 25.4 (C10), 9.1 (C11’).  The 
quaternary C1’’ (~132 ppm) and another signal at ~115.3 ppm (based on the acetylated 
precursor) were not visible above the baseline noise and were not assigned.   
 
HRMS m/z: Calcd for C32H36N2O8S 608.2192; Found 609.2266 [M+H], 631.2113 [M+Na]. 
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Appendix 
1. 1H NMR Spectra of Synthesised Compounds Described in Chapter 2 
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2. 1H NMR Spectra of Synthesised Compounds Described in Chapter 3 
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NDW35 
NDW35 In DMSO 
12.5 11.5 10.5 
NDW21 
NDW-2/1 in COCIJ 
9.0 8.5 8.0 7.5 7.0 
~590&580Z5Z0&5&O~550~5~0353~L52~1.5 1~05M 
f1 (ppm) 
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 
f1 (ppm) 
Un
ive
rsi
ty 
of 
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NDW31 
NDW-3. 1 In COO3 
8.5 8.0 
NDW4+7-2 
NDW_4+7/2 in DMSO 
.3.5 12.5 
7.5 
11.5 
7.0 6.5 6.0 5.5 
10.5 9 .5 8.5 
5.0 4.5 4.0 
f1 (ppm) 
7.5 7.0 6.5 
f1 (ppm) 
3.5 3.0 2.5 
5.5 4.5 4.0 3.5 
2.0 1.5 1.0 0.5 0.0 
2.5 1.5 0.5 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
202 
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3.32
NOW22INT 
NOW 22 INT In COCIJ 
ffi5 10.0 95 U L5 8.0 ~5 ~ L5 U ~5 5~ ~5 ~ 3.5 ~ 25 2.0 1.5 I~ ~ ~O 
f1 (ppm) 
9.5 ~O L5 LO ~5 ~O L5 U 5.5 5~ 45 ~ ~5 3.0 L5 ~ 1.5 I~ ~5 M 
f1 (ppm) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
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O
HO
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NH
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O
O
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3.35
NDW48 
8.5 8.0 
Final compound glutaric 
RF 986/1 In D6-DMSO 
IH Spectrum 
Fo~, 
12.5 
7.5 
11 .5 
/ 
7.0 6.5 6.0 5.5 
10.5 9.5 8.5 
5.0 4.5 4.0 
f1 (ppm) 
7.5 7.0 6.5 
f1 (ppm) 
5.5 
3.5 3.0 2.5 
4.5 4.0 3.5 
2.0 1.5 1.0 0.5 0.0 
2.5 1.5 0.5 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
204 
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3.37
O
HO
HO
NH
OH
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N
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O
Anal ~ adipic 
RF 988-1 In D6-DMSO 
IH Spectrum 
Nkl< 
12.5 11.5 
RF987.1 
RF 987-1 In D6-DMSO 
IH Spectrum 
Nkl< 
I 
8.5 8.0 7.5 
\ 
10.5 
7.0 6.5 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 
fI (ppm) 
6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 
fI (ppm) 
